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Abstract 
The Myeloproliferative Neoplasms are a clinically heterogenous group of bone 
marrow haemopoietic disorders that result in the overproduction of myeloid blood 
cells.  The identification of recurrent gene mutations has aided positive identification 
of disease in a substantial proportion of patients, however, a significant number of 
individuals with classical MPNs do not have a detectable aberration.  The clinical 
and laboratory presentation of these disorders shows significant overlap with features 
associated with reactive conditions, which, in patients without detectable genetic 
mutations, can lead to ambiguity in their diagnosis.   
 
Traditionally, the decision to investigate an individual for a suspected classical MPN 
has been based upon thresholds in blood count parameters.  In this work, current 
working practices have been audited to ascertain the extent to which diagnostic 
guidelines are adhered toe.  We demonstrate that a significant proportion of referrals 
for the investigation of suspected classical MPNs do not meet these criteria.  
Furthermore, this work objectively assesses the diagnostic sensitivity and specificity 
of current guidelines in the identification of patients with classical MPNs. 
 
The use of predictive statistical modelling is a contemporary approach to the 
identification of individuals with increased likelihood of suffering from a classical 
MPN.  In this work, several predictive modelling methods were applied to a data set 
of laboratory and basic demographic information taken from a series of patients 
investigated for suspected classical MPNs.  This work shows that predictive 
statistical modelling can reproducibly identify those patients who are likely to have a 
classical MPN from those who do not.  These models offer increased specificity and 
sensitivity compared with the use of published investigatory and diagnostic 
guidelines.  Predictive statistical modelling also offers the ability to triage those 
patients who are likely to have classical MPNs prior to further investigation, 
resulting in potentially significant cost savings to both clinical and laboratory 
services. 
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1. Introduction 
 
1.1 What are myeloproliferative neoplasms? 
 
The term Myeloproliferative Neoplasm (MPN) is used to describe a group of cancers 
which affect certain blood cells, known as myeloid cells.  In human haematopoiesis 
(blood cell production), the cells can be broadly divided into two groups; myeloid 
and lymphoid cells.  Myeloid cells include populations known as granulocytes, 
erythrocytes and megakaryocytes (see 
 
Figure 1-1).  
 
19 
 
The World Health Organisation (WHO) recognises over 70 different forms of 
myeloid malignancy (cancer).  These are sub-categorised into acute myeloid 
leukaemias (AML), myelodysplastic syndromes (MDS) and the MPNs.  Current 
WHO 2016 diagnostic criteria categorise 7 entities as MPNs (Arber et al., 2016).  
These are: - chronic myeloid leukaemia (BCR-ABL1 positive), chronic neutrophilic 
leukaemia, chronic eosinophilic leukaemia (not otherwise specified), 
myeloproliferative neoplasms (unclassifiable), polycythaemia vera, essential 
thrombocythaemia and primary myelofibrosis.  The lattermost three are collectively 
known as the classical MPNs.
  
 
2
0
 
 
Figure 1-1 Schematic of human haematopoiesis, showing the shared ancestry of myeloid cells.    The common myeloid progenitor (CMP)  
gives rise to the myeloid cell lineages.  (reproduced from (Doulatov et al., 2012).  CD nomenclature indicates the immunophenotypic 
characteristics at each stage of development/differentiation.
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1.1.1 Essential Thrombocythaemia 
 
Essential Thrombocythaemia (ET) is the most frequently diagnosed of the classical 
MPNs, with a reported annual incidence ranging from 0.21 – 2.27 per 100,000 
(Titmarsh et al., 2014).  It is characterised by increased proliferation of 
megakaryocytes in the bone marrow, and consequently, an increased peripheral 
blood platelet count (>450 x 109/L) (Arber et al., 2016).  The incidence of ET 
increases with age, peaking at 71.5 years (Roman et al., 2016)  and it occurs more 
frequently in females than males (F/M ratio 2.6:1)  (Jensen et al., 2000).  The female 
bias in ET diagnoses is an uncommon feature in malignancies, where an excess 
diagnostic burden in males is well documented across the majority of cancers.  It is 
thought that hormonal, immunological and lifestyle difference contribute to a lower 
frequency of cancer diagnoses in women.  The increased frequency of female ET 
diagnoses may also be related to these differences.  It is reported that females have 
an increased platelet count in comparison to males, and that this may be related to 
hormonal differences associated with the female reproductive cycle.  Blood loss 
associated with menstruation and childbirth.    The prognosis of ET is generally 
good, with survival estimates close to those expected in comparable disease-free 
populations (Barbui et al., 2011b).  However, a small number of patients undergo 
disease progression with the risk of developing overt fibrosis or acute leukaemia 
reported to be between 1.4 and 3.9% (Passamonti et al., 2008; Wolanskyj et al., 
2006)   
 
1.1.2  Polycythaemia Vera 
 
Polycythaemia Vera (PV) primarily affects the production of erythrocytes and is 
characterised by an unregulated increase in the production of red blood cells.  Whilst 
the erythrocytosis is a defining feature of PV, it is often also accompanied by 
increased proliferation of both megakaryocytes and granulocytes (Arber et al., 2016).  
The annual incidence of PV is estimated to be between 0.01 and 2.8 per 100000 in 
European and North American populations (Mesa et al., 2012; Moulard et al., 2014; 
22 
 
Phekoo et al., 2006; Rollison et al., 2008; Roman et al., 2016).  Lower incidence 
rates are reported in Asian populations (Japan and Korea) (Byun et al., 2017; Kurita, 
1974).  The median age at diagnosis is similar to that seen in ET (Roman et al., 
2016).  In contrast to ET, PV is more commonly diagnosed in males than females, 
with an estimated male to female ratio of 1.2:1 ((Marchioli et al., 2005). 
 
PV has a poorer prognostic outcome than ET.  Without treatment, the median 
survival in PV is reported to be less than 2 years (McMullin et al., 2003).  Current 
therapeutic approaches, have significantly improved this with 10 year survival 
reaching levels comparable to the general population (Tefferi et al., 2018).  
Progression to overt fibrosis or acute leukaemia is more frequent in PV than in ET, 
with studies indicating a risk of progression of around 7%  (Marchioli et al., 2005; 
Tefferi et al., 2014a).  
 
1.1.3 Primary Myelofibrosis 
 
Primary Myelofibrosis (PMF) is the least common of the classical MPNs with an 
annual incidence estimated to be between 0.5 and 1.5 per 100000 (Arber et al., 
2016).  Characterised by the increased proliferation of both granulocytic and 
megakaryocytic cells alongside the deposition of fibrotic connective tissue within the 
bone marrow (Fujiwara, 2018; Koopmans et al., 2012).  With disease progression, 
bone marrow fibrosis increases and extramedullary haematopoiesis occurs (the 
formation of blood cells in tissues/organs outside of the bone marrow, such as the 
spleen and liver) with a  resultant leucoerythroblastic blood picture (Laszlo, 1975). 
 
Prognostically, PMF has the poorest prognosis of the classical MPNs, with an 
estimated median survival of 6 years (Tefferi et al., 2014a), and AML transformation 
frequency of approximately 14% (Mudireddy et al., 2018). 
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1.1.4 Gender bias in ET and PV 
 
Gender bias in cancer diagnoses is a well-documented phenomenon (Cook et al., 
2011; White et al., 2010).  An excess male burden is widely reported in the majority 
of (non-gynaecological/urological) malignancies, with the exception of thyroid 
cancer (2016; Cook et al., 2011).  This is thought to be, in part, related to differences 
in epigenetic, hormonal and immunological characteristics between the sexes 
(Edgren et al., 2012).  Lifestyle factors are also implicated, with higher intake of 
alcohol and tobacco and increased exposure to occupational hazards associated with 
males (Jaggers et al., 2009; Parkin et al., 2011).  The gender bias seen in PV is in 
keeping with this general observation. 
 
The increased frequency of ET in females is less typical and the reasons for this are 
not fully understood.  Studies have shown that from the onset of puberty, average 
platelet counts are higher in females than males (Biino et al., 2013; Segal and 
Moliterno, 2006; Stevens and Alexander, 1977).  It is postulated that this may be 
related to changes experienced during the female reproductive cycle.  The 
physiological requirement for platelets during blood loss, through menstruation 
and/or childbirth may contribute to an increase in platelet production (Balduini and 
Noris, 2014).  Studies in mouse models has shown oestrogen to promote 
megakaryocyte production (Nagata et al., 2003).  Additionally, the associated 
reduction in iron stores may promote platelet production (as seen in iron deficiency 
anaemia) (Kadikoylu et al., 2006).  One may postulate that chronic stimulation of 
platelet production may contribute to the increased frequency of ET in females or 
conversely, that a proportion of females categorised as ET may have physiologically 
increased platelet counts. 
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1.1.5 Overlap between ET, PV and PMF 
 
In their text-book forms, each of the classical MPNs appears easily distinguishable 
from one another.  However, in practice the distinction is less clear; the 
transformation/progression of ET and PV into fibrotic or blastic phase results in a 
clinical picture not dissimilar to that seen in PMF (Marchioli et al., 2005; Passamonti 
et al., 2004) .  Likewise, all three diseases can undergo transformation to AML 
(Mudireddy et al., 2018; Wolanskyj et al., 2006) .  This continuum of disease can 
cause blurring in the distinction between the three conditions. 
 
Overlapping features are not confined to late stage/aggressive disease.  In PV, the 
proliferation of erythroid cells is often accompanied by increases in the production of 
both granulocytes and megakaryocytes (Dameshek, 1951).  In the event that a patient 
with PV has concurrent iron deficiency, the production of erythrocytes is decreased 
and as a result polycythaemia is often masked (Shih and Lee, 1994).  In these cases, 
the presentation appears to be that of ET rather than PV (Barbui et al., 2014b).  
Furthermore, in early PMF, fibrotic changes in the bone marrow can be subtle 
(referred to as pre-fibrotic PMF), making the distinction between PMF and ET 
challenging (Giovanni Barosi 2012; Guglielmelli et al., 2017).   
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1.2 The biological basis of the classical MPNs 
 
Classical MPNs share a common biological ancestry, with the affected cell lineages 
arising from a common progenitor.  As shown in Figure 1-1, all human blood cells 
are derived from a multipotent haematopoietic stem cell (HSC).  HSCs can divide 
and differentiate into any of the mature haemopoietic cell forms according to the 
body’s requirements.   
 
Briefly, HSCs divide to produce multi-potent stem cells (MPP), which can 
differentiate into one of two committed progenitors - the common myeloid 
progenitor (CMP) or the multi-lymphoid progenitor (MLP) (which in turn gives rise 
to early thymic (ETP) and B/NK cell progenitors (B/NK)) (Tenen et al., 1997).  
CMPs then undergo further differentiation to form either granulocyte/macrophage 
progenitor (GMP) or megakaryocyte/erythroid progenitor (MEP) (Doulatov et al., 
2010; Doulatov et al., 2012).  Classical MPNs primarily affect the production of 
megakaryocytes and erythrocytes (as well as granulocytes to a lesser extent), 
indicating a potential common underlying pathobiological basis for all MPNs at 
either the MEP or GMP stage of differentiation. 
 
1.2.1 Determination of haematopoietic lineage fate 
 
Haematopoiesis is a dynamic process which responds to the requirements of the 
human body (Kaushansky, 2014).  Each type of mature blood cell has a different role 
within the body, as shown in Table 1-1, and their demand may be increased, for 
example during infection or following injury.  The bone marrow responds to this 
need by adjusting the proportion of cells which differentiate into a given mature cell 
form  (2014). 
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Cell type Role 
B lymphocyte Adaptive immune response, antibody production 
T lymphocyte Cell mediated immune response 
NK cell Direct killing of foreign cells 
Monocyte Antigen presentation, removal of damaged and dead cells 
Neutrophil Phagocytosis of bacteria 
Basophil Histamine reaction, vasodilation, anticoagulation 
Eosinophil Kill parasites, allergic reactions 
Erythrocyte Transportation of oxygen to tissues 
Platelet Formation of blood clots, attract cells to site of 
inflammation/damage 
Table 1-1. Basic function of mature blood cell types. 
 
Overlap in the presentation and transformation of the classical MPNs hints at a 
biological relationship between the conditions.  This is further supported by a 
shared/overlapping spectrum of molecular aberrations associated with the conditions.  
Mutations in one of 3 genes; JAK2, MPL and CALR, are found in the majority of 
patients presenting with classical MPNs.  The frequency with which they occur 
varies between diseases, however, significant overlap is seen (see Figure 1-2). 
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Figure 1-2. Frequency of mutations in JAK2 (V617F and Exon 12), CALR and 
MPL found in the classical MPNs alongside the proportion of patients with no 
mutation detected in the listed genes.  The data used to prepare these 
illustrations was obtained from (Nangalia and Green, 2014). 
 
The JAK2 V617F mutation has been reported to be present in more than 97% of 
patients with PV and in 50% of those patients with ET and PMF (Cross, 2011).  A 
further 65-70% of patients with JAK2 wild-type ET or PMF have been reported as 
having a CALR mutation (Klampfl et al., 2013b; Nangalia et al., 2013).  MPL 
mutations occur less frequently, with W515L/K/A/R mutations reported in 3-4% of 
patients with ET and approximately 7% of patients with PMF (Beer et al., 2008).   
 
1.2.2 JAK2 mutations 
 
The most frequently mutated gene in the classical MPNs is JAK2 (Janus Kinase 2).  
JAK2 is a non-receptor tyrosine kinase which is implicated in a wide variety of 
cellular processes, including cellular growth, development and differentiation 
(Gocek et al., 2014).  JAK2 has many potential binding partners, the most relevant to 
its role in the development of classical MPNs are the Erythropoietin Receptor 
(EpoR) and thrombopoietin receptor, commonly referred to as MPL (The UniProt, 
2014).   
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The most frequently identified JAK2 gene mutation in MPN patients has been 
characterised as a single amino acid substitution of valine for phenylalanine at codon 
617 of the protein (V617F). (Baxter et al., 2005; James et al., 2005; Jones et al., 
2005; Kralovics et al., 2005; Vainchenker and Constantinescu, 2005).  Mutated 
JAK2 kinase is constitutively activated, initiating the downstream STAT5 pathway 
which ultimately results in the uncontrolled proliferation of erythroid and 
megakaryocytic cells. (James et al., 2005) (Figure 1-3).   
 
Additional mutations have been identified within the exon 12 region of the JAK2 
gene (Butcher et al., 2008; Martinez-Aviles et al., 2007; Pietra et al., 2008).  In 
contrast to the V617F mutation, these mutations are diverse and include; deletions, 
substitutions and duplications, all of which affect the structure of JAK2 kinase.  
JAK2 exon 12 mutations have been identified in approximately two thirds of those 
cases of PV which lack the JAK2 V617F mutation (Scott et al., 2007).  
 
Figure 1-3. JAK-STAT signalling.  Normal activation of the JAK-STAT 
signalling pathway is initiated by the binding of a ligand to a receptor (for 
example, EPO binding to EPOR).  In the presence of the JAK2 V617F mutation 
signalling occurs independently of ligand binding (image reproduced from 
(Vainchenker and Constantinescu, 2012). 
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1.2.3 Calreticulin gene mutations 
 
In late 2013, two research groups reported the presence of somatic mutations within 
the calreticulin (CALR) gene in ET and PMF patients without JAK2 mutations 
(Klampfl et al., 2013; Nangalia et al., 2013).  CALR is a multifunctional chaperone 
protein, localised within the endoplasmic reticulum (ER) and is involved in the 
folding and localisation of cellular proteins, including the regulation of expression of 
cell surface receptors (Jiang et al., 2014).   
 
Mutations identified within CALR are restricted to the exon 9 region of the gene.  
Importantly, the mutations are varied, but all cause a net insertion or deletion which 
alters the reading frame.  This consistently results in the production of a truncated 
protein which is missing a sequence of 4 amino acids at the C terminal end.  The 
missing amino acid sequence has been found to form a KDEL motif (Klampfl et al., 
2013; Nangalia et al., 2013; (Chi et al., 2013).   
 
KDEL acts as a signal for the localisation of proteins to the lumen of the ER and is 
found at the extreme carboxyl terminus of a number of proteins including Bip, 
calreticulin and protein disulphide isomerase.  Loss of the KDEL motif results in the 
secretion of these proteins (Capitani and Sallese, 2009; Kraus et al., 2007).   
 
Initially, the mechanism by which the cellular secretion of mutated CALR would 
give rise to ET/PMF phenotype was unknown.  Studies have now shown that 
mutated CALR interacts directly with MPL by binding to the N-glycosylation sites 
on the extracellular domain of the receptor (Araki et al., 2016).  This is thought to 
induce a conformational change which brings the intracellular portions of the 
receptor into close proximity and stimulates activation of the JAK/STAT pathway 
independently of TPO (Araki et al., 2016; Chachoua et al., 2016; Marty et al., 2016) 
(Figure 1-4). 
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Figure 1-4 Ligand binding induces conformational changes in MPL, resulting in 
JAK2 phosphorylation and activation.  The somatic mutations W515A/K/L 
alter the shape of MPL, mirroring the effect of ligand binding, allowing JAK2 
phosphorylation to take place in the absence of ligand stimulation.  In the 
presence of a CALR exon 9 mutation, CALR is secreted by the affected cells.  It 
has been shown to specifically interact with MPL, mimicking TPO binding.  
(Chachoua et al., 2016; Lee et al., 2011; Mead and Mullally, 2017; Pecquet et 
al., 2010)     
 
The pattern of mutations occurring in CALR exon 9 is highly variable, with over 50 
different indels identified, the most frequently reported of these are a 52bp deletion 
and a 5bp insertion (Chi et al., 2013).  Analysis of the resulting amino acid structure 
shows that these mutations affect the overall charge of the protein, impairing its 
calcium-binding abilities to different degrees (Pietra et al., 2015).  Significantly, a 
difference in clinical behaviour has been observed in both mouse models and human 
patients carrying the two different mutations (Pietra et al., 2015).  A more aggressive 
form of ET, with significantly higher risk of transforming to PMF was documented 
in those carrying the 52bp deletion, in contrast to those with the 5bp insertion who 
displayed an ET phenotype with little progression or transformation (Marty et al., 
2016; Pietra et al., 2015).  This work demonstrates the value in both identifying 
CALR mutated MPNs and of the characterisation of the CALR mutation itself.  
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1.2.4 MPL gene mutations 
 
Mutations within the MPL gene have been identified in a small proportion of cases 
of JAK2 V617F wild-type/CALR wild-type ET or PMF, and have been reported to  
occur in the exon 10 region of the gene (Pardanani et al., 2006; Pikman et al., 2006).  
A number of these mutations affect codon 515 of the MPL gene, resulting in the 
substitution of the normal amino acid tryptophan (W) with either Leucine (L), 
Alanine (A), Arginine (R) or Lysine (K) .  The presence of a mutation induces a 
conformational change in MPL (Figure 1-4), which simulates the change which takes 
place following TPO binding (Mead and Mullally, 2017; Pecquet et al., 2010).  This 
results in ligand-independent activation of the JAK-STAT pathway, leading to 
cellular proliferation (Pikman et al., 2006) 
 
1.2.5 Unifying feature of MPN associated gene mutations 
 
The unifying feature of these different mutations is their activation of the JAK-STAT 
signalling pathway.  Each of the mutations initiates ligand-independent signalling, 
which ultimately results in cellular proliferation.  To further emphasise the key role 
of this pathway in the development of MPNs, mutations in genes which regulate 
JAK-STAT signalling (such as LNK, SOCS and c-CBL) have also been shown to 
induce an MPN phenotype (Grand et al., 2009; Oh et al., 2010; Sanada et al., 2009; 
Vainchenker et al., 2011). 
 
Whilst the presence of these JAK-STAT activating mutations is implicated in the 
development of MPNs, the mutation alone may not always be disease inducing.  
Low level somatic mutations in haematological malignancy associated genes, 
including JAK2 V617F mutations, have been reproducibly identified in otherwise 
healthy individuals (termed clonal haematopoiesis of indeterminant potential) 
(Genovese et al., 2014; Jaiswal et al., 2014; Steensma et al., 2015).  In these studies, 
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the presence of additional gene mutations is associated with an increased risk of 
developing a malignancy.  
Furthermore, several studies in Denmark have identified low level JAK2 V617F 
mutations in the general population, with longitudinal analysis showing progression 
to an MPN was frequent, but not universal (Nielsen et al., 2013; Nielsen et al., 2011; 
Nielsen et al., 2014).  This may suggest that the development of MPNs follows a 
multi-hit model, with additional mutational events required for the MPN phenotype 
to develop. 
 
1.2.6 Additional genetic mutation in MPNs 
 
Somatic mutations in epigenetic modulators are widely reported in myeloid 
malignancies, including MPNs (Bejar et al., 2011; Cross, 2011; Nangalia and Green, 
2014; Patel et al.; Shih et al., 2012).  These include mutations in genes involved in 
DNA methylation (such as TET2, DNMT3a and IDH1/2), chromatic structure 
(ASXL1 and EZH2) and mRNA splicing (SF3B1, U2AF1, SRSF2).  Within the 
MPNs, mutations in TET2, ASXL1 and DNMT3a are most frequently reported 
(Nangalia and Green, 2014) and are found in varying frequencies among the 
disorders, with PMF patients showing the highest frequency of additional mutations.  
The acquisition of additional mutations in MPNs is associated with transformation to 
acute leukaemia and an adverse prognosis (Abdel-Wahab et al., 2010).   
 
The order in which mutations are acquired has been shown to impact on disease 
behaviour.  Research has shown that a TET2 mutation acquired prior to JAK2 V617F 
mutation is associated with a MPN phenotype (Delhommeau et al., 2009; Ortmann et 
al., 2015), whereas a TET2 mutation acquired in an already JAK2 V617F mutated 
clone is associated with transformation to acute leukaemia (Abdel-Wahab et al., 
2010; Ortmann et al., 2015).   
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1.2.7 Disease heterogeneity within molecular subgroups 
 
The impact of JAK2/CALR/MPL mutations on the JAK-STAT pathway explains 
how the different mutations can give rise to the same disease phenotype, and the 
transitional entities seen in disease progression.  However, it does not explain how, 
conversely, the heterogeneity of disease phenotypes that can arise from each 
molecular subgroup.  For example, the JAK2 V617F mutation, is reported in all 3 
classical MPNs, each with a distinct clinical phenotype. 
 
Studies have identified that JAK2, CALR and MPL mutations are detectable in 
haemopoietic stem cells as well in differentiated cell populations (Chaligne et al., 
2007; Jamieson et al., 2006; Nangalia et al., 2013).  This may offer some explanation 
of the diverse nature of MPN phenotypes.  Whilst CALR and MPL mutations are 
detected in HSCs, the mutation specifically affects MPL, and its impact, therefore, is 
restricted to megakaryocytic cells.  JAK2 mutations are less specific in their target, 
and the development of heterogenous disease phenotypes in JAK2 V617F mutated 
MPNs is less well understood. 
 
There are a number of hypotheses as to how different disease phenotypes arise in 
JAK2 V617F mutated MPNs.  Firstly, PV has been shown to be associated with 
homozygous JAK2 V617F mutations suggesting that a higher allelic burden may 
influence clinical phenotype (Godfrey et al., 2012).  Quantitative differences in 
downstream signalling activation are also implicated, with increased STAT-1 
activity inducing megakaryocytic differentiation and reduced STAT-1 activity 
favouring erythroid development in cell culture experiments (Chen et al., 2010).  The 
acquisition of a TET2 mutation in a JAK2 V617F clone has been associated with a 
PV phenotype, suggesting additional mutations may influence clinical phenotype 
(Ortmann et al., 2015).   
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1.3 Clinical Presentation of classical MPNs 
 
The distinction between the various classical MPNs can be challenging, as 
highlighted by the continuum of disease and the transitional entities as described in 
1.1.5.  The dynamic nature of haematopoiesis described in 1.2, coupled with the 
varied, non-malignant causes of increased erythroid/megakaryocytic and fibroblast 
activity also contribute to the difficulties in the accurate diagnosis of classical MPNs. 
 
1.3.1 Essential thrombocythaemia 
 
A peripheral blood thrombocytosis is the sine qua non of ET with thrombocytosis 
defined as demonstrating a platelet count greater than 450 x 109/L in adults (Schafer, 
2004).  This increase in platelets may be classed as a primary thrombocytosis, due to 
an underlying abnormality in haematopoiesis processes, or as secondary (also 
referred to as ‘reactive’) thrombocytosis, when the increase can be attributed to an 
external cause (Buss et al., 1994). 
 
The body’s requirement for platelets can be increased under a range of 
circumstances, some examples of which are shown in Error! Reference source not f
ound..  This includes circumstances in which there is an increased requirement for 
platelets, for example during blood loss following injury or surgery.  Inflammatory 
mediators such as interleukin-6 can cause stimulate platelet production (Burmester et 
al., 2005; Kaser et al., 2001; Wolber et al., 2001), under circumstances where an 
increase in platelet production is not necessarily required (secondary increase).   
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Increased platelet requirement Secondary increase 
Tissue damage/vascular injury Infection 
Post-operative Inflammation 
Haemorrhage Iron deficiency 
 Malignancy 
 Therapy related 
Table 1-2. Causes of reactive thrombocytosis (Harrison et al., 2010). 
 
Thrombocytosis is often first identified as an incidental finding following a routine 
blood count.  The most common cause of a raised platelet count would be a reactive 
thrombocytosis which is typically transient in nature and resolves without causing 
clinical complications or requiring intervention (Griesshammer et al., 1999).  If 
platelet counts are assessed at only a single time point, it is impossible to determine 
whether the thrombocytosis was due to a reactive process.   
 
Primary thrombocytosis is rarer and is most frequently attributable to ET.  
Complications within this group are more prevalent, with data suggesting that 
approximately 20% of patients present have symptomatic disease, presenting with 
features such as headaches, visual disturbances or thromboembolytic events 
(Brodmann et al., 2000).   Differentiating between primary and secondary 
thrombocytosis has a significant impact on patient management.  The identification 
of underlying reactive causes should be pursued alongside the confirmation of 
persistence of thrombocytosis.  In cases where no reactive cause is identified, 
evidence of malignant causes should be sought (Harrison et al., 2010). 
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Symptomatically, ET can be difficult to diagnose.  The symptoms associated with 
ET are primarily related to vascular occlusive events, which can also occur as a 
result of many other conditions (Rumbaut and Thiagarajan, 2010).  Major thrombotic 
events affecting cerebrovascular, cardiac, pulmonary, hepatic or splenic circulation 
may be fatal (Sagripanti et al., 1996).  Vascular occlusions within the micro-vessels 
are also common, causing a wide range of symptoms including pain and 
discolouration of the fingers and toes, headaches and visual dysfunction, which 
occur as a result of the transient suspension of blood flow (Frewin and Dowson, 
2012). 
 
1.3.2 Polycythaemia Vera 
 
Polycythaemia is defined as an elevated haemoglobin (>185g/L in adult males and 
165g/L in adult females).  This may be classed as a true or apparent polycythaemia 
on the basis of whether the patient has an increased red cell mass (McMullin et al., 
2005).  Apparent polycythaemia occurs when plasma volume is decreased; this may 
be seen in individuals with increased alcohol intake (Biswas et al., 2003).  True 
polycythaemia can be further separated according to whether the cause is primary 
and secondary (see Figure 1-5).  Secondary polycythaemia occurs as a result of 
hypoxia or in some hereditary conditions (as shown in Table 1-3). 
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Congenital Acquired 
High oxygen-affinity haemoglobin 
variant 
Cardiac disease 
2,3-biphosphoglycerate mutase 
deficiency 
Chronic lung disease 
Erythropoietin receptor-mediated Carbon monoxide poisoning 
Chuvash erythrocytosis (vhl mutation) Smoker's erythrocytosis 
 End-stage renal disease 
 Hepatocellular carcinoma 
 Renal cell cancer 
Table 1-3. Example of causes of secondary polycythaemia (adapted from 
McMullin et al., 2005b). 
  
3
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Figure 1-5. Differential diagnosis of polycythaemia.  Patients presenting with increased haemoglobulin and/or haematocrit levels can be 
separated according to the presence or absence of increased red cell mass, allowing those with apparent polycythaemia to be identified.  
Where true polycythaemia is present, this can be further discriminated into primary polycythaemia (PV) and secondary polycythaemia. 
Increased 
Haemoglobin and 
Haematocrit
Increased Red Cell 
Mass
True Polycythamia
Primary
Secondary
Increased EPO
Inherited
Normal Red Cell Mass
Decreased Plasma 
Volume
Apparent 
Polycythaemia
39 
 
EPO production is stimulated by low tissue oxygen levels.  Hypoxia can arise in a 
wide range of conditions, as shown in Table 1-3, giving rise to increased levels of 
EPO and subsequently an increase in red cell mass (Lee and Percy, 2011).  
Polycythaemia may be asymptomatic, and only be identified as an incidental finding 
following a routine blood count.  However, prolonged polycythaemia is associated 
with a range of symptoms including (Koopmans et al., 2012; Radia and Geyer, 
2015);  
 
o Fatigue 
o Pruritis (Itching) 
o Erythromelalgia (burning sensation in extremities) 
o Headaches 
o Dizziness 
o Reddening of skin 
o Splenomegaly 
o Thrombosis    
 
The symptoms associated with PV are primarily related to the thickening of 
peripheral blood and occlusive events which result from hyperviscosity (Emanuel et 
al., 2012; Geyer et al., 2014; Mesa et al., 2007).   Similarly to patients with ET, 
major thrombotic events affecting cerebrovascular, cardiac, pulmonary, hepatic 
(Budd-Chiari) or splenic circulation can occur and may be fatal. (Sagripanti et al., 
1996).  Complications arising from PV are common, with data suggesting that 
approximately 30-40% of patients present with symptomatic disease and 
splenomegaly (Geyer et al., 2014).   
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1.3.3 Primary myelofibrosis 
 
The presentation of PMF is highly variable, as PMF can arise as a de novo condition, 
or as a progression/transformation of an existing PV/ET (Bose and Verstovsek, 
2016).  Additionally, de novo PMF can present in both the prefibrotic stage of 
disease as well as in its overt form (Tefferi, 2018).  As a result of these varying 
aetiologies patients may present with features ranging from hyper-cellularity  
(polycythaemia, leucocytosis, thrombocytosis) through to pancytopenia (anaemia, 
leucopoenia, and thrombocytopenia) and hepato-splenomegaly attributable to 
extramedullary haematopoiesis (Guglielmelli et al., 2017).  Overt PMF is associated 
with a more severe clinical presentation than is reported in pre-fibrotic PMF (Rumi 
et al., 2018).  The severity of symptoms may be contributed to the increasing 
hepato/splenomegaly; and can include portal hypertension, pain, and splenic 
infarction, as well as progressive bone marrow failure due to the increasing areas of 
fibrosis within the marrow (Guglielmelli et al., 2017).   
 
1.4 Laboratory diagnosis of classical MPNS 
 
Distinguishing between patients with classical MPNs and those with reactive 
conditions is essential for appropriate patient management.  A number of laboratory 
investigations can be used alongside clinical examinations to achieve this.   
 
1.4.1 Full blood count analysis 
 
Full blood count (FBC) analysis is probably the most accessible and rapid of the 
laboratory investigations employed in the diagnosis of MPNs.  Performed on a 
sample of peripheral blood, the FBC measures the major components of blood, with 
FBC reference values denoted in Table 1-4.   
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The white blood cell (leucocyte) populations (neutrophils, lymphocytes, monocytes, 
basophils and eosinophils) are quantified, along with erythrocytes (red blood cells) 
and platelets.  The amount of haemoglobin carried within the red blood cells is 
measured as both a total (haemoglobin level (Hb), and per cell (mean cellular 
haemoglobin (MCH)).  The size and shape characteristics of each cellular component 
is also measured. 
 
Adult reference ranges Male Female ET PV PMF 
Haemoglobin (g/l) 130-180 115-165 ↔ ↑ ↓ 
White cell count (x109/l) 4-11 4-11 ↑ ↑ ↑ 
Platelet count (x109/l) 150-450 150-450 ↑ ↑ ↑ 
Red cell count (x1012/l) 4.5-6.5 3.8-5.8 ↔ ↑ ↓ 
Mean cell volume (fl) 80-100 80-100 ↔ ↔ ↔ 
Haematocrit (%) 40-52 0.37-0.47 ↔ ↑ ↓ 
      
Table 1-4. Commonly measured full blood count parameters with their normal 
adult reference range alongside possible changes associated with classical 
MPNs. (↔ = within reference range, ↑ = increased, ↓ = decreased). (reference 
range from Leeds Teaching Hospitals NHS Trust, Leeds, UK). 
 
Patients presenting with classical MPNs may show abnormalities within their full 
blood count parameters (2009).  Increased haemoglobin and red cell counts are 
frequently associated with PV, and can be accompanied by an increased in both 
platelet and white cell counts (Arber et al., 2016).  In cases of PV with concurrent 
iron deficiency, haemoglobin levels may not appear raised, but evidence of iron 
deficiency (such as a low mean cell volume) may be documented (Barbui et al., 
2014a).   
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In ET, red blood cell associated parameters are typically within the expected range.  
Raised platelet counts are characteristically seen, along with increased white cell 
counts (Arber et al., 2016). The blood picture associated with PMF is more variable, 
with increased levels of platelets and white cells often present in early stages of 
disease, however, in patients with progressive disease, impaired bone marrow 
haematopoiesis can lead to reduced production of all blood cell types (pancytopenia) 
(Arber et al., 2016; Orazi et al., 2006). 
 
These changes are not restricted to the classical MPNs.  As described in 1.2, 
increased platelet counts and white cell counts commonly seen in patients with 
reactive conditions and raised haemoglobin and red cell parameters can be found in 
response to hypoxia. 
 
1.4.2 Peripheral blood morphology 
 
Morphological examination of peripheral blood and bone marrow cells can be 
valuable in the diagnosis of the classical MPNs.  The increased numbers of red blood 
cells and/or platelets associated with PV and ET are visible on examination of a 
peripheral blood smear, as shown in Figure 1-6.      
 
  
4
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Figure 1-6. Peripheral blood morphology showing typical changes associated with (A) ET (increased platelets and platelet clumping) 
and (B) PV (increased red blood cells) (images from Ash Image Bank). 
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In PMF, morphological changes to the red blood cells are visible.  The fibrous 
depositions in the bone marrow are thought to be the cause of damage to the 
membrane of red blood cells which alters their appearance (2009).  Tear-drop 
poikylocytes (also called dacrocytes) are a characteristic feature of PMF (Figure 
1-7), however, their presence is also documented in a wide range of other conditions 
including severe thalassaemia and haemolytic anaemia (Arber et al., 2016; Orazi et 
al., 2006; Zhao et al., 2009). 
 
 
Figure 1-7. Teardrop-shaped red blood cells (teardrop poikylocytes/dacrocytes) 
are a prominent feature of PMF (image from ASH image bank). 
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1.4.3 Bone marrow examination 
 
Bone marrow morphology is considered by many to be the gold standard method of 
diagnosing the classical MPNs (Schalling et al., 2017).  Characteristics features 
present in classical MPNs allow them to be distinguished from reactive conditions as 
well as discriminating between diagnoses in cases of classical MPNs with 
ambiguous features from other tests (such as ET vs Prefibrotic PMF) (Arber et al., 
2016; Orazi et al., 2006).  Figure 1-8 shows examples of bone marrow morphology 
associate with the 3 classical MPNs. 
 
1.4.4 Red cell mass 
 
Polycythaemia can be seen as a result of reduced plasma volume (hyperviscosity), 
this phenomenon is known as apparent or relative polycythaemia.  In these cases, full 
blood count analysis shows an increase in haematocrit (the proportion of the blood 
sample composed of red blood cells), however, the overall mass of red blood cells is 
not increased.  Both smoking and alcohol consumption are associated with 
hyperviscosity and therefore, can present with an apparent polycythaemia (Biswas et 
al., 2003).   
 
The measurement of red cell mass is performed using a radio-isotopic assay.  This 
requires the incubation of peripheral blood with a radio-nucleotide, such as 
chromium 51, followed by reinjection back into the patient.  Further blood samples 
are taken at 10, 20- and 40-minutes post reinjection.  The proportion of chromium 51 
labelled red cells is measured and used to determine overall red cell mass. 
Unfortunately, despite being a very useful assay in distinguishing between apparent 
and true polycythaemia, the complexity of this assay means it is not widely available 
in UK blood science or specialist pathology laboratories.   
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Figure 1-8. Typical bone marrow morphology seen in classical MPNs.  Image A shows BM from a patient with ET, the predominant 
feature of which is the increased number of large megakaryocytes, with no associated increase in erythroid activity or fibrosis present.  
Image B shows the bone marrow of a patient with PV.  The characteristic features of this bone marrow are the erythroid hyperplasia, 
accompanied by an increase in large megakaryocytes (similar to those seen in ET).  Image C is an example of the morphology associated 
with overt PMF, with deposition of reticulin fibrosis throughout the biopsy. (All images obtained from the ASH image bank).   
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1.4.5 Serum Erythropoietin 
 
The quantification of serum EPO levels is a useful tool in distinguishing between 
primary and secondary causes of polycythaemia.  As shown in Table 1-3, secondary 
polycythaemia primary occurs as a result of hypoxia associated with a range of 
medical conditions and behavioural traits (such as smoking and high altitude 
training) (Biswas et al., 2003; Haase, 2013).  Hypoxic conditions stimulate the 
secretion of EPO from the renal cortex resulting in increased serum EPO levels.  In 
true polycythaemia, there is no increase in serum EPO levels (McMullin et al., 
2007).  
 
1.4.6 Molecular screening assays 
 
As described in Error! Reference source not found., the classical MPNs are f
requently associated with mutations in the JAK2, CALR and MPL genes, amongst 
others.  The frequency of each mutation in the classical MPNs is shown in Figure 
1-2.  Screening for these mutations is an essential aspect of the diagnosis of classical 
MPNs as the majority of patients will have one of these abnormalities.  However, 
although none of the mutations are restricted to a specific classical MPN, the 
presence of a mutation in combination with the results of the other tests detailed in 
this chapter allows for accurate diagnosis of disease. 
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1.5 Diagnostic guidelines in classical MPNs 
 
1.5.1 Historical aspects 
 
The concept of MPNs was first proposed in 1951 by William Dameshek, whereby he 
referred to them as myeloproliferative disorders (Dameshek, 1951).  In this work, 
Dameshek proposed that 5 conditions (chronic granulocytic leukaemia (CGL), 
polycythaemia vera (PV), idiopathic or angiogenic myeloid metaplasia of the spleen, 
megakaryocytic leukaemia and erythroleukaemia (including diGuglielmo 
syndrome)) should be considered as an interrelated family of conditions (Dameshek, 
1951).  Prior to this publication, each of these disorders had been described 
individually, in papers published as early as 1845 (see Figure 1-9). 
 
At the time of Dameshek’s publication there were no formally recognised guidelines 
for the diagnosis of haematological malignancies.  In the years which followed, there 
began to be a recognition that variation existed in not only the clinical and laboratory 
features of haematological malignancies, but also in their responsiveness to 
treatments and movement towards formal classification schemes began.   
 
In 1967 the International Polycythaemia Study Group (PVSG) was founded with the 
aim of undertaking a prospective study to assess the long-term effects of different 
treatment regimes in PV (Wasserman, 1971).  In order to undertake this, it was 
necessary to develop diagnostic criteria for the inclusion of patients into the study.  
The group published its first recommendations for the diagnosis and management of 
PV in 1971 (Wasserman, 1971).  The main features required for a diagnosis of PV 
are shown in Table 1-5. 
 
 
  
 
 
4
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Figure 1-9. Timeline of major events in the understanding of classical Myeloproliferative Neoplasms. (Koumas et al., 2013; Nangalia et 
al., 2013; Tefferi, 2008).
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Major criteria Elevated Red Cell Mass 
Normal Arterial O2 Saturation 
Splenomegaly 
Minor criteria* 
2 minor criteria must be met in 
absence of splenomegaly 
Leucocytosis >12000 
Thrombocytosis >400,000 
Leukocyte alkaline phosphatase >100 
Serum B12 >900 or B12 binding 
capacity >2200 
Table 1-5. 1971 PVSG diagnostic criteria for PV (Wasserman, 1971). 
 
Recommendations for the diagnosis of ET followed much later with interim 
guidelines for the diagnosis of ET published by the PVSG in 1986 (Murphy et al., 
1986) followed by definitive recommendations for the diagnosis and management of 
ET  in 1997 (Murphy et al., 1997).  Concurrently, the recently formed 
Thrombocythaemia Vera Study Group (TVSG) also published a set of diagnostic 
guidelines for ET (Michiels and Juvonen, 1997).  The two sets of guidelines differed 
mainly in the increased emphasis placed upon the bone marrow histology within the 
TVSG guidelines thereby allowing a lower platelet count threshold to be used in the 
diagnosis of ET.  A summary of the two is shown in Table 1-6. 
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PVSG TVSG 
Platelet count >600x109/l Platelet count >400x109/l 
No evidence of reactive 
causes 
No evidence of fever or infection 
Normal red cell mass and 
normal mcv 
Normal ESR 
Normal BM iron stores Normal bone marrow cellularity 
with an increase in megakaryocytes 
No evidence of fibrosis or 
dysplasia 
 
No bcr/abl  
 Table 1-6. 1997 PVSG and TVSG criteria for the diagnosis of ET. 
 
The first formal guidance for the diagnosis of Myeloid Metaplasia, more commonly 
referred to as PMF was published in 1975 by one of the founding members of the 
PVSG, John Laszlo.   The main criteria for diagnosis included; fibrosis involving 
more than a third  of the section of bone marrow examined, splenomegaly, 
leucoerythroblastic features on morphological assessment, no evidence of increased 
red cell mass and the absence of the Philadelphia chromosome (Laszlo, 1975). 
 
1.5.2 Current classification schemes 
 
Current classification of the classical MPNs has evolved from these original 
guidelines.  As our understanding of the underlying biology of these diseases has 
advanced, the guidelines have been adapted to accommodate this knowledge in order 
to refine and improve diagnostic processes.   
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There are two main publications currently in use for the diagnosis of MPNs in the 
UK.  The diagnostic criteria as defined within the World Health Organisation 
(WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues, most 
recently the revised 2016 classification (Arber et al., 2016) and the recommendations 
published by the British Committee for Standards in Haematology (BCSH) 
(Harrison et al., 2010; Harrison et al., 2014; McMullin et al., 2005; McMullin et al., 
2007; Reilly et al., 2012a; Reilly et al., 2014; Reilly et al., 2012b).   
 
The WHO classification scheme is intended to provide a detailed description of the 
features of disease and define criteria for their identification.  They are developed by 
leading experts within each clinical field and based upon both previous guidelines 
and published clinical and scientific evidence (Swerdlow et al., 2008).  However, the 
criteria for classification do not cover best practice approaches for the 
implementation of the diagnostic and clinical processes, nor do they necessarily 
reflect the practical challenges faced by different geographic regions in terms of 
clinical and laboratory resources.   
 
The BCSH publish guidelines which set the benchmark for the diagnosis and 
management of patients with Haematological Conditions in the UK and include, but 
are not restricted to, malignancy (BCSH, 2016; GRADE, 2016).  Each set of BCSH 
guidelines is developed by a panel of clinical and scientific professionals with expert 
knowledge of the disorder.  The panel use the recommendations of the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) working 
group for the assessment of quality of published evidence to inform the guidelines 
(GRADE, 2016).   
 
There are subtle differences within the guidelines between the two groups which 
reflect the different evidence and opinion of the panel of experts authoring the 
guidelines as well as the difficulties in diagnosing these conditions from reactive 
processes and from each another. 
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1.5.2.1 WHO recommendations 
 
The current 2016 WHO classification scheme for MPNs is an update of the 
previously published 2008 WHO classification of myeloid neoplasms (Vardiman et 
al., 2009a) which, in turn, are based upon the original PVSG/TVSG 
recommendations in conjunction with more recent scientific and clinical findings.  
The Myeloproliferative Neoplasms category, within the WHO classification scheme, 
contains 9 different diagnostic entities, as shown in Table 1-7.  Similarly to 
Dameshek’s original proposal for the myeloproliferative disorders, the WHO 
grouping of these entities is based upon the shared feature of the increased 
proliferation of morphologically normal mature cells of myeloid lineage. 
 
The main revisions from the 2008 version of these guidelines are the inclusion of 
additional molecular markers and introduction of a new, lower, threshold for 
haemoglobin introduced (reduced from 185g/L to 165g/L in males and from 165g/L 
to 160g/L in females) (Barbui et al., 2015).  These reduced thresholds have been 
selected to minimise the risk of missing cases of PV with mildly elevated 
haemoglobin levels and to avoid confusing these cases with ET (Barbui et al., 2014a; 
Barbui et al., 2014b). 
 
These guidelines also see the separation of PMF into two distinct forms.  The first of 
these is Pre-fibrotic Myelofibrosis (PrePMF), in which the fibrotic changes 
associated with PMF have not yet occurred and which previously would have been 
classified as ET on the basis of their lack of fibrosis.  The inclusion of this 
subclassification is based on several studies by a group in Cologne, which have 
demonstrated that subtle changes are present and that patients displaying these Pre-
fibrotic characteristics have an inferior outcome to those without pre-fibrotic 
characteristics (true ET) (Barbui et al., 2011a; Barbui et al., 2015; Gisslinger et al., 
2016; Thiele et al., 2011).  The second class of PMF is named “overt PMF” and 
represents those cases which would have met the criteria for PMF in earlier iterations 
of the guidelines.  A summary of the WHO diagnostic criteria for each of the 
classical MPNs can be seen in Tables 1-8.   
54 
 
 
 
Myeloproliferative Neoplasms 
Chronic Myeloid Leukaemia (CML) BCR-ABL+ 
Chronic Neutrophilic Leukaemia (CNL) 
Polycythaemia Vera (PV) 
Primary Myelofibrosis (PMF) 
     PMF, prefibrotic/early stage 
     PMF, Overt fibrotic stage 
Essential Thrombocythemia (ET) 
Chronic Eosinophilic Leukaemia not otherwise specified 
(NOS) 
MPN, unclassifiable 
Table 1-7. 2016 WHO classification of MPNs with the classical MPNs shown in 
bold (Arber et al., 2016). 
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PV ET PrePMF Overt PMF 
Major 
criteria 
Haemoglobin >165g/dL (M), >160g/dL (F)                                  
or Haematocrit >49% (M), >48% (F)                                  
or Increase red cell mass (RCM) 
1. Platelet count ≥450 × 109/L 
1. Megakaryocytic proliferation and 
atypia, without reticulin fibrosis 
>grade 1, accompanied by increased 
age-adjusted BM cellularity, 
granulocytic proliferation, and often 
decreased erythropoiesis 
 1. Presence of megakaryocytic 
proliferation and atypia, 
accompanied by either reticulin 
and/or collagen fibrosis grades 2 
or 3 
2. BM biopsy showing hypercellularity for 
age with trilineage growth (panmyelosis) 
including prominent erythroid, 
granulocytic, and megakaryocytic 
proliferation with pleomorphic, mature 
megakaryocytes (differences in size) 
2. BM biopsy showing 
proliferation mainly of the 
megakaryocyte lineage with 
increased numbers of enlarged, 
mature megakaryocytes with 
hyperlobulated nuclei. No 
significant increase or left shift in 
neutrophil granulopoiesis or 
erythropoiesis and very rarely 
minor (grade 1) increase in 
reticulin fibers 
2. Not meeting the WHO criteria for BCR-ABL1+ CML, PV, ET, 
myelodysplastic syndromes, or other myeloid neoplasms 
3. Presence of JAK2V617F or JAK2 exon 
12 mutation 
 3. Not meeting WHO criteria 
for BCR-ABL1+ CML, PV, PMF, 
myelodysplastic syndromes, or 
other myeloid neoplasms 
 3. Presence of JAK2, CALR, or 
MPL mutation or in the absence of 
these mutations, presence of another 
clonal marker, or absence of minor 
reactive BM reticulin fibrosis 
 3. Presence of JAK2, CALR, or 
MPL mutation or in the absence of 
these mutations, presence of 
another clonal marker, or absence 
of reactive myelofibrosis 
  4. Presence of JAK2, CALR, or 
MPL mutation 
  
Minor 
criterion 
Subnormal serum erythropoietin level 
Presence of a clonal marker or 
absence of evidence for reactive 
thrombocytosis 
a. Anaemia not attributed to a comorbid condition                                         
b. Leucocytosis ≥11 × 109/L                                                                      
c. Palpable splenomegaly                                                                              
d. LDH increased to above upper normal limit of institutional reference 
range 
Table 1-8. Summary of the WHO classification criteria for the classical MPNs (Arber et al., 2016).
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1.5.2.2 BCSH recommendations 
 
The BCSH do not published a single document which encompasses all MPN’s.  
Separate guidelines are produced for PV, ET and PMF and include best practice 
recommendations for investigation and clinical management.  The guidelines for the 
investigation and management of PV were published in 2005 (McMullin et al., 2005) 
and updated in 2007 (McMullin et al., 2007) following the identification of a 
recurrent mutations with in the JAK2 gene (Baxter et al., 2005; James et al., 2005; 
Kralovics et al., 2005; Levine et al., 2005; Scott et al., 2007).  Diagnostic 
recommendations were amended to include molecular screening for these defects. 
 
Guidance for the investigation and management of ET were originally published in 
2010 (Harrison et al., 2010) and further modified in 2014 (Harrison et al., 2014) to 
include recommendations for additional mutational screening following the 
identification of mutations with the CALR gene (Klampfl et al., 2013a; Nangalia et 
al., 2013; Rotunno et al., 2013a). 
 
Recommendations for the investigation and management of PMF were published in 
2012 (Reilly et al., 2012b), with an amended version released in 2014 (Reilly et al., 
2014).  As in the case of ET, the updated recommendations include screening for 
CALR gene mutations alongside updated clinical recommendations.  A summary of 
the BCSH diagnostic guidelines for each of these disorders are shown in Table 1-9 to 
1-11.  
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JAK2-positive Polycythaemia Vera 
A1 High haematocrit (52 in men, 48 in women) or raised red cell mass 
(>25% above predicted) * 
A2 Mutation in JAK2 
*DIAGNOSIS REQUIRES BOTH CRITERIA TO BE PRESENT 
 
JAK2-negative Polycythaemia Vera 
A1 Raised red cell mass (>25% above 
predicted) or haematocrit >60 in 
men, >56 in women. 
A2 Absence of mutation in JAK2 
A3 No cause of secondary erythrocytosis 
A4 Palpable splenomegaly 
A5 Presence of an acquired genetic 
abnormality (excluding bcr-abl) in the 
haematopoietic cells 
B1 Thrombocytosis (platelet count 
>450 × 109/l) 
B2 Neutrophil leucocytosis (neutrophil 
count > 10 × 109/l in non-smokers; 
>12.5 × 109/l in smokers) 
B3 Radiological evidence of splenomegaly 
B4 Endogenous erythroid colonies or low 
serum erythropoietin 
*DIAGNOSIS REQUIRES A1 + A2 + A3 + EITHER ANOTHER A OR 
TWO B CRITERIA 
Table 1-9. BCSH diagnostic criteria for PV (McMullin et al., 2005). 
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A1 Sustained platelet count >450 × 109/l 
A2 Presence of an acquired pathogenetic mutation (e.g. in the JAK2, CALR 
or MPL genes) 
 
A3 
No other myeloid malignancy, especially PV, PMF, CML or MDS 
A4 No reactive cause for thrombocytosis and normal iron stores 
A5 Bone marrow aspirate and trephine biopsy showing increased 
megakaryocyte numbers displaying a spectrum of morphology with 
predominant large megakaryocytes with hyperlobated nuclei and 
abundant cytoplasm. Reticulin is generally not increased (grades 0–2/4 
or grade 0/3) 
*DIAGNOSIS REQUIRES A1–A3 OR A1 + A3–A5 
Table 1-10. BCSH diagnostic criteria for ET(Harrison et al., 2014). 
 
A1 Bone marrow fibrosis ≥3 (on 0–4 scale) 
A2 Pathogenetic mutation (e.g. in JAK2, CALR or MPL), or absence of 
both BCR-ABL1 and reactive causes of bone marrow fibrosis  
B1 Palpable splenomegaly 
B2 Unexplained anaemia 
B3 Leuco-erythroblastosis 
B4 Tear-drop red cells 
B5 Constitutional symptoms (drenching night sweats, weight loss >10% 
over 6 months, unexplained fever (>37·5°c) or diffuse bone pains). 
B6 Histological evidence of extramedullary haematopoiesis 
*DIAGNOSIS REQUIRES A1 + A2 AND ANY TWO B CRITERIA 
Table 1-11. BCSH diagnostic criteria for PMF (Reilly et al., 2014). 
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1.5.3 Differences between classification systems 
 
The most significant difference between the two groups is the emphasis placed upon 
bone marrow histology in the WHO classification (Arber et al., 2016).  The 
assessment of morphological features in the bone marrow is a major criterion in each 
of the classifications shown.  Within the BCSH guidelines, bone marrow histology is 
a major criterion in the diagnosis of PMF, however, in the diagnosis of PV and ET, it 
may not be clinically indicated (Harrison et al., 2014; McMullin et al., 2007; Reilly 
et al., 2012a). 
   
This difference, particularly in relation to the diagnosis of ET, has caused some 
controversy, as it does not allow for the diagnosis of so-called Pre-PMF, where all 
other features would mimic those seen in ET (Gisslinger et al., 2016).   A large 
independent cohort study had been able to identify morphological subgroup with the 
histological features said to indicate Pre-PMF, although longitudinal analysis did not 
show any evidence of increased fibrotic transformation within those patients and  the 
adverse clinical impact of the original finding could not be confirmed (Wilkins et al., 
2008).   
 
There are small differences in the full blood count thresholds set out by each group.  
Within the criteria for the diagnosis of PV, the WHO includes a raised haemoglobin, 
whereas it is not included in the BCSH guidelines (Arber et al., 2016; McMullin et 
al., 2007).  Differences are also present in the threshold level of haematocrit in the 
two sets of guidelines (Arber et al., 2016; McMullin et al., 2007).  Numerical 
thresholds are used within all of these guidelines; however, it should be noted that 
there is no reference within the guidelines as to the underlying statistical basis of 
these values. 
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1.5.4 The use of thresholds in diagnostic guidelines 
 
The use of thresholds is commonplace within diagnostic criteria and disease scoring 
schemes.  Within the wider diagnosis of myeloid malignancy, the use of arbitrary 
thresholds applied to parameters such as blast percentage can make the difference 
between a diagnosis of myelodysplastic syndrome (MDS) and acute myeloid 
leukaemia (AML), albeit, a demonstrable clinical and outcome differences between a 
patient presenting with 19% blasts (MDS with excess blasts) versus 21% blasts 
(AML) has not been established (Lichtman, 2013). 
 
Within the diagnosis of MPNs thresholds applied to laboratory parameters are 
equally vague.  For example, the use of a platelet count threshold of 450 x 109/L 
reflects the upper limit of the recognised reference range.  However, by definition, a 
reference range only encompasses 95% of the population and as such 2.5% of 
individuals will have a platelet count exceeding the upper value under normal 
circumstances.  To date there are no published studies within the field of MPNs 
which systematically assess the probability of diagnosing an MPN with increasing 
laboratory and clinical parameters to establish the most appropriate threshold to use 
in diagnostic guidelines. 
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1.6 Clinical outcomes in classical MPN 
 
Prognostic outcomes differ between the diseases, as well as showing variability 
within the disease itself.  To enable clinicians to give patient’s appropriate 
information about their prognosis, and make plans for their management, an accurate 
diagnosis is critical. 
 
1.6.1 Prognosis according to disease type 
 
The prognosis of patients diagnosed with PMF is significantly worse than in both ET 
and PV.  Data published by Price et al from a series of 3364 MPN patients diagnosed 
in the USA shows inferior overall survival in all three classical MPNs compared to a 
control population (Figure 1-10) (Price et al., 2014).  The most significant of which 
was associated with PMF, where median survival was 24 months (vs 106 months in 
the control group) (Price et al., 2014).    
 
Figure 1-10. Kaplan-Meier survival estimates by MPN subtype compared to a 
control population.  Figures reproduced from (Price et al., 2014). 
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1.6.2 Prognostic significance of genetic mutations 
 
The prognosis for patients with ET and PMF also varies according to the underlying 
genetic lesion.  As shown in Figure 1-11, ET patients with JAK2 V617F mutations 
have an inferior prognosis to those with CALR and MPL mutations (Price et al., 
2014).  Patients with ET, who do not have a detectable mutation in any of these three 
genes, are referred to as triple negative or wild type (WT), and are shown to have 
superior outcomes (Rotunno et al., 2013a; Tefferi et al., 2014c)  compared to those 
with a JAK2 V617F, CALR or MPL.   
 
Conversely, patients with triple negative PMF are shown to have a poorer prognosis 
than those with a mutation in either JAK2, MPL or CALR, with a median overall 
survival (OS) of 2.5 years (Tefferi et al., 2014b).  In contrast, in those patients with 
PMF, CALR mutations are associated with the longest OS (median 8.2 years), 
followed by JAK2 and MPL which have similar survivals (median OS 4.3 and 4.1 
years respectively) (Tefferi et al., 2014b).  
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Figure 1-11. Kaplan-Meier survival estimates in (A) ET and (B) PMF according 
to molecular subtype (Tefferi et al., 2014b; Tefferi et al., 2014c) 
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1.6.3    Importance of distinguishing between ET and Prefibrotic 
PMF 
    
As described in 1.5.2.1, the most recent revisions to the WHO classification of 
MPNs has separated PMF into two distinct entities – overt PMF and Prefibrotic PMF 
(Arber et al., 2016).  Historically, many cases of prefibrotic PMF would have been 
classified as ET due to their similar morphological appearances and failure to meet 
the previous criteria for diagnosis of PMF (Barbui et al., 2018; Gisslinger et al., 
2016; Thiele et al., 2011).  Studies of patient with pre-fibrotic PMF have 
reproducibly shown an inferior prognosis in this group (Figure 1-12) (Giovanni 
Barosi 2012; Guglielmelli et al., 2017). 
 
 
Figure 1-12. Overall (A) and leukaemia free (B) survival in ET vs Pre- and 
Overt-PMF (figure reproduced from (Guglielmelli et al., 2017).  This data 
shows superior outcomes for individuals with ET compared to those with pre- 
and overt-PMF. 
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1.7 The diagnostic challenge 
 
1.7.1 Understanding the practical limitations of investigating 
suspected classical MPNs 
 
The data presented in the previous section highlights the importance of making an 
accurate diagnosis.  This is particularly so in the case of those patients presenting 
with peripheral blood features consistent with ET where a mutation within 
JAK2/CALR or MPL is not detected.  This is made difficult due to the 
aforementioned significant overlap between the presentation features of classical 
MPNs with those of reactive conditions.  Whilst the presence of a raised platelet 
count could indicate that a patient has ET or Prefibrotic PMF, it is more likely to be 
the result of an underlying reactive process.  In these instances, the absence of a 
mutation in JAK2, CALR or MPL would not exclude a diagnosis of ET or Prefibrotic 
PMF.  In order to confirm or exclude these diagnostic entities, the patient would 
have to undergo a bone marrow biopsy for morphological assessment.  If this 
approach was taken in all cases of thrombocytosis, it would not only be costly, but 
would also result in a large number of non-diagnostic, invasive bone marrow aspirate 
procedures.  Which, whilst considered a relatively safe procedure is a cause of 
significant discomfort and distress to the patients undergoing investigation  
 
1.7.2 Managing patient expectations without giving false 
reassurance 
 
It is important to balance the practical implications of testing patients in whom 
clinical suspicion is low with the expectations of the patients and the reassurance that 
performing blood tests can offer.  It is widely perceived that patients expect blood 
tests to be performed during clinical investigations and consider active testing 
approaches to be an indicator of quality of care (Hartley et al., 1987; Prochazka et 
al., 2005; van Bokhoven et al., 2006).  However, there is also a perception that the 
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results of blood tests will be conclusive in the diagnosis or exclusion of disease (van 
der Weijden et al., 2002).  In the case of suspected MPNs, this would be an 
unrealistic expectation.  Clinicians may experience difficulties in conveying the 
limitations of performing JAK2 V617F and CALR mutational screening to patients 
who are anxious, and who may have a limited understanding of biology.  
Furthermore, there is also evidence that when a patient is given the ‘all clear’ 
following cancer-related investigations, they can become dismissive of new or 
worsening symptoms prolonging the time taken to seek medical advice  (Renzi et al., 
2015; Renzi et al., 2016).  This may occur in the investigation of suspected classical 
MPNs as peripheral blood screening alone is not capable of fully excluding the 
presence of disease.  If a JAK2 V617F wild-type/CALR wild-type result is conveyed 
as being an ‘all clear’ result, and no further investigations are performed, a patient 
who may have an MPN associated with another mutational profile (such as a 
mutation in the MPL gene or triple negative disease) may be falsely reassured and 
dismissive of symptoms which may indicate progressive disease.   
 
One possible solution would be to better identify those individuals within the 
population who should be investigated for a possible MPN.  Additionally, a tool 
capable of identifying those patients who would benefit from further testing when a 
definitive diagnosis cannot be made from peripheral blood screening would be 
valuable in addressing the challenges faced by clinicians. 
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2. Aims and objectives 
Although clinical guidelines exist for the referral of patients with a suspected 
classical MPN, the actual referral pathways are not prescriptive, and it is unclear 
how efficient these guidelines are in identifying classical MPN patients in a real-
world setting.  It is hypothesised that the referral of patients with suspected classical 
MPN represents an increasing proportion of the haematopathology laboratory 
workload without a concomitant increased proportion or absolute number of 
confirmed classical MPN diagnoses.  As any increase in samples referred for 
laboratory-based investigatory testing places a significant burden on laboratory and 
clinical resources, the overall aim of the study is to better develop methods to target 
patients with suspected MPNs for further investigation. 
 
To achieve this aim, this study will: 
• Develop, implement, and validate an assay for the detection of CALR 
mutations in patients referred for the investigation of a suspected MPN. 
• This assay will then be applied in conjunction with JAK2 V617F mutation 
screening to create an assay which is applicable in a routine, clinical laboratory-
based setting. 
•  Evaluate both the numbers of referred cases, and the existing clinical referral 
pathway, to examine the potential to offer better value and increase efficiency in 
testing. 
• Quantify the performance of current clinical guidelines and the extent to 
which they are followed in a real-world setting. 
• Develop, test and validate predictive statistical models to ascertain whether 
such an approach would offer a benefit over existing referral strategies. 
• Assess the potential impact a change in referral practise would have on an 
independent, real world cohort.  
• Develop an interactive user interface to enable the proposed predictive model 
to be accessed prospectively by the diagnostic community at large. 
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3. Materials and methods 
 
3.1 Rationale and introduction 
 
This chapter describes the setting in which this research has taken place along with 
the relationship between the populations included in the analyses.  The study 
population and methods of selection are discussed, along with the rationale for 
inclusion/exclusion criteria.  In depth protocols are provided for each of the 
laboratory methodologies used in this thesis, with details of their interpretation.  
Details of the study designs chosen, and statistical methods employed, along with 
their interpretation and levels of significance are also included. 
 
3.2 Setting 
 
The work described in this thesis was performed at the Haematological Malignancy 
Diagnostic Service (HMDS) laboratory based within St James’s Institute of 
Oncology; a part of Leeds Teaching Hospitals NHS Trust in the UK.  Established in 
1992, the department specialises in the diagnosis of haematological malignancies, 
including MPNs.  Today, HMDS provides a comprehensive, diagnostic service to a 
population of over 6 million people (Figure 3-1) and receives approximately 35,000 
patient referrals per annum, making it the largest department of its kind in the UK.   
 
The department brings together all the laboratory techniques required to diagnose 
haematological malignancies in a single, multidisciplinary centre and all the data 
generated by the HMDS laboratory is stored centrally in a purpose-designed 
laboratory database, HMDS Integrated Laboratory Information System, ‘HILIS’. 
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Figure 3-1. Map indicating the geographical regions containing hospitals which 
are served by HMDS, including those with the HMRN region. 
 
The UK 2007 Cancer Reform Strategy recognised that integrating these technologies 
into a single diagnostic service was the best way to ensure diagnostic accuracy and 
optimal treatment for patients with haematological malignancies (DOH, 2007)   
Since its inception this approach has been strengthened by the rapid development of 
diagnostic technology and is now regarded as the national standard of care by the 
National Institute for Health and Care Excellence (NICE, 2015).  
 
In 2004 The Haematological Malignancy Research Network (HMRN) was 
established, a collaboration between HMDS, a unified clinical network of 14 
hospitals (comprising the Yorkshire & Humber and Yorkshire Coast Cancer 
Networks) and the Epidemiology and Cancer Statistics Group (ECSG) at the 
University of York (Figure 3-2) (Smith et al., 2010).   
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Figure 3-2. The geographical area and 14 hospitals served by both HMDS and 
HMRN. 
 
The HMRN region covers a population of approximately 3.8 million people.  
Measures of the socio-demographic profile of individuals within the catchment 
region, as well as age and sex distribution are comparable to data collected from 
across the UK (Figure 3-3).  This enables researchers to extrapolate data findings 
from the HMRN region to the national population (Smith et al., 2010).   
 
 
 
Figure 3-3. The Age and Sex distribution of HMRN population vs UK average 
(Smith et al., 2018). 
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Specimens from any patient with a suspected haematological malignancy visiting a 
hospital within the HMRN are referred to HMDS for diagnostic investigations.  
HMRN then tracks all patients diagnosed with a haematological malignancy within 
this region; obtaining information from clinical and laboratory records and linking to 
nationally compiled administrative records (mortality, cancer registration and 
hospital episode statistics), as well as collecting self-reported information from 
patients (Smith et al., 2018). 
 
3.3 Clinical pathway for patients with suspected classical 
MPNs 
 
HMDS receives specimens from hospitals both within and outside of the 
geographical region forming HMRN, the majority of these are sent by 
haematologists working within haematology outpatient clinics.  An overview of the 
pathway a patient with a suspected MPN follows in Leeds Teaching Hospitals is 
shown below (Figure 3-4) with approximate timescales shown alongside each step.  
Discussion with clinical colleagues indicated that the same, or similar, approach was 
used throughout the HMRN region and beyond. 
 
The patient is initially referred to the haematology clinic by a health care 
professional, generally a general practitioner.  The first clinic appointment usually 
takes place within 14 days of this referral, at this visit, the patient is seen by a 
haematologist who takes a detailed medical history and performs a physical 
examination.  The clinician also reviews the most recent peripheral blood counts 
available on the hospital result service.  Following this consultation, the clinician 
requests the appropriate investigations to be undertaken and the patient is sent to the 
phlebotomist for venepuncture.  It is at this point that a JAK2/CALR mutation screen 
would be requested, along with any other blood tests indicated (full blood count, 
biochemical markers). 
72 
 
 
 
 
 
 
Figure 3-4. Clinical investigatory pathway followed by suspected MPN patients 
at Leeds Teaching Hospitals NHS Trust. 
 
The patient returns for a follow-up appointment around 2-4 weeks later where the 
results of these investigations are reviewed.  On the basis of these results, further 
tests may be arranged (such as bone marrow aspirates) and treatment may be 
initiated (if appropriate).  Patients are then seen at intervals depending their clinical 
need. 
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3.4 Laboratory processes in HMDS 
 
Upon their arrival at HMDS, specimens are prepared for morphological examination.  
A small volume of blood or bone marrow is spread onto a glass microscope slide and 
stained with cellular dyes (May-Grünwald Geimsa) before being viewed by light 
microscopy.  Further laboratory tests are requested based on clinical information 
provided alongside morphological features and peripheral blood count data (where 
available).  Details of each request are registered into HILIS and include the patients 
name, date of birth and NHS number as well as the referring hospital/clinician.  A 
record is made of any laboratory tests requested and performed, the results of which 
are added to HILIS as they become available.  If the patient has been investigated 
previously by HMDS, the computer records are linked to allow chronological 
monitoring. 
 
The department is arranged in sections according to laboratory techniques employed 
– flow cytometry/immunophenotyping, histopathology/immunohistochemistry, 
molecular diagnostics (including Fluorescent in situ hybridisation, PCR based 
assays, gene sequencing and SNP analysis).  Each section of the laboratory reports 
the results of its own tests and when every section has completed their tests, a single 
unified report is collated by specialist haematopathologists. 
 
3.4.1 Diagnostic workflow for suspected classical MPNs 
 
In HMDS, the diagnosis of a classical MPN is a multistep process, which may 
require the analysis of a second specimen in some patients.  The workflow process 
followed by the HMDS laboratory is shown in Figure 3-5, briefly, where a blood 
sample is received with a suspected diagnosis of a classical MPN, JAK2 V617F and 
CALR mutational screening is performed.  If a mutation is identified, a diagnosis of a 
classical MPN can be made, if clinical features support this.  If no mutations are 
detected, it is not possible to diagnose or exclude a classical MPN and a further 
sample (bone marrow) is requested for analysis.  If a bone marrow is received by 
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HMDS from such a patient, it is tested for the presence of rarer mutations (MPL 
and/or JAK2 Exon 12) and the bone marrow is morphologically assessed for features 
consistent with a classical MPN. 
 
HMDS introduced JAK2 V617F mutational screening in October 2005, and CALR 
mutational screening in February 2014.  The department currently receives 
approximately 2500 referrals per annum for the investigation of suspected MPNs.  
The laboratory data stored by HMDS offers an unparalleled resource for the analysis 
of data related to the investigation of suspected classical MPNs and provides an 
excellent framework for this research. 
 
  
Figure 3-5. HMDS laboratory workflow process for the investigation of a 
suspected classical MPN. 
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3.5 Sample groups 
 
Several groups of patient specimens have been analysed in this work.  These have 
been divided into “Experimental” specimens, that is those which underwent 
additional laboratory analysis in order to generate data presented in this work, and 
“Statistical” specimens, that is those where only stored data has been used to perform 
the statistical analyses presented in this work. 
 
3.5.1 Experimental specimens (Sample group 1)  
 
 
Figure 3-6. Summary of specimens used to develop CALR mutational screening 
assay. 
 
The identification of CALR mutations in JAK2 V617F wild type classical MPNs 
necessitated the development of a diagnostic assay capable of detecting these 
mutations for routine use in HMDS.  HMDS records were searched for bone marrow 
specimens with a diagnosis of ET (n=875).  Any specimen in which a JAK2 or MPL 
mutation had been detected was excluded from further analysis (n=507).  For 
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convenience and accessibility of stored DNA, specimens referred prior to 2012 were 
excluded (n=233).  The remaining referrals (n=135) were reviewed and excluded if a 
peripheral blood sample was not received at the same timepoint (n=39) or DNA was 
not stored (n=11) (Figure 3-6).    Paired PB and BM specimens from the remaining 
48 patients were used to validate the PCR assay.   
 
To comply with UKAS Medical Laboratory Accreditation (ISO 15189) standards, 
further external validation of the assay was performed through a mutual specimen 
exchange with Nottingham City Hospital’s molecular diagnostic laboratory.  
Following analysis in HMDS, 20 of the specimens which had been tested were sent 
to Nottingham and a further 20 samples were received by HMDS in exchange.  
Following testing by each respective laboratory, the samples were returned, and the 
test results compared.   
 
In addition to this reciprocal sample exchange, 30/48 of the HMDS patients included 
in this group had been analysed by the Wessex Regional Genetics Service as part of 
their Genome Wide Association Studies (GWAS) which led to the identification of 
CALR mutations.  The results of the CALR analysis performed on these samples 
were made available to us for comparison.    
 
3.5.2 Statistical Specimens (sample groups 2-6) 
 
3.5.2.1 Sample group 2: All suspected MPNs (2005-2014) 
 
Specimens received by HMDS for the investigation of a suspected MPN were 
identified from HILIS using structured query language searches.  All records 
received between the beginning 2005 and the end of 2014 (when the search was 
performed) were included.  The data collected included age, gender, molecular 
screening results and full blood count parameters (where available) as well as a 
unique patient identifier (NHS number) which was used to remove duplicate requests 
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on the same individual and to positively identify those patients who had a subsequent 
bone marrow examination to confirm or exclude a diagnosis of an MPN.  Where the 
final diagnosis was not given a specific MPN subtype, data was reviewed with a 
clinician (Dr C Cargo or Dr R Kelly) to determine the most appropriate diagnosis.  
These specimens (see Figure 3-7) form a core sample group from which two further 
subgroups of specimens have been generated (Sample groups 3 and 4). 
 
 
Figure 3-7. Summary of sample groups used in statistical analyses. 
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3.5.2.2 Sample group 3: Comparison of JAK2 and CALR mutated ET 
 
To compare the demographic and laboratory features associated with CALR mutation 
against those seen in JAK2 V6147F mutated counterparts, diagnoses of ET with a 
CALR mutation identified between January and December 2014 (n=88) was 
compared to the JAK2 V617F mutated ET diagnoses made during the same period 
(n=311).    
 
3.5.2.3 Sample group 4: Predictive model development 
 
This work aimed to develop a statistical model which could be used to aid in the 
investigation of suspected MPNs received by HMDS.  Statistical models were 
developed using data collected from all suspected MPN referrals which had 
undergone both JAK2 V617F and CALR mutational screening in HMDS with full 
blood count data available at the time of referral (n=2970). 
 
3.5.2.4 Sample group 5: Model validation 
 
Each of the statistical models developed using sample group 4, was then validated on 
a further dataset using samples received between January and March of 2015 
(n=515) (see Figure 3-8). 
 
3.5.2.5 Sample group 6: model assessment 
 
Finally, the best performing model, was then applied to a third dataset, containing all 
suspected MPN requests received between January and December 2016 (n=2174) 
(see Figure 3-8).   
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Figure 3-8. Overview of samples used in the validation and assessment of 
predictive modelling in the investigation of suspected MPNs. 
 
3.6 Laboratory investigations 
 
The laboratory methods described in this thesis were undertaken in the HMDS 
laboratory, Leeds, United Kingdom.  Development of the fluorescent PCR and 
fragment analysis assay used in the determination of JAK2 V617F and CALR 
mutations was undertaken by the author.  Following development, the assay has been 
incorporated in routine laboratory practice and the data used in this thesis has been 
collected by all members of the HMDS Molecular Diagnostics team, including the 
author.  Full details of reagents and protocols are available in the appendix. 
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3.6.1 Isolation of leucocytes 
 
Leucocytes were isolated by selectively removing erythrocytes by differential lysis 
with 0.86% ammonium chloride solution (NH4CL).  A 1mL aliquot of 
Ethylenediaminetetraacetic acid (EDTA) anticoagulated peripheral blood or bone 
marrow was incubated with 9mL of ammonium chloride solution in a 13mL Röhren 
tube, which was then incubated for 10 minutes at room temperature.  The suspension 
was then centrifuged for 4 minutes at a relative centrifugal force (RCF) of 470 and 
the supernatant discarded.  The resulting cell pellet was washed twice with 10mL 
volumes of FACSFlow containing 0.3% Bovine Serum Albumin (BSA), centrifuging 
at 470 RCF for 4 minutes and discarding supernatant between washes.  The washed 
cells were then re-suspended in 200µL of FACSFlow prior to genomic 
Deoxyribonucleic acid (DNA) extraction. 
 
3.6.2 Genomic DNA extraction 
 
Genomic DNA was extracted from the 200µL aliquot of leucocytes using the 
QIAamp DNA Mini Kit (QIAGEN Ltd, U.K.) according to the manufacturer’s 
instructions.  In this method, the aliquot of cells was added to a 1.5mL Eppendorf 
tube.  Twenty microlitres of proteinase K (activity of 600U/mg protein) and 200µl of 
lysis buffer (buffer AL) were added together and the mixture was then incubated in a 
water bath at 56°C for 10 minutes. Following incubation, the samples were briefly 
centrifuged to remove droplets from the inside of the lid and 200µL of ethanol (96-
100% concentration) was added and the sample mixed by pulse-vortex. The mixture 
was then applied to a QIAamp Spin Column and centrifuged for 1 minute at 6000 
RCF to bind the DNA to the silica-gel column membrane.  The supernatant was 
decanted and 500µL of wash buffer (AW1) applied to the column.  The column was 
then centrifuged for 1 minute at 6000 RCF and the effluent discarded.  A further 
500µL of wash buffer (AW2) was added to the column, which was then centrifuged 
for 3 minutes at 18,400 RCF. The QIAamp Spin Column was then transferred into a 
fresh collection tube and 200µL of elution buffer (buffer AE) added. The column 
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was left to stand for 2 minutes, prior to centrifugation for 1 minute at 6000 RCF to 
elute the extracted genomic DNA into the filtrate.  DNA was stored at room 
temperature prior to amplification.  
 
3.6.3 CALR / JAK2 V617F mutation screening 
 
For CALR mutational screening, amplification of exon 9 is performed using a 
fluorescently labelled forward primer and unlabelled reverse primer.  An allele 
specific oligonucleotide (ASO) polymerase chain reaction (PCR) assay is 
traditionally used for the detection of the JAK2 V617F mutation, in combination 
with agarose gel electrophoresis.  In this work, the ASO strategy has been modified 
by the author, to incorporate a fluorescent dye into the reverse primer.  The exon 14 
region of the gene was amplified using the fluorescently labelled reverse primer in 
combination with an unlabelled mutant specific forward primer and a consensus 
JAK2 wild type forward primer.  Full primer sequences and reagent mixes are shown 
in the appendix (Table 10-3Table 10-4).   This allows the simultaneous visualisation 
of the PCR products from both the CALR and JAK2 V617F assays using fragment 
analysis software.  Amplifications were performed in separate PCR reactions and the 
resulting products were combined in equal volumes for analysis. 
 
3.6.3.1 Thermal cycling conditions 
 
Both PCR reactions were performed simultaneously using a unified programme.  
Cycling Conditions for JAK2 V617F / CALR exon 9 PCR amplification are included 
in the appendix (Table 10-5). 
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3.6.4 Fluorescent fragment analysis 
 
A 1µL aliquot of each of the paired PCR products was added to a 96 well microtitre 
plate along with 10µL of Hi-Di formamide solution (Applied Biosystems) and 1µL 
of Rox-500 size standard (Life Technologies).  The microtitre plate was centrifuged 
briefly to ensure that samples were in the bottom of the well and then loaded onto the 
ABI PRISM 3130 Avant Genetic Analyser.  Results were analysed using the generic 
microsatellite analysis protocol (ABI, Warrington, U.K.).   
 
3.6.5 Expected results and interpretation 
 
Data was interpreted using Genemapper Analysis Software (v3.1) (Applied 
Biosystems).  Product peaks were measured in relation to the ROX-500 size 
standards to identify wild type and mutated PCR products.  The expected size of 
both wild type and mutated PCR products are shown in Table 3-1. 
 
Product Fragment size 
JAK2 wild type 362bp 
JAK2 V617F mutated 202bp 
CALR wild type  292bp 
CALR mutated  Various - most common 240bp (52bp 
del) and 297 (5bp ins) 
Table 3-1. Expected fragment sizes for JAK2 V617F and CALR PCR products. 
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Figure 3-9. Electrophoretogram examples of JAK2 and CALR mutational analysis.  Genemapper software allows visualisation of PCR 
products according to their relative size.     In this case the wild type JAK2 product is 362bp and V617F mutant is 202bp (shown as blue 
peaks); wild type CALR is 292bp and mutant products vary (the example shown is 240bp) (shown as green peaks).
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Figure 3-9 shows examples of the results of this PCR assay.  The top panel shows 
1results from a specimen with wild type JAK2 V617F and CALR amplification.  The 
green peak at 292bp corresponds to the wild type CALR product and the blue peak at 
362bp the wild type JAK2 product, no further peaks are present.  The middle plate 
shows a case with mutated JAK2 V617F showing blue peaks representing both the 
wild type product at 362bp and a second peak at 202bp, the mutated product. The 
CALR gene is normal in this case with only the 292bp green peak present.  The 
bottom plate shows a case with mutated CALR.  The wild-type 292bp PCR product 
can be seen in green alongside a mutant peak measuring 240bp – this represents a 
52bp gene deletion.  The JAK2 gene is normal in this case with only the 362bp peak 
present.  
 
3.7 Statistical modelling methodologies 
 
3.7.1 Basic analyses 
 
The demographic and laboratory features of CALR mutated classical MPNs were 
compared against JAK2 V617F mutated counterparts using standard statistical tests.  
Mann-Whitney U tests were used to establish whether statistically significant 
differences existed between groups.  A p value of <0.05 was used to indicate 
significance in these analyses.  The sensitivity and specificity of the current clinical 
guidelines were calculated using the metrics described below in 3.7.4 
 
3.7.2 Approach 
 
To determine which modelling approaches to test in this work a preliminary side by 
side comparison of a range of supervised predictive modelling methods was 
performed using the automated software, WEKA (Waikato Environment for 
Knowledge Analysis).  This software platform contains a collection of machine 
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learning classifiers/algorithms which can be applied to user imported data sets.  
Using default settings, a set of 8 different supervised classification methods was 
applied to sample group 4 (see 3.5.2.3).  Performance measures were compared 
between approaches and the three which gave the ‘best’ results were chosen for 
further development and tuning.  These were logistic regression, random forest 
analysis and gradient boosted analysis. 
 
3.7.3 Software 
 
Further, detailed statistical analysis was undertaken in R studio using R version 3.5.1 
(Team, 2018), using packages shown in Table 3-2. 
 
PACKAGE REFERENCE 
SURVIVAL (Therneau, 2015; Therneau and Grambsch, 2000) 
MASS (Venables and Ripley, 2002) 
FARAWAY (Faraway, 2014) 
RGL (Adler and Murdoch, 2015) 
CARET (Kuhn et al., 2015 ) 
GMODELS (Warnes et al., 2013) 
ROCR (Sing et al., 2005) 
RMS (Harrell Jnr, 2015) 
RANDOMFOREST (Liaw and Wiener, 2002) 
GBM (Ridgeway, 2015) 
SHINY (Chang et al., 2018) 
Table 3-2. Statistical Packages used in data analysis. 
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3.7.3.1   Logistic regression 
 
In this work, the specified outcome was a diagnosis of MPN, and the candidate 
explanatory variables were the following measured laboratory and demographic 
attributes: 
• Age (years) 
• Gender (male(M) or female(F)) 
• Platelet count (Plt) x109/L 
• Haemoglobin (Hb) g/L 
• Red cell count (RBC) x106/L 
• Haematocrit (HCT) % 
• Mean cell volume (MCV) fl 
• White cell count (WBC) x109/L 
• Neutrophils (Neutr) x109/L 
• Lymphocytes (Lymph) x109/L 
• Monocytes (Mono) x109/L 
• Mean cell haemoglobin (MCH) pg 
• Mean corpuscular haemoglobin concentration (MCHC) g/L 
 
The explanatory variables were evaluated for collinearity using paired distribution 
plots and where identified one variable of the pair was chosen to be excluded based 
on biological information and frequency of missing data.  The selected explanatory 
variables were also assessed for statistical significance using a Least Absolute 
Shrinkage and Selection Operator (LASSO) analysis.  LASSO regression performs 
attribute selection to enhance the predictive accuracy of the model by shrinkage.  
This involves penalising the absolute size of the regression coefficients, and in doing 
so, some of the coefficients were shrunk to zero, at which point they were removed 
from the model.    
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Overfitting may occur when a statistical model is too complicated, contains larger 
numbers of variables than necessary and is consequently too specific to the dataset 
used to develop it.  Whilst a model may perform exceptionally well during 
development, if overfitted to the data, it will perform poorly on unseen data 
(Hawkins 2004).  Cross validation was performed to estimate the effect of overfitting 
within the logistic regression model.  This approach, an example of a repeated 
holdout method, randomly divides the original dataset into a specified number of 
smaller datasets as shown in Figure 3-10 (Lantz 2013 page 319).   
 
 
Figure 3-10.  Schematic representation of cross-validation. 
 
In this case the data was randomly divided into 10 new datasets.  The regression 
analysis was repeated using 9 of the 10 data subsets to train the model and the 
remaining 1 used to validate the performance of the model.  The logistic regression 
model tested on each of the datasets in turn.  The statistical significance of each 
explanatory variable was measured for each sampling, and the overall effect of 
overfitting estimated. 
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88 
 
 
 
3.7.3.2 Random forest analysis 
 
The random forest is an example of an ensemble technique.  It is based on the 
common decision tree method, where data is separated into branches depending upon 
how it responds to the set criteria (see example in Figure 3-11).  Random forest 
utilised a plethora of randomly selected decision trees and combines their output to 
provide an overall prediction of outcome.  Overfitting does not occur as the large 
number of decision trees provide better generalisation (Breiman 2001)   In this case, 
500 individual decision trees were created to build the random forest. 
 
 
Figure 3-11.  Random forest decision tree process. 
 
Decision trees are created which bifurcate samples using simple threshold values and 
yes/no responses relating to the predictor variables, for example; is the patient male? 
(yes/no), is the patient over 50 years old? (yes/no). 
 
 
 
 
Data
Tree 1 Tree 2
Tree 3
Prediction 1 Prediction 2
Prediction 3
Vote
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3.7.3.3 Gradient-boost 
 
Similarly to Random Forest analysis, Gradient Boost is an ensemble technique in 
which a series of weak classifiers, typically decision trees, are combined to produce 
an overall prediction.  In this approach, each observation is initially assigned an 
equal weighting.  When a model is applied to the data, misclassified observations 
gain weight and correct classifications lose weight.  With the addition of each 
subsequent classifier there is increased focus on misclassified observations, due to 
their increasing weighting (Schapire and Fruend 2012).  The overall effect is that 
each classifier contributes proportionally to the prediction based on its predictive 
accuracy. 
 
3.7.4 Model performance evaluation 
 
Each of the statistical models developed were then applied to the original dataset and 
the model’s performance was tested.  Several measurements were assessed to 
evaluate the model as shown in Table 3-3. 
 
 Predicted MPN Predicted no 
mutation 
Total 
Actual MPN True Positive (TP) False Negative 
(FN) 
TP+FN 
Actual no 
mutation 
False Positive (FP) True Negative 
(TN) 
FP+TN 
Total TP+FP FN+TN  
Table 3-3. Confusion Matrix. 
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Performance measurements are centred on measuring how often the model gets the 
correct answer.  The focus is not only on how many times a positive case is correctly 
identified, but also how often a negative case is mistakenly called positive and visa-
versa, a confusion matrix separates the predicted data into 4 categories when 
compared to the actual diagnostic status (Table 3-3).    Depending upon the intended 
use of the model, it may be desirable to weight the model towards one of these 
categories.  For example, if the consequences of missing a case were severe, there 
emphasis may be placed on minimising false negatives, which may have a 
consequential impact on the frequency of false positives predicted by the model.  
Using the categories, a series of metrics can be calculated which are reproducible 
between modelling approaches and allow different models to be directly compared.  
The performance measures and their calculations are shown in Table 3-4.  
 
3.7.5 Model validation 
 
Validation is a key step in the assessment of a statistical predictive model and 
essential prior to introduction into clinical practice.  Ideally, the model should be 
applied to a ‘new’ dataset, that is, data which did not form part of the original dataset 
on which the model is built.  This is especially important where a model has been 
built using a sample of data in which the proportion of ‘MPNs’ and ‘No mutations’ 
does not necessarily reflect the actual frequency of each group in the population to 
which the model will be applied.  For these reasons, each model was applied to a test 
dataset and the performance measures reassessed to determine the applicability to 
‘real world’ data (Figure 3-12).  
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Figure 3-12. Process of model development and validation. 
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Measure Description  Formula  
Accuracy  Degree of closeness to the actual results from the predicted results  = (TP + TN)/(TP+FP+FN+TN)  
Sensitivity  Proportion of actual cases predicted to be cases  = TP/(TP + FN)  
Specificity  Proportion of controls predicted to be controls = TN/(FP + TN)  
Kappa Statistic  Compares the accuracy of the classifier compared to the random 
accuracy of the classifier  
See (Cohen, 1960) 
F-measure  A measure of the test’s accuracy taking into account sensitivity and 
precision  
= 2 x TP/(2 x TP + FP + FN)  
Area under the Receiver 
Operating Curve (AUROC)  
Reduces the ROC performance (FN and FP for every cut-off) to a 
single value thereby allowing classifier comparison  
See (Fawcett, 2006) 
Table 3-4. Standard performance characteristics and their formulae. 
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4. Development and validation of a screening assay for 
the simultaneous detection of JAK2 V617F and CALR Exon 
9 mutations. 
 
4.1 Rationale and introduction 
 
Molecular screening for JAK2 V617F mutations was introduced into routine practice 
in HMDS shortly after it was described (Baxter et al., 2005), using an Allele-specific 
oligonucleotide (ASO) PCR technique based upon the method presented in the 
literature.  CALR mutations were later identified through whole exome sequencing 
experiments.  This technique is not suitable as a screening tool in routine diagnostic 
practice – due to the cost implications, processing and data analysis time.  To be able 
to identify CALR mutations for the diagnosis of suspected MPNs in HMDS an 
alternative laboratory approach was required.  To maximise sample processing 
efficiency, an approach which would be used to detect mutations both JAK2 V617F 
and CALR mutations simultaneously was most desirable. 
 
4.2 Current approach to detecting JAK2 V617F mutations 
 
At the outset of this work, JAK2 V617F mutations were detected using an ASO-PCR 
assay.  This technique utilised two different forwards primers, in conjunction with a 
consensus reverse primer as shown in Figure 4-1.  The first was a consensus forward 
primer (a) binds upstream of the mutation point and will amplify independently of 
the mutational status.  The second was a mutant specific forward primer (b), 
designed to terminate at the point of the mutation, this primer would only anneal and 
amplify in the presence of the mutant sequence.  A consensus reverse primer was 
used to amplify both products.  
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Figure 4-1.  Schematic showing ASO-PCR. 
 
Following amplification, the PCR products were visualised using agarose gel 
electrophoresis.  The wild-type JAK2 PCR product is 364bp in length, whereas the 
product produced by DNA carrying the JAK2 V617F mutation is 203bp in length.  
This difference in size allowed easy distinction between the wild type and mutant 
JAK2 PCR products. 
 
ASO-PCR followed by agarose gel electrophoresis was not deemed to be a suitable 
approach for the detection of CALR mutations.  Mutations within the exon 9 region 
of the CALR gene are varied and therefore a single mutant specific primer would not 
be applicable. The published data indicated that CALR mutations were always 
associated with a change in amplicon size, although the reported mutations varied in 
size and included compound mutations resulting in size changes of as little as 1bp 
(Chen et al., 2014; Klampfl et al., 2013; Nangalia et al., 2013).  The resolution of 
electrophoresis of a 2% agarose gel is widely accepted to be in the region of 20-
30bp.  This limitation excluded gel electrophoresis from being utilised in this setting 
as a method of product visualisation.  
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4.3 Fragment size analysis for the detection of CALR exon 
9 and JAK2 V617F mutations 
 
Both the existing approach to JAK2 V617F analysis and amplification of the CALR 
exon 9 region would result in PCR products which differ in size between wild type 
and mutant DNA.  For this reason, fragment size analysis was considered as a 
potentially suitable approach.  The technique had been used extensively in our 
laboratory across a wide range of assays and was sufficiently sensitive to detect 
single base pair size changes as would be required for CALR mutation screening.  
The technique can be used to analyse multiple products simultaneously, to allow for 
both JAK2 V617F and CALR mutations to be identified in a single assay.   
 
The approach utilised fluorescent markers which were incorporated into the 5’ end of 
one of the primers used to amplify the target DNA.  The products were mixed with a 
size standard and analysed using capillary electrophoresis.  Instrument software 
measured the size of the DNA fragments relative to the corresponding size standards 
and displayed this information for user interpretation. 
 
Validation of a JAK2 V617F / CALR mutation screening assay was critical.  As a 
new diagnostic technique, extensive validation was undertaken prior to the 
introduction of this assay into routine laboratory use.  Standards for the validation of 
new diagnostic techniques are outlined in the standards set out by ISO 15189 (BSI, 
30 November 2012).      
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4.4 Primer selection 
 
As the JAK2 V617F assay was already well established, the same primer sequences 
were used for the fluorescent fragment analysis, with the addition of a 6-
carboxyfluorescein (6-FAM) label at the 5’end of the consensus reverse primer.  
These primers retained a melting temperature (Tm) of 60˚C which allows the use of 
the existing thermal cycling conditions for amplification. 
 
The genomic sequences described in the supplementary information from the 
original manuscript by Nangalia et al. (Nangalia et al., 2013) were used to design 
primers for the amplification of CALR exon 9.  The appropriate genomic region was 
identified using the University of California Santa Cruz (UCSC) genome browser, 
BLAT search (http://genome.ucsc.edu/). Once identified the corresponding sequence 
information spanning the whole of exon 9 was retrieved and imported into the 
Primer 3 software package (http://simgene.com/Primer3).  Primers were designed to 
have a Tm of 60˚C to allow amplification in the same reaction as those for JAK2 
V617F.  A hexachlorofluorescein (HEX) label was incorporated into the 5’ end of 
the CALR forward primer to enable visualisation. 
 
Following design, the primers were checked to ensure suitability.  Firstly, the primer 
sequence was checked to ensure that they would not bind to any other region of 
DNA using the Basic Local Alignment Search Tool (BLAST) from the National 
Centre for Biotechnology Information (NCBI) 
https://blast.ncbi.nlm.nih.gov/Blast.cgi).  Neither the CALR not JAK2 V617F primers 
were found to be homologous to any other region of human genomic DNA.  The 
primer binding region of DNA was also checked to ensure that it did not contain a 
recognised single nucleotide polymorphism (SNP) site using the online SNPCheck 
database search facility (www.snpcheck.net/), which would potentially prevent 
binding.  Again, neither set of primers was found to bind over a reported SNP site. 
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4.5 Confirming amplification of CALR exon 9 gene region 
 
Firstly, it was demonstrated that the primers worked satisfactorily under the selected 
PCR conditions, and furthermore, were amplifying the correct region of DNA. To 
determine this, 6 DNA samples were selected from archived material and analysed 
using the assay described.  Following amplification, the PCR products were 
visualised by agarose gel electrophoresis to determine the presence of the amplicon.  
Amplification was evident at a satisfactory level using the existing thermal cycling 
conditions and these were used for all subsequent work.  The PCR products were 
analysed by Sanger sequencing and the resulting data compared to the corresponding 
CALR exon 9 gene region as detailed in the UCSC genome browser, BLAT search.  
The primers were found to be amplifying the appropriate region of DNA and were 
validated as being suitable for use. 
 
4.6 Validating assay in JAK2 wild type ET/PMF samples 
 
4.6.1 Demographic details and diagnoses 
 
A critical aspect of validation was to confirm that the assay would discriminate 
mutant CALR products from wild type.  To achieve this, the assay needed to be 
performed on samples with varying CALR mutations.  As no suitable reference 
material was available, the published data was used to identify a group of samples 
which would be most likely to have mutations present.  The literature indicated that 
CALR mutations were found in a significant proportion of patients with JAK2 V617F 
wild-type ET or PMF (Nangalia et al., 2013) and so a group of patients with these 
diagnoses were identified from laboratory records.   
 
Sample group 1 (Figure 3-6 and section 3.5.1) was used to validate the assays ability 
to detect mutations in CALR.  As described in 3.5.1, this group consisted of a cohort 
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of 48 patients with a confirmed diagnosis of ET or PMF, but where no demonstrable 
mutation in JAK2 V617F or MPL had been identified.  In the absence of such a 
mutation, this diagnosis could only be made by morphological assessment of bone 
marrow and therefore, archived DNA from bone marrow was available for testing.  
In addition, all 48 cases also had DNA stored from a peripheral blood sample 
received alongside the bone marrow sample.  The patient characteristics are shown in 
Table 4-1 . 
 ET PMF 
Number 42 6 
Median age (years) 64.6 71 
Male 23 (52.3%) 5 (83.3%) 
Table 4-1. Summary of patients in sample group 1 - for the validation of CALR 
mutation screening assay. 
 
4.6.2 Identification of CALR mutations 
 
DNA from all samples was amplified with both CALR and JAK2 primers in a single 
PCR reaction.  The fluorescent PCR products were analysed using Genemapper 
fragment analysis software (ABI, ThermoFisher).  CALR mutations were identified 
in a total of 24 patients (50%).  The characteristics of these mutations are shown in 
Table 4-2, with corresponding electrophoretograms shown in Figure 4-2.  Of note, 
the most frequently seen mutation was the 52bp deletion, followed by the 5bp 
insertion – which is in keeping with published data (Chen et al., 2014; Klampfl et al., 
2013b; Nangalia et al., 2013).    
 
Complete concordance was seen between peripheral blood and bone marrow samples 
for the same patient.  The majority of referrals for the investigation of a suspected 
MPN are peripheral blood samples and JAK2 V617F screening has been routinely 
performed on peripheral blood since its introduction.  The ability to perform CALR 
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mutation screening on the same specimen was a key aspect of incorporating the 
assay into routine laboratory use.   
 
Figure 4-2 Results of fluorescent fragment analysis obtained during assay 
validation.  Each panel showing a distinct mutation, the wild-type CALR peak 
is shown in the highlighted box.  The second green peak shows the mutated 
CALR PCR product and its relative size (number identified shown in brackets).  
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(A) 5bp insertion (n=8), (B) 10bp deletion (n=1), (C) 20bp deletion (n=1), (D) 
22bp deletion (n=1), (E) 32bp deletion (n=1), (F) 52bp deletion (n=12). 
 
Mutation Number 
of cases 
Diagnosis Gender Median age  
(years) ET PMF M F 
5bp insertion 8 7 1 4 4 64.54 
10 bp deletion 1 1 0 1 0 64.30 
20 bp deletion 1 1 0 1 0 62.06 
22 bp deletion 1 0 1 1 0 63.02 
32 bp deletion 1 0 1 1 0 47.63 
52 bp deletion 12 11 0 8 4 67.78  
Table 4-2. Characteristics of CALR mutations in the validation group (sample 
group 1). 
  
 
4.6.3 Increased sensitivity of JAK2 V617F assay 
 
This innovative approach showed a higher level of sensitivity over the existing 
assay.  All samples used in the validation assay had been originally reported as JAK2 
wild type.  Following analysis using the fluorescent fragment analysis approach, one 
case showed the presence of a JAK2 V617F mutation in the DNA from both the 
peripheral blood and bone marrow sample.  The sensitivity of agarose gel 
electrophoresis had been previously estimated to be 2-3% allelic burden in our 
hands, whereas fluorescent fragment analysis is estimated to be capable of 
identifying a much lower level of mutated DNA, ~1% allelic burden.  The increased 
sensitivity of the fluorescent assay would account for this discordant result and as it 
was expected that clinicians would want existing patients to be investigated for 
CALR mutations, this would be taken into consideration when analysing and 
reporting assay results.  
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4.6.4 Inter-laboratory validation 
 
HMDS has long standing collaborations with several groups within the UK, 
including one with Professor N Cross of the Wessex Regional Genetics Service, 
Salisbury, UK.  A series of 322 DNA samples from JAK2 V617F wild type MPN 
patients diagnosed by HMDS had been provided by for Genome Wide Association 
Studies (GWAS) in Salisbury.  As the group performing this analysis had also 
characterised the CALR mutation (Nangalia et al., 2013) the samples provided by 
HMDS had also been analysed for the presence of CALR mutations.  This included 
30/48 patients selected for test validation.  The results of mutational screening in 
HMDS was 100% concordant with the findings from the GWAS. 
 
A sample exchange was requested by Dr I Carter from Nottingham City Hospital 
who was in the process of setting up an assay using the same CALR primers and a 
similar approach.  DNA samples from 20 patients were exchanged between our two 
centres.  Concordance was 97.5% (39/40 cases), with Dr Carter detecting a 5bp 
insertion in one sample which was not detected using the assay developed in this 
work.  Following discussions, it was found that there was a small difference between 
our techniques.  In Nottingham, the JAK2 V617F and CALR amplifications were 
being performed in two separate PCR reactions, whereas I had amplified both targets 
in a single multiplex reaction.  It was hypothesised that a multiplex approach may 
have a reduced sensitivity compared with single target amplification.  The mutation 
was detectable when the two targets were reamplified separately and mixed prior to 
fragment analysis and therefore, this approach was adopted for all future testing.     
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4.7 Discussion 
 
Following their identification, the importance of being able to screen for CALR exon 
9 mutations was considered a priority from a diagnostic point of view.  The varied 
mutations found within the CALR exon 9 gene region, restricted the type of approach 
that could be used to identify them in routine laboratory practice.  However, the 
consistent feature of altered PCR product size made it a model candidate for a 
fluorescent fragment analysis approach.  As the existing assay used to detect JAK2 
V617F mutation was also associated with a size change, there was opportunity to 
develop a technique for the simultaneous detection of both abnormalities.  This 
approach was appealing as it would maximise productivity, whilst minimising bench 
work and processing times/costs. 
 
Internal laboratory validation demonstrated that CALR exon 9 mutations are 
consistently detectable in both peripheral blood and bone marrow samples from 
affected individuals, this offers a minimally invasive approach for patients 
undergoing screening for suspected MPNs.  The fluorescent fragment analysis assay 
also offers an increased sensitivity over the existing assay for detecting JAK2 
V617F.  This presents the possibility that patients previously diagnosed as being 
JAK2 V617F wild type could be found to be mutated if rescreened using this 
approach.     
 
External validation demonstrated almost complete concordance between results from 
two independent sample exchanges.  DNA from one sample was found to have a 
demonstrable CALR exon 9 mutation when analysed in Nottingham, which was not 
identified in Leeds.  A comparison of assay protocol identified a single difference in 
approach, with the laboratory in Nottingham performing separate PCR reactions to 
amplify the JAK2 V617F and CALR exon 9 regions rather than the multiplex 
approach I had used.  When the assay was repeated using 2 separate PCR reactions 
as per the approach used in Nottingham, the mutation was detectable.   
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This discrepancy was thought likely to be due to a reduction in the sensitivity of the 
two assays by amplifying them together and as a result, separate assays were used 
from this point onwards.  This highlights the importance of performing thorough 
validation of an assay prior to its introduction into routine laboratory use.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
 
5. Assessing current practice in the referral and 
diagnosis of suspected classical MPNs 
 
5.1 Rationale and overview 
 
The diagnosis of MPN can be made difficult by the significant overlap in clinical and 
laboratory features with other reactive conditions.  Current guidelines indicate that 
the clinical features should be confirmed as being persistent and reactive causes 
(such as infection or inflammation) excluded prior to investigation (Harrison et al., 
2010; McMullin et al., 2007; Reilly et al., 2012a).  There is no published data to 
indicate how strictly clinical guidelines are adhered to, nor the efficiency of the 
referral process as it occurs in current practice.  The high frequency of genetic 
aberrations in classical MPNs is a valuable indicator of disease where detected; 
however, the absence of a recognised mutation is not sufficient to exclude the 
presence of disease.  The impact that the availability of molecular screening assays 
has had on referral behaviour is currently unknown.   
 
The purpose of this chapter is to evaluate the investigation of suspected classical 
MPNs in a regional diagnostic setting.  Extensive SQL searches were performed 
using the HILIS database to investigate how efficient current practice is in the 
identification of patients with MPNs.  The laboratory parameters of each referral 
were compared against current guidelines to identify the proportion of referrals 
which met the criteria for investigation.  These data were used to analyse the affect 
that the introduction of molecular screening assays have had on both referral 
behaviour and frequency of diagnosis.   
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5.2 How many patients are referred to HMDS for the 
investigation of a suspected classical MPN per annum? 
 
The number of referrals for suspected classical MPN has increased annually over the 
past decade.  The JAK2 V617F mutation was identified in 2005 with the first 
publications available in July of that year.  Routine mutational screening was 
introduced by HMDS in late October 2005.  The total number of referrals for 
suspected classical MPNs are shown for a 10-year period commencing from 2005 
(Figure 5-1).   In 2005, a total of 356 referrals were received for the investigation of 
a suspected classical MPN, equating to 2.4% of the laboratory’s total workload. This 
has shown a continued yearly increase and, in 2014 (at the commencement of this 
analysis), this figure stood at a total of 2114 referrals, accounting for 7.2% of 
samples.   
 
This increased number of referrals has not been accompanied by a comparable 
increase in diagnoses.  Whilst, the number of referrals has increased almost 6-fold 
over the past decade, the number of confirmed diagnoses of classical MPN has 
remained consistent with an average of 314 new cases per annum.  This figure is in 
keeping with the estimate published by HMRN (Smith et al., 2010).  Prior to the 
introduction of JAK2 V61F screening, the proportion of referrals which resulted in a 
confirmed diagnosis of a classical MPN was 56% (201/356 cases received in 2005).  
Following the introduction of mutational screening for JAK2 V617F, this figure has 
declined with an average of 26.3% of referrals resulting in a confirmed diagnosis of 
a classical MPN per annum (range 20.2-37.9% per annum) in the period from 2006-
2013 inclusive. 
 
 
 
 
 
106 
 
 
The identification of CALR mutations and subsequent introduction of CALR 
mutational screening has led to a further increase in the number of referrals received.  
Following the routine implementation of CALR mutation screening in early 2014, 
there was a significant rise in the number of referrals for investigation, with a 32.8% 
increase over the previous year.  However, the total proportion of referrals which 
resulted in a confirmed diagnosis of MPN declined further, to 19.0%, the lowest 
value to date. (Figure 5-1).   
 
 
Figure 5-1. Annual number of referrals for suspect MPN received by HMDS 
2005-2014. 
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5.3 How frequently are bone marrow investigations 
performed on suspected classical MPNs when a JAK2 
V617F or CALR mutation is not been detected? 
 
JAK2 V617F and CALR mutations are shown to be present in a significant 
proportion of patients diagnosed with classical MPNs (Chen et al., 2014; Klampfl et 
al., 2013b; Nangalia et al., 2013).  However, the absence of these mutations cannot 
be used to exclude the presence of disease.  In both the WHO and BCSH 
recommendations, morphological assessment of a bone marrow aspirate is required 
to conclusively diagnose or exclude disease in patients where clonal markers are not 
detected (Arber et al., 2016; Harrison et al., 2010; McMullin et al., 2007; Reilly et 
al., 2012a).  Using sample group 2, which consisted of all referrals of suspected 
classical MPNs received by HMDS between 2005 and the end of 2014 (see 3.5.2.1 
for further details), it was possible to identify patients who had undergone bone 
marrow assessment following receipt of a blood sample which did not have a 
detectable JAK2 V617F or CALR mutation.  On average 178 bone marrow samples 
are received annually on patients with suspected classical MPNs, where a peripheral 
blood sample did not show a mutation (range 119-239). 
 
As a proportion of the peripheral bloods received which do not have a detectable 
JAK2 V617F or CALR mutation reported each year this represents an average of 
19.01%.  However, as Figure 5-2 illustrates there is ongoing divergence of the two 
groups and this proportion has declined annually from 31.82% in 2006, to 10.86% 
by the end of 2014. 
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Figure 5-2 Number of bone marrow aspirates received following a peripheral 
blood sample with no detectable JAK2 V617F or CALR mutation, compared 
with the total number of non-diagnostic blood samples referred annually from 
patients with suspected classical MPNs. 
 
BM sampling was performed most frequently in cases of suspected ET (69.39%) 
with suspected PV and PMF accounting for 8.16% and 3.06% of BM referrals 
respectively.  The suspected diagnosis was not clear in the remaining 19.39% of BM 
samples received.  Haemoglobin and platelet counts were compared between JAK2 
V617F/CALR exon 9 wild-type referrals, separated into 2 groups on the basis of 
whether a follow-up BM sample was received.  There were statistically significant 
differences in both parameters between the two groups (boxplots are shown in Figure 
5-3), with patients who underwent subsequent bone marrow sampling have a lower 
haemoglobin (mean 134g/L in vs 155g/L in PB only group) and higher platelet 
counts (mean 666 x109/L vs 329 x109/L in PB only group).  p values were reported 
as <0.001 in both analyses. 
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Figure 5-3. Significant differences in haemoglobin and platelet count were 
observed between JAK2 V617F/CALR exon 9 wild type referrals which 
underwent subsequent bone marrow investigations versus those with peripheral 
blood screening only. 
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5.4 What proportion of referrals for investigation meet 
laboratory criteria set out in clinical guidelines for 
investigation? 
 
The low proportion of referrals which result in a confirmed diagnosis of MPN would 
indicate that there are inefficiencies somewhere within the referral process, although 
this has not been formally audited to identify where or why.  One potential cause 
could be that referrals are made which do not meet the recommendations set out in 
clinical guidelines.  To ascertain whether this is the case, full blood count parameters 
and clinical details were compared to the recommendations set out both in the BCSH 
guidelines as well as in the WHO recommendations in place at the time of referral.  
This analysis was performed on 4576 referrals received during three consecutive 
years (2012-2014 inclusive) selected from sample group 2.  This time-frame reflects 
the introduction of routine recording of full blood count data into the HILIS 
database.  Prior to this time, electronic records were not available for the full blood 
count performed in HMDS.     
 
5.4.1 BCSH guidelines 
 
Each sample was categorised as either meeting or failing to meet the laboratory 
elements of the BCSH recommendations (Harrison et al., 2014; McMullin et al., 
2007; Reilly et al., 2012) on the basis of meeting one of the following 3 criteria: 
• Haematocrit >48 in females, >52 in males 
• Platelet count >450x109/L 
• Clinical suspicion of PMF 
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Figure 5-4. Proportion of referrals for suspected MPN received by HMDS 
during 2012-2014 which meet / fail to meet BCSH recommended laboratory 
criteria for investigation. 
 
The proportion of referrals with full blood count indices and/or clinical details which 
would support investigation according to BCSH published guidelines averages at 
57.48% of annual referrals (range 56.34-58.08%) over the 3-year period 2012-2014 
(Figure 5-4).  
 
5.4.2 WHO criteria 
 
Full blood count indices and clinical details were then compared to the 2008 WHO 
recommendations (Barbui et al., 2015; Vardiman et al., 2009b) and each referral 
categorised as either meeting or failing to meet the criteria on the basis of the 
following parameters: 
• Haemoglobin >165g/L 
• Haemoglobin >185g/L 
• Platelet count ≥450x109/L 
• Clinical suspicion of PMF 
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Figure 5-5. Proportion of referrals for suspected MPN received by HMDS 
during 2012-2014 which meet / fail to meet WHO recommended laboratory 
criteria for investigation. 
 
The proportion of referrals meeting the laboratory criteria published by the WHO 
was consistently lower than that meeting the BCSH criteria.  On average 51.15% of 
referrals had features which would support investigation for a suspected classical 
MPN (range 50.67.-52.52%) as show in Figure 5-5. 
 
5.5 Are reactive causes excluded and symptoms 
demonstrated to be persistent at the time of referral? 
 
A cohort of the first 50 consecutive referrals from Leeds Teaching Hospitals NHS 
Trust (LTHT) made in 2014 were selected from sample group 2 and clinical records 
audited to ascertain whether reactive and secondary causes of symptoms had been 
excluded prior to molecular investigation, as per the recommendations set out by the 
BCSH and WHO.   
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Twenty three of these 50 referrals had abnormal blood count results on at least 2 
consecutive samples prior to referral, thus meeting the recommended criteria for 
investigation.  In the remaining 27 referrals, abnormal results were only recorded on 
1 sample prior to investigation.  Eight out of the 50 referrals were found to have an 
MPN (6/8 with a JAK2 mutation, 1/8 with a CALR mutation and 1/8 with no 
identifiable genetic abnormality) of which 7/8 had abnormal blood count results 
prior to referral. 
 
A reactive or secondary cause for their laboratory features was noted in the clinical 
history in 35/40 patients who did not have a detectable mutation.  These included a 
pre-existing medical condition (cardiovascular disease (n=6), liver disease (n=3), 
surgery (n=3), carcinoma (n=1) and rheumatoid disorder (n=1)) or elevated 
inflammatory markers (n=21).  Of these 40 patients only one subsequently had a 
bone marrow which excluded the diagnosis of an MPN.   
 
In patients with raised inflammatory markers, this test had been performed prior to 
being seen in haematology in 13/21 patients, indicating that this information was 
available at the time of clinical assessment.  In the remaining 8 patients, tests for the 
presence of inflammatory markers were requested alongside or after the request for 
molecular screening. 
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5.6 How sensitive and specific are the current diagnostic 
guidelines in the identification of classical MPNs? 
 
A significant proportion of referrals did not meet any of the laboratory criteria set out 
in the published guidelines at the time of referral, however, it is important to 
establish how effective the current guidelines themselves are in positively identifying 
patients with classical MPNs.  To ascertain this, 4576 specimens received between 
January 2012 and December 2014 (taken from sample group 2) were divided into 
four groups based on whether they a) met the criteria set for investigation/diagnosis 
and b) whether they were diagnosed with a classical MPN on the basis of peripheral 
blood analysis (that is, having a JAK2 V617F or CALR mutation). The data is 
presented in 2 confusion matrices shown below (Table 5-1 and Table 5-2). 
 
The platelet count used in the diagnosis of ET has remained unchanged between the 
2008 and 2016 revisions of the WHO diagnostic criteria, however, the thresholds 
used to diagnose PV have been modified.  The upper threshold for haemoglobin 
levels has been reduced to 160g/dL in females and 165g/dL in males.  An upper limit 
has also been introduced for haematocrit levels, 48 in females and 49 in males.  In 
this analysis the thresholds in use at the time of referral have been used (WHO 
2008).  
 
Using the calculations detailed in Table 3-4, the performance of each set of 
guidelines was calculated.  When the laboratory thresholds detailed in the BCSH 
guidelines are applied to the data set, the criteria have an average sensitivity of 
86.96% compared with 88.07% when the WHO guidelines are applied.  The 
specificity of the BCSH guidelines is 49.55% compared with 33.65% with the WHO 
guidelines. 
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 Met BCSH criteria Did not meet BCSH criteria 
MPN  780 117 
No mutation 1856 1823 
Table 5-1 Confusion matrix of referrals according to BCSH guidelines. 
 
 Met WHO criteria Did not meet WHO criteria 
MPN  790 107 
No mutation 2441 1238 
Table 5-2. Confusion matrix of referrals according to WHO criteria. 
 
5.7 Can we identify other markers that discriminate 
patients with classical MPN from those without? 
 
5.7.1 Basic Demographic features 
 
It is well documented that the frequency of the classical MPNs increases with age 
and shows a slight bias toward female subjects (Roman et al., 2016; Smith et al., 
2010; Visser et al., 2012).  However, neither age nor gender are included in 
published guidelines.  Age is widely used to inform malignancy screening in a 
number of diseases including breast, bowel and cervical cancer (England, 2016).  
These two features were recorded for all referrals and compared between those with 
a confirmed diagnosis of MPN and those with non-diagnostic results. 
 
5.7.1.1  Age of patients at time of referral 
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Sample group 2 contains a total of 12187 specimens referred to HMDS for the 
investigation of a suspected classical MPN, received between January 2005 and 
December 2014.  The sample group was separated into two categories on the basis of 
diagnostic outcome – those in which a mutation of JAK2 V617F or CALR was found, 
and those in which no mutation of JAK2 V617F or CALR was detected.  Age 
distribution was plotted as a histogram with the two groups highlighted in different 
colours in order to visualise any overlap (Figure 5-6).  Full details of R script used is 
shown in appendix section 10.2 .  A difference in the referral ages was evident 
between the two categories.  A T-test was performed to confirm that this difference 
was statistically significant (Table 5-3). 
 
 
Figure 5-6 Comparison of age distribution between referrals with a diagnostic 
outcome of MPN and those without. 
 
Category N Mean age 
(years) 
T DF Significance 
(p) 
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MPN 
2976 69.49 
36.857 5776.3 <0.001 
No mutation 
9211 58.05 
Table 5-3. Statistical comparison of Age between diagnostic categories. 
 
5.7.1.2 Red cell indices 
 
In addition to haemoglobin (Hb) and haematocrit (HCT), full blood count analysers 
also commonly measure the total red cell count (RBC) and mean red cell volume 
(MCV) amongst others.  Using the cohort of referrals described in section 5.4, these 
indices were compared between samples with a mutation in either JAK2 V617F or 
CALR (referred to as “MPN” in the following analyses) and those with no detectable 
mutation in these two targets (referred to as “No mutation” for analytical purposes) 
 
The box plots in Figure 5-7 show that there is overlap in the range of values seen 
between the MPN and No mutation groups.  Significance testing by Wilcoxon rank 
sum test demonstrated a statistically significant difference between the two groups 
for all but one parameter.  In our data set haematocrit was not shown to be 
significantly different between MPN and No mutation (Table 5-5). 
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Figure 5-7. Comparison of red cell indices between referrals with a mutation of JAK2 V617F or CALR (MPN) and those without (No 
mutation). 
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5.7.1.3 Gender of referred patients 
 
A total of 6468 females and 5719 males were investigated for suspected classical 
MPN.  The gender distribution of cases is shown in Table 5-4. 
 
Diagnostic group Males (n) Females (n) Ratio 
MPN 1423 1583 0.90 
No mutation 4296 4885 0.88 
Combined 5719 6468 0.89 
Table 5-4. Gender distribution of referred cases according to diagnostic 
outcome. 
 
The gender distribution both overall and for referrals resulting in a diagnosis of a 
classical MPN are comparable and in keeping with published values (Roman et al., 
2016). 
 
5.7.2 Other blood count features 
 
Data analysed in section 5.4 shows that the majority of referrals meet the minimum 
blood count criteria set out by either the BCSH and WHO (Barbui et al., 2015; 
Harrison et al., 2014; McMullin et al., 2007; Reilly et al., 2012b).  However, only 
three laboratory parameters are included in the criteria – Platelet count, Haematocrit 
and Haemoglobin.  Even the most basic full blood analysers produce a much wider 
range of indices, which may conceivably be of value in discriminating between 
specimens from patients with classical MPNs and those without.   
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5.7.2.1 Leucocyte parameters 
 
White blood cell features are not used as a primary criterion in the diagnosis of 
classical MPN according to either BCSH or WHO publications.  The full blood 
count analyser used in HMDS measures the total white cell count (WBC), 
lymphocyte count (Lymph) and neutrophil count (Neutr) and monocyte count 
(Mono).  In this dataset (sample group 2), all leucocyte parameters were shown to 
have a statistically significant difference between the two groups, with white cell 
count, neutrophil and monocyte counts having a higher mean value in patients with a 
classical MPN compared with those who do not.  For lymphocyte counts, the inverse 
pattern was seen.  A comparison can be seen in Figure 5-9. 
 
5.7.2.2 Platelet count 
 
A comparison of platelet count between groups showed a significant increase in the 
mean platelet count associated with classical MPNs versus those with no mutation 
detected (Figure 5-8). 
 
Figure 5-8. Comparison of platelet count between referrals with a mutation 
detected (MPN) and those without (No mutation). 
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Figure 5-9. Comparison of leucocyte indices between referrals with a detectable mutation (MPN) and those without (No mutation). 
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Parameter MPN No mutation Significance (p) 
Hb (g/l) 147.71 151.10 <0.001 
HCT (%) 45.36 44.80 0.7267 
RBC (X1012/l) 5.16 4.88 <0.001 
MCV (fl) 89.45 92.02 <0.001 
WBC (x109/l) 11.49 9.04 <0.001 
Lymph (x109/l) 1.85 2.21 <0.001 
Neutr (x109/l) 8.27 5.79 <0.001 
Mono (x109/l) 1.29 1.01 <0.001 
Plt (x109/l) 649.62 338.50 <0.001 
 
Table 5-5. Comparison of mean red cell indices values between MPN and No 
mutation groups with significance level. 
5.8 Discussion 
 
The data presented in this chapter highlights the significant burden that molecular 
screening for suspected MPNs places upon diagnostic laboratory resources.  The 
disproportionate increase in requests over the past decade shows no indication of 
slowing which, when paired with the modest increase in the number of diagnoses of 
MPN, suggests that referrals are not being made in a systematic or efficient way.  
The small proportion of patients who undergo bone marrow examination following a 
non-diagnostic result from peripheral blood assessment would also indicate over-
requesting, which may suggest that there is either a lack of understanding of the 
limitations of JAK2 and CALR screening in the diagnosis of MPNs or that the test is 
being requested in patients with low clinical suspicion of disease.   
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Between 30-40% of referrals received for investigation of suspected MPN do not 
meet the diagnostic criteria outlined by the either WHO or BCSH recommendations.  
In both sets of guidelines, the presence of abnormally high blood parameters is a 
central feature of the diagnostic criteria.  Therefore, screening patients who do not 
meet these criteria could not result in the diagnosis of an MPN without the 
assessment of bone marrow morphology. 
 
The exclusion of reactive/secondary causes for symptoms and laboratory features is 
also a key feature of the diagnostic guidelines.  The audit of local referrals 
undertaken in section 5.5 demonstrates that alternative reasons for the abnormalities 
seen were identified by the clinician in 70% (35/50) referrals.  However, molecular 
investigations were requested regardless of patient history.  In those where a reactive 
or secondary cause was not identified from patient history, and inflammatory 
markers had not been assessed prior to clinical assessment, molecular screening was 
not delayed until a later time point.  Molecular screening was deferred in only one of 
the audited cases and was requested at the patient’s second clinic appointment when 
the blood counts had normalised.  The patient notes indicated that it was been 
performed for completeness not because a clinical suspicion remained. 
 
Part of this can be accounted for by the clinical pathway process described in Figure 
3-4.  During the first clinic visit, patients are seen by a haematologist who takes a 
detailed medical history and performs a physical examination.  The clinician also 
reviews the most recent peripheral blood counts available on the hospital result 
service.  Following this consultation, the clinician requests the appropriate 
investigations to be undertaken and the patient is sent to the phlebotomist for 
venepuncture.  In all the cases audited, it is at this point that a JAK2 mutation screen 
is requested, along with a full blood count and other basic blood tests for chemical 
pathology. 
 
The main problem with this approach is that the full blood count results, on which 
the clinician bases their further investigations, can be several weeks old.  Platelet 
counts, for example, can be increased during acute phase responses (during infection, 
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following surgery or blood-loss) and it is not uncommon to see an anomalous raised 
result.  A sustained increase in platelet count would be indicative of an underlying 
pathology, however, there was often no history/evidence of this.   
 
Ideally, a repeat full blood count would be performed prior to consultation to assess 
whether the results continue to be abnormal.  Performing venepuncture in clinic prior 
to seeing the consultant as well as afterwards, would be impractical.  It would cause 
additional time delays and discomfort to the patient.  Therefore, requesting the 
molecular screening assays upfront is the most practical approach for the 
patient/clinician. 
 
In addition to establishing current referral practice, this chapter also aimed to assess 
how useful the current clinical guidelines were in positively identifying patients with 
MPNs.  Despite evidence that many referrals for JAK2/CALR screening are not 
clinically indicated, there is still a large proportion of referrals which do meet the 
laboratory criteria set out by the WHO and BCSH.  However, the low number of 
diagnoses would suggest that the criteria are not specific in identifying potential 
MPNs. 
 
Comparisons of diagnostic outcomes in patients according to whether they met one 
of the two guidelines showed that whilst the sensitivity of these criteria is high 
(86.96% for BCSH and 88.07% for WHO guidelines), the specificity is much lower 
(49.55% for the BCSH guidelines and 33.65% for the WHO).  The data 
demonstrates that the guidelines have a very high negative predictive value.  This 
clearly shows that there is minimal benefit to investigating patients who do meet the 
guidelines in terms of laboratory features.  However, the low specificity of the 
guidelines does mean that a significant proportion of patients in whom testing would 
be indicated (according to blood parameters) would not be diagnosed with an MPN.   
 
Both sets of guidelines use a minimal number of parameters in their diagnostic 
criteria.  This does have the benefit of being easy to interpret by clinicians however; 
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the guidelines use arbitrary thresholds for these variables.  Research in other 
haematological malignancies has shown that risk of disease increases on a linear 
scale and the use of such thresholds is of little significance in patients around the cut-
off value ((Lichtman, 2013)).  For example, a patient with a platelet count of 
449x109/L would not be investigated whereas a patient with a platelet count of 
451x109/L would be although the actual difference in risk of disease would be 
negligible.  
 
There are also many other demographic and laboratory variables which are readily 
available to clinicians at the point of consultation.  Statistical analyses can be 
performed to assess whether other information could be of value in the positive 
identification of patients with MPNs.  Patient age and gender are well reported in 
MPNs and it is known that the risk of MPN increases with age.  There was a 
statistically significant difference in the age of patients diagnosed with an MPN 
versus those with non-diagnostic results in our referral population.  It would also be 
possible to attach a higher risk to male referrals as they too are known to have an 
increased incidence of MPN.  Additional laboratory parameters including additional 
red blood cell indices such as MCV were found to show significant differences 
between MPN and non-diagnostic referrals, as were white cell parameters. 
 
The wide range of variables that could potentially be used to guide suspected MPN 
referrals may be too complex to include in a simple algorithm, especially when there 
may be interaction between variables that can affect the overall risk.  This suggests a 
potential role for predictive statistical model which can calculate an individual’s risk 
of disease on the basis of a wide range of variables.  It is anticipated that such a 
model would be capable of identifying MPN patients with at least the same level of 
sensitivity as the current guidelines but with an improved level of specificity.  
Implementation of such a model could reduce the total number of referrals for 
investigation, without impacting on patient safety. 
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6. Features of CALR mutations in prospective cohort 
 
6.1 Rationale and context 
 
Clinical data suggests that CALR mutated ET has distinct clinical and laboratory 
features compared to their JAK2 V617F mutated counterparts, with JAK2 V617F and 
CALR mutated ET presenting at a younger median age, and having a higher platelet 
count and lower haemoglobin than JAK2 V617F ET  (Chen et al., 2014; Rotunno et 
al., 2013b; Rumi et al., 2013).  However, these studies have focussed on cases which 
had an existing diagnosis of ET according to the WHO criteria.  In the absence of a 
JAK2 V617F or MPL mutation, this would have required a bone marrow to be 
assessed.  Data shown in 5.3 shows that in our setting BM sampling is performed 
infrequently, compared with the number of blood samples received for JAK2 V617F 
and CALR mutational screening.  Furthermore, bone marrow sampling was found to 
be biased towards younger patients with higher platelet counts and lower 
haemoglobin levels.  If a similar bias was present in the cohort of patients examined 
in the published studies, this could contribute towards the documented differences 
between the JAK2 V617F and CALR mutated subgroups.   
 
At the time of analysis, no published data had assessed the features of CALR mutated 
ET in the context of a diagnostic setting, nor in prospectively tested patients.  The 
aim of this chapter was to determine if the features of CALR mutated ET diagnosed 
prospectively in the population referred to a clinical laboratory setting are 
comparable to those identified through the retrospective testing performed in the 
literature.  To achieve this, the clinical and laboratory features associated with CALR 
mutated ET have been compared to their JAK2 V617F mutated counterparts which 
have been identified in HMDS through routine investigations.   
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6.2 Data overview and comparability of selected cohorts 
 
The data set used in this analysis is taken from sample group 3 (shown in Figure 
3-7).  Briefly, this comprised all the cases of ET with a demonstrable CALR mutation 
identified prospectively in 2014 following assay introduction, alongside a group of 
JAK2 V617F mutated ET’s identified during the same time period.  Briefly, this 
group consists of a total of 88 patients who were found to have a CALR mutation 
during this period, along with 311 patients with the JAK2 V617F mutation.  
 
6.3 Do the laboratory or demographic features of CALR 
and JAK2 V617F mutated MPNs differ? 
 
6.3.1 Laboratory features 
 
The mean values of the full blood count indices were compared between the groups 
and tested for significance (Table 6-1).  Statistically significant differences were seen 
in nine of the 11 parameters assessed.  As reported in the literature (Rumi et al., 
2013) CALR mutated ET presented with a significantly lower mean hb and wbc 
compared with JAK2 V617F mutated cases.  The observed mean plt count was 
higher in the CALR mutated cohort but this was not statistically significant as was 
indicated in the published data. 
6.3.2 Demographic features of patients with CALR mutated ET  
 
Age at presentation was significantly lower in the CALR mutated group with a mean 
of 63.61 years group compared to 71.66 years in the JAK2 V617F mutated patients 
(p=<0.01).  This is in keeping with the findings of Rumi et al (Rumi et al., 2014). 
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Parameter CALR mutated JAK2 V617F mutated P 
Plt (x109/l) 716 655 0.38 
Hb (g/l) 127.3 152.9 <0.01  
RBC (x106/µl) 3.93 5.43 <0.01 
HCT (%) 38.00 46.96 <0.01 
MCV (fl) 98.25 88.11 <0.01 
WBC (x109/l) 7.90 11.48 <0.01 
Neutr (x109/l) 5.74 8.67 <0.01 
Lymph (x109/l) 1.81 1.79 0.68 
Mono (x109/l) 1.07 1.32 0.01 
MCH (pg)  33.01 28.85 <0.01 
MCHC (g/dl) 33.52 32.64 <0.01 
Table 6-1. Comparison of mean full blood count indices between CALR and 
JAK2 mutated referrals.  
6.4 Discussion 
 
The identification of CALR mutations in patients with JAK2 wild-type ET and PMF 
had significant implications from a diagnostic standpoint.  However, understanding 
the clinical relevancy of these mutations is a key consideration for clinicians.  CALR 
mutations were first identified in patients with a previously confirmed diagnosis of 
JAK2 /MPL wild-type ET which had been made according to the criteria set out by 
the WHO.  As discussed in section 1.5.2.1, in the absence of a recognised genetic 
lesion, a diagnosis of ET cannot be made without the examination of bone marrow 
morphology. 
 
In our setting, bone marrow assessment is infrequently performed on patients 
following inconclusive peripheral blood investigations for suspected classical MPNs.  
Data presented in 5.3 shows that in our experience, bone marrow testing is 
performed on patients with more abnormal blood features than seen in those who 
have peripheral blood screening alone (lower haemoglobin and higher platelet 
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counts).  In routine clinical practice, it is not always feasible to perform a bone 
marrow assessment.  Patients may decline invasive tests or may have existing 
comorbidities which would outweigh the benefits of confirming a diagnosis of a 
classical MPN.  Taking these factors into account it is possible that the group of 
patients in whom CALR mutation were originally identified may not be 
representative of those who would be identified through prospective peripheral blood 
screening.  At the outset of this work, there were no publications which assessed the 
impact of CALR mutations in a prospective cohort nor in the population of patients 
referred in routine clinical practice. 
 
An assessment of the laboratory and clinical features associated with CALR mutated 
ET diagnosed in routine clinical practice were found to be in keeping with those 
described in the literature.  In a routine diagnostic setting CALR mutations were 
associated with lower haemoglobin and white cell counts and higher platelet counts 
than JAK2 V617F mutated counterparts.  Age at presentation was significantly lower 
in the CALR mutated ET cohort compared to the JAK2 V617F mutated counterparts 
in keeping with the published data.   
 
Overall, this data would suggest that the data presented in this work should be 
applicable to diagnostic practise on a wider scale.  Routine diagnostic laboratories 
see a wide range of patients at various stages of disease development and the ability 
to generalise the findings of this work is encouraging.  In addition, this data indicates 
that prognostic findings from large scale retrospective studies can be applied to 
patients in routine clinical practise which is of immense value to both patients and 
clinicians.   
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7. Selection and design of a predictive statistical model  
 
7.1 Rationale and overview 
 
The limited specificity of diagnostic guidelines in the positive identification of 
patients with classical MPNs combined with the potential value of additional 
biological and demographic variables discussed in 5.7 would suggest that classical 
MPN diagnosis would be an ideal candidate for the development of a predictive 
statistical model.  The aim of this chapter is to identify suitable statistical modelling 
approaches for the data available and the intended research outcome.   
 
Selecting the most appropriate methodology to apply to the data is of key importance 
in the development of a statistically sound model.  There is a vast range of statistical 
approaches available for the interpretation of complex data.  The research question 
provides the best indication as to which methodological approaches are suitable.  
The aim of this thesis is not to further the understanding of the biological basis of 
classical MPNs, nor to disclose previous unidentified relationships between 
biological variables.  The primary purpose of the statistical model is in its ability to 
predict an outcome on the basis of diagnostic measurements.  For this reason, 
predictive statistical models are the most appropriate choice. 
 
Predictive modelling approaches can be broadly divided into supervised and 
unsupervised techniques depending upon whether the class of data is known or 
unknown.  As the statistical model will be developed using a case control data set, 
with the class (MPN or no Mutation) known from the outset, this work focusses on 
supervised, predictive modelling techniques. 
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The aim of the statistical model will be to predict whether an individual referral with 
suspected classical MPN is more likely to have a JAK2 V617F or CALR mutation 
(MPN) or not (No mutation) based on the presentation full blood count data in 
combination with demographical information, such as age and gender.  The 
classification produced by the statistical model is used to inform downstream 
investigations. 
 
7.2 Selection of supervised modelling approach 
 
A large scale comparison of supervised, predictive modelling approaches was 
performed using Waikato Environment for Knowledge Analysis (WEKA) version 
3.8, an open source suite of software developed specifically for the purpose of data 
mining (Frank et al., 2016).  The analyses were performed on sample group 4, which 
was comprised of 2970 referrals which underwent both JAK2 V617F and CALR 
mutational screening in HMDS with full blood count data available at the time of 
referral (see 3.5.2.3 and Figure 7-2). 
 
7.2.1 Classifier comparison 
 
A set of eight different supervised classifier approaches were assessed during this 
initial analysis.   
• Naïve Bayes 
• J48 Decision Trees 
• Random Forest 
• Logitboost 
• AdaboostM1 
• SMO (sequential minimal optimisation/support vector classifier) 
• Multilayer Perceptron (neural network) 
• Logistic Regression 
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The classifiers were all run using the default settings in WEKA.  The following 
performance characteristics were assessed to compare and evaluate classifier 
performance: Accuracy, sensitivity, specificity, precision and F-measure.  Sensitivity 
and specificity measure the proportion of true positive classical MPNs identified 
correctly and the proportion of true negative referrals which were correctly 
identified, respectively. Precision (also referred to as positive predictive value) 
assesses the likelihood of a false positive, whilst the F-measure is the mean of both 
precision and sensitivity (see Table 3-4 for details of their calculation).  
 
Figure 7-1. Comparison of supervised classifier approaches using WEKA. 
  
7.2.2  Classifier selection 
 
The primary aim of the predictive model was to improve on the specificity achieved 
using guidelines alone (as described in section 5.6), without reducing the sensitivity, 
therefore modelling approaches which showed high levels of both characteristics 
were determined to be most desirable.  In this general comparison Logistic 
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Regression, Random Forest and Boosted analysis showed the best balance between 
sensitivity and specificity and were selected as the modelling approaches to develop 
further in this work.  Details of the principles of each approach are described in 
section 3.7.3.   
7.3 Development of predictive statistical model in R 
software 
 
Standard methods from predictive modelling were used to design, optimise and 
validate the predictive models as outlined in section 3.7.3.  This was performed in 
RStudio using R statistical software version 3.3.2 and the packages listed in Table 
3-2.  The data scripts used to perform the analyses described within this chapter are 
available in the appendix (section 10.2). 
 
7.3.1  Data preparation 
 
A data set comprising all referrals of suspected classical MPN received by HMDS 
was extracted from HILIS as described in section 3.5.2.3.  This data set was initially 
comprised of 12499 individual referrals made between the beginning of 2005 and the 
end of 2014.  Prior to further analysis the data was subjected to a series of ‘clean-up’ 
procedures as shown in Figure 7-2. 
 
Missing or empty values were identified and replaced with a missing data indicator 
(‘NA’) to prevent interference with statistical analysis.  The data was then read into 
the R software and summary statistics were displayed to identify potentially 
erroneous data such as typographical or transcription errors or changes in units of 
measurements.  Data points which appeared to be outliers were identified, reviewed 
and corrected if appropriate. 
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Figure 7-2. Data 'clean up' process undertaken prior to statistical modelling. 
 
Following data clean-up, a data set containing only referrals received during the year 
2014 was selected and these data was used for the development of the statistical 
models.  The dataset (sample group 4) contained 2970 referrals, of which 42.63% 
(n=1266) were confirmed classical MPN (JAK2 V617F mutated n=1122, CALR 
mutated n=131 and concurrent JAK2 V617F/CALR n=2) and the remaining 57.37% 
(n=1704) did not have a detectable mutation for comparison. 
 
7.3.2 Data comparison group 
 
The laboratory process for investigating suspected classical MPNs in HMDS has 
been described in 3.4.1, briefly, following receipt of a peripheral blood sample the 
laboratory performs a full blood count and morphological assessment followed by 
screening the specimen for JAK2 V617F and CALR mutations.  If no mutation is 
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detected, the report suggests that a repeat specimen is sent (preferably a bone 
marrow) to exclude the presence of disease.  If received, the bone marrow sample is 
tested for the presence of MPL and/or JAK2 Exon12 mutations.  The proportion of 
patients with no JAK2 V617F or CALR mutation who are referred with a subsequent 
sample is low, at approximately 10%, as shown in 5.3.  Consequently, the number of 
specimens in which an MPN is conclusively excluded is insufficient for use in 
statistical modelling.   
 
Primarily, this issue relates to ET/PMF patients where approximately 25% of cases 
will not have a mutation in JAK2 V617F or CALR.  The number of potentially 
undiagnosed MPNs (ET/PMF) has been calculated using the published frequencies 
of gene mutations to give an approximate CALR:MPL ratio of 6:1 and CALR:Triple 
Negative ratio of 3:1.  The data set used for statistical modelling contained 133 
CALR mutated specimens, therefore the expected number of MPL mutated 
specimens is calculated to be 22 and triple negative ET/PMF to be approximately 44.  
The comparison group contains 1704 specimens, therefore undiagnosed MPNs may 
represent 3.9% of this group.     
  
7.3.3 Data normalisation 
 
Prior to logistic regression analysis each variable was normalised.  This was 
performed by visualisation of a quantile-quantile (QQ) plots which compare the data 
distribution seen in each variable with theoretical values were the data distributed 
normally.   Where significant skewing occurred transformations (logarithmic or 
square root) were applied and QQ plots redrawn as shown in Figure 7-3 .  Red cell 
parameters (Hb, RBC, HCT, MCV and MCH) were unchanged following QQ plot 
visualisation.  The platelet count required a square-root transformation, whilst the 
white cell parameters (WBC, Lymph, Neutr and Mono) required a logarithmic 
transformation. 
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Figure 7-3. Examples of normal Q-Q plots and data transformations required 
for normalisation and further statistical analysis. 
 
7.3.4 General analysis of data relationships 
 
Using the pairs function, a series of scatter plots was displayed which plotted each of 
the variables against one another to visualise trends between attributes which may 
impact on later analysis.  Linear relationships were visible between Hb and HCT, 
WBC and Neutr, MCH and MCHC.  A linear relationship is indicated by the data 
points forming a diagonal line rather than a cloud; an example of each is shown in 
Figure 7-4.  These relationships are easily explained as one of the linear parameters 
Normal Q-Q plot
Age
Normal Q-Q plot
Platelet count
Normal Q-Q plot
sqrt(Platelet count)
Normal Q-Q plot
Neutrophil count
Normal Q-Q plot
Log(Neutrophil count)
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in each pair is a derivative of the other.  For example, neutrophils are the largest 
subpopulation of white blood cells, and it was expected that in the majority of cases 
as the white cell count increases, the neutrophil count would follow suit.  It was 
anticipated that it would be necessary to correct for multicollinearity in the models.  
 
 
Figure 7-4. Example of full blood count parameters which show collinear (A) 
and non-linear (B) relationships. 
 
7.3.5 Setting a base performance against which to evaluate model 
performance 
 
The performance of the current clinical guidelines was calculated in section 5.6 
using the data obtained from all suspected MPN referrals received over a 3-year 
period (2012-2014).  This sets the base performance level against which the 
statistical models developed in this chapter will be assessed.  For the model to be 
deemed successful, it should outperform the guidelines in terms of these metrics as 
shown in Table 7-1. 
 
 Sensitivity (%) Specificity (%) 
BCSH 86.96 49.55 
WHO 88.07 33.65 
Table 7-1. Performance metrics associated with current clinical guidelines. 
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7.4 Logistic regression model development 
 
A basic overview of the premise of logistic regression is described in 3.7.3.1.  One 
possible advantage of logistic regression, from the point of the end user, is that the 
weighting of each variable is quantified, and it is possible to present the user with a 
formula that can be interpreted.  The ability to understand and compare how different 
biological and demographic variables contribute to the probability of disease may 
make this approach more readily acceptable in clinical practice. 
 
7.4.1  The logistic regression equation 
 
Logistic regression gives each explanatory variable a coefficient that measures the 
weight of its contribution to the outcome (dependent variable).  Overall the output of 
the logistic regression equation is the odds of belonging to one of the categories of 
dependent variable – in this case the probability of having an MPN. 
 
The equation takes the following form: 
 
𝑙𝑜𝑔𝑖𝑡(𝑝(𝑥)) = log (
𝑝
1 − 𝑝
) = 𝑎 + 𝑏1𝑥1 + 𝑏2𝑥2+ . .. 
 
Where 𝑙𝑜𝑔𝑖𝑡(𝑝(𝑥)) is the log-odds of patient 𝑥 having an MPN and is equal to the 
sum of the intercept ‘a’ plus the value of each explanatory variable ‘𝑥𝑛’ multiplied 
by its regression coefficient ‘𝑏𝑛’.  A larger regression coefficient indicates a greater 
the contribution of the associated explanatory variable to the overall probability of 
disease.  A positive value indicates that the variable increases the probability, 
whereas a negative coefficient subtracts from it. 
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7.4.2 Initial variable selection and model design 
 
The first step in the development of the logistic regression model was the selection 
of the explanatory variables that would be used in the analysis.  Initially the model 
included all variables collected – Age, Gender, Hb, RBC, HCT, MCV, MCH, 
MCHC, WBC, Neutr, Lymph, Mono and Plt. 
 
Analysis was performed using the core R function ‘glm’ with data family set to 
“binomial” in order to link to logistic regression analysis.  The output of the initial 
regression analysis (shown in Table 7-2) identifies highly significant weightings for 
Age, Hb, RBC, Lymph and Plt.  With statistically significant weightings also seen in 
MCV, Gender, MCHC and HCT.  
 
 Estimate PR(>|Z|) 
(Intercept) 112.86 <0.01 
Age  -0.03 <0.01 
Gender (male) -0.31 0.02 
Hb  0.18 <0.01 
RBC  -4.90 <0.01 
MCV -0.27 0.01 
MCH 2.33 0.82 
MCHC -19.93 0.05 
WBC -0.23 0.84 
Lymph 1.12 <0.01 
Neutr -0.62 0.43 
Mono -0.02 0.93 
Plt  -0.23 <0.01 
HCT -5.34 0.02 
Table 7-2. Results of logistic regression analysis showing weighting and 
significance of each explanatory variable. 
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7.4.3 Assessment of multicollinearity within model 
 
Paired plots indicated linear relationships between some of the explanatory variables.  
Collinearity can occur when explanatory variables are not independent, for example 
where two variables are closely related and are effectively measuring the same 
effect.  This can result in a statistical model which is unstable and can reduce the 
statistical power of the model and make it difficult to interpret.  To assess the level 
of collinearity within this logistic regression model, the variance inflation factor 
(VIF) for each explanatory variable was calculated.  
 
Variance inflation factors are computationally defined as the reciprocal of tolerance 
(Marquaridt, 1970) and can be denoted as:  
𝑉𝐼𝐹𝑖 =
1
1 − 𝑅𝑖
2 
Where ‘𝑖’ is the explanatory variable and ‘𝑅𝑖
2’ is the coefficient of determination (the 
square of the correlation between predicted and actual scores). 
 VIF 
Age 1.07 
Gender 1.21 
Hb 121.51 
HCT 56.04 
MCV 168.36 
MCH 358.83 
MCHC 62.43 
WBC 50.28 
Neutr 38.12 
Lymph 4.06 
Mono 2.56 
Plt 1.53 
Table 7-3. Size of VIF associated with each explanatory variable from logistic 
regression analysis. 
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The size of VIF is an estimate of the magnitude by which standard errors are inflated 
than would be case if the variables were unrelated.  Acceptable levels of VIF have 
been recommended in the literature, with a maximum of 10, which corresponds to a 
tolerance of 0.1, commonly indicated (Mansfield and Helms, 1982; Marquaridt, 
1970).  The size of the VIF associated with each of the explanatory variables is 
shown in Table 7-3. 
 
It was evident that a high level of multicollinearity exists within the model in its 
current form.  This level of multicollinearity was likely to affect the validity of our 
statistical model and needed to be addressed. 
 
7.4.4 Rationale behind removal of attributes causing collinearity 
 
Prior to further analysis it was necessary to reduce the level of multicollinearity 
within the model.  To achieve this, a number of explanatory variables needed to be 
removed from the model.  Linear relationships were present between WBC, Neutr 
and Mono variables.  As neutrophils and monocytes are both subpopulations of 
leucocytes (WBC) this was expected.  The decision was made to remove WBC from 
the analysis and it did not represent a specific cellular population.  Examination of 
the data showed that mono counts were not always reported by the full blood count 
analyser and for this reason, it was also removed from the analysis.      
 
Linear relationships were also identified between MCV and MCH as well as Hb, 
RBC and HCT.  The parameters are all measures relating to erythrocytes.  Of these 
parameters, HCT and MCH were not directly measured by our instrument and were 
instead derived from other measured parameters.  The decision was made to remove 
these from the analysis as they represented duplicated information.  The logistic 
regression model was rerun with the more restricted range of explanatory variables.  
All variables now show statistically significant weightings (Table 7-4). 
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             Estimate PR(>|Z|) VIF 
(Intercept) 81.14 <0.01 - 
Age  -0.03 <0.01 1.06 
Gender(male) -0.30 0.02 1.14 
Hb 0.15 <0.01 66.58 
RBC  -5.12 <0.01 68.46 
MCV -0.26 <0.01 11.21 
MCHC -13.28 <0.01 4.62 
Neutr -0.74 <0.01 1.14 
Lymph 1.01 <0.01 1.15 
Plt -0.23 <0.01 1.48 
Table 7-4. Results of revised logistic regression analysis showing weighting and 
significance of refined set of explanatory variables and corresponding VIF 
values. 
Re-evaluation of the VIF shows that there was still significant collinearity.  The 
highest VIF values were associated with Hb, RBC and MCV.  These three variables 
are all measurements associated with the red blood cells and therefore biologically 
related.   
 
Using a series of regression analyses, excluding each of these variables in turn the 
VIF and √VIF were calculated.  The lowest VIF values were obtained when RBC 
was removed from the analysis (Table 7-5). These variables were selected for 
inclusion in the final logistic regression analysis. 
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 VIF 
Age 1.04 
Gender 1.15 
Hb 1.62 
MCV 1.23 
MCHC 1.39 
Neutr 1.13 
Lymph 1.15 
Plt 1.51 
Table 7-5. Size of VIF associated with final selection of explanatory variables 
chosen for logistic regression model. 
 
7.4.5 Attribute selection 
 
Following the removal of variables contributing to the multicollinearity in the model, 
attribute selection was performed using the least absolute shrinkage and selection 
operator (LASSO) method.  LASSO regression performs attribute selection to 
enhance the predictive accuracy of the model by shrinkage.  This involves penalising 
the absolute size of the regression coefficients, and in doing so, some of the 
coefficients will be shrunk to zero, at which point they are removed.   
 
When the variables selected in section 7.4.4 were analysed using LASSO regression, 
and the ‘best’ model selected, none of the variables were ‘shrunk’ away by the 
analysis, confirming that these variables share similar weightings within the model 
and should be included in the logistic regression analysis. 
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7.4.6 Cross validation of logistic regression model 
 
The explanatory variables selected were incorporated into a final logistic regression 
model.  For this analysis the “lrm” function from the package ‘rms’ was used as this 
provides a series of performance metrics that can be used to assess the model (Table 
7-6). 
 
  Discrimination indexes Rank discrimination indexes 
Observations 2298 R2 0.55 C 0.89 
Case 1033 Brier 0.13 Dxy 0.78 
Control 1265     
 Coefficient Pr(>|Z|) 
Intercept -29.99 <0.01 
Age -0.03 <0.01 
Gender (male) -0.29 0.02 
Hb -0.02 <0.01 
MCV -0.01 0.16 
MCHC 11.89 <0.01 
Neutr -0.60 <0.01 
Lymph 1.09 <0.01 
Plt  -0.24 <0.01 
Table 7-6. Performance metrics of final logistic regression model. 
 
The highlighted ‘C’ denotes the ‘c’ index’, which represent the area under the 
receiver operating characteristic (ROC) curve.  ‘Dxy’ denotes the Somers’ Dxy rank 
correlation between the predicted probabilities and the observed responses.  There is 
a simple relationship between ‘C’ and ‘Dxy’ (Somers, 1962): 
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𝐷𝑥𝑦 = 2(𝐶 − 0.5) 
Again, a Dxy of 1 denotes perfect discrimination of observations by the model.  In 
this case the ‘C’ index is 0.887, indicating a strong predictive model. 
 
Following analysis, cross validation of the model was performed using the 
“validation” function from within the “rms” package selecting the cross-validation 
method. 
 
 Original Training Test Optimism Corrected 
DXY 0.7747 0.7748 0.7704 0.0044 0.7703 
R2 0.5470 0.5471 0.5582 -0.111 0.5581 
C index 0.88735 0.8874 0.8852 0.0022 0.8852 
Table 7-7. Cross-validation performance metrics of logistic regression analysis. 
 
The cross-validation process described in 3.7.3.1 is intended to detect overfitting and 
estimate the extent to which it is affecting the model.  Whilst it is desirable to 
maximise the performance of the model on the training data set, the performance of 
the model on unseen data will determine its success.  Cross validation of this logistic 
regression model results in slight reductions in the performance metrics (Table 7-7).     
  
7.4.7 Model evaluation  
 
To determine the performance of the model on the training set, the metrics described 
in Table 3-4 were assessed.  As the model returns the likelihood of disease as a 
probability, it was necessary to choose a threshold level of probability at which the 
model would classify each sample as either MPN or No mutation. 
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7.4.7.1 Identifying the threshold giving best model performance 
 
Optimisation of the threshold was performed in two ways; the first was to identify 
the threshold of probability which yielded the highest sensitivity plus specificity.  
This was achieved using features of the ROCR package, Figure 7-5 shows sensitivity 
vs specificity with increasing thresholds of probability in ROCR in the form of a 
graph.  A threshold of 0.56 was calculated as returning the greatest sensitivity plus 
specificity, achieving a combined value of 1.65.      
 
Figure 7-5. Graphical representation of yielded sensitivity vs specificity with 
increasing threshold of probability in ROCR. 
 
This threshold was applied to the model and performance measured using the 
confusionMatrix function from the CARET statistical package. 
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 Actual MPN Actual no mutation 
Predicted MPN 848 215 
Predicted no mutation 185 1050 
Table 7-8. Performance of logistic regression model at optimal prediction 
threshold calculated by ROCR analysis. 
 
Using a threshold of 0.56 to determine class returned the predictions shown in Table 
7-8.  This gave a sensitivity of 0.82 and specificity of 0.83.  Whilst this represents a 
substantial increase in specificity over that achieved using the clinical guidelines 
(which has been determined to be 49.55% at best), the sensitivity of the model falls 
below the 86.96% minimum the guidelines achieved with 185/1033 actual MPNs 
predicted to have no mutation. 
 
Maintaining the level of sensitivity achieved by the guidelines and minimising the 
number of false negatives produced by the model was more important that achieving 
maximum levels of specificity.  Therefore, a second approach was taken to optimise 
the threshold of probability within the model. 
 
7.4.7.2 Optimising the threshold to give the best model for purpose 
 
To determine the threshold which would give maximum specificity whilst 
maintaining sensitivity above that achieved by the clinical guidelines was determined 
by assessing the sensitivity and specificity of the model across a range of thresholds 
(Table 7-9). 
 
Using a threshold of 0.7 to determine class membership gave a sensitivity marginally 
higher that that achieved using the guidelines alone, alongside an increase in 
specificity (72.73% compared with 49.55% achieved by guidelines).  When a 
threshold of 0.7 was applied to the dataset, the confusion matrix gave the results 
shown in Table 7-10.  This threshold has been applied to all further analyses.   
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Threshold Sensitivity Specificity 
0.05 0.17 1.00 
0.10 0.29 0.98 
0.15 0.38 0.97 
0.20 0.47 0.96 
0.25 0.54 0.94 
0.30 0.61 0.92 
0.35 0.66 0.91 
0.40 0.72 0.90 
0.45 0.74 0.88 
0.50 0.77 0.86 
0.55 0.82 0.84 
0.60 0.84 0.81 
0.65 0.87 0.77 
0.70 0.89 0.73 
0.75 0.92 0.66 
0.80 0.94 0.58 
0.85 0.94 0.48 
0.90 0.97 0.33 
0.95 0.98 0.12 
Table 7-9. Logistic regression model performance over a range of increasing 
thresholds of probability. 
 
 Actual MPN Actual no mutation 
Predicted MPN 920 345 
Predicted no mutation 113 920 
Table 7-10 Predictive performance of logistic regression model with a threshold 
of 0.7. 
 
7.4.8 Validating the logistic regression model on a test dataset 
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The logistic regression model was built using data cohort containing a ratio of 
MPNs:No mutation of 0.74.  Data presented in 5.2 shows that the actual frequency of 
MPNs is much lower than this (in the region of 0.2:1).  In addition to this difference 
in MPN representation, there is the inherent issue of overfitting, whereby the model 
has been optimised for its performance on a specific data set which may not be 
applicable to ‘real world’ data.  To accurately assess the suitability of the model in 
clinical practice it needs to be validated using a ‘test’ data set – this is a set of data 
that has not been ‘seen’ by the model. 
 
7.4.8.1 The test data set 
 
A data set of 515 referrals received for the investigation of a suspected MPN was 
identified through the SQL searches performed on the HILIS database.  These 
referrals were received during the first calendar quarter of the year 2015 and 
comprised 112 JAK2 V617F or CALR mutated classical MPNs and 403 samples in 
which no mutation in JAK2 V617F or CALR was identified.  This data set was 
completely independent of that used to build to model and therefore suitable for 
model validation.   
 
7.4.8.2 Model performance on test data 
 
The logistic regression model described in 7.4.6 was applied to the test data set and 
performance characteristics determined using the probability threshold of 0.7 as 
determined to be optimal in 7.4.7.2.  The model performance is shown in Table 7-11. 
 
 
 
 Actual MPN Actual no mutation 
Predicted MPN 70 82 
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Predicted no mutation 6 203 
Table 7-11. Performance of logistic regression model on test dataset. 
 
The model gave a sensitivity of 92% and specificity of 71%, compared with 89% 
sensitivity and 72% specificity achieved using the model-build data-set.  
 
7.4.9 Analysis of misclassified data 
 
7.4.9.1 Analysis of false negative classifications 
 
When the logistic regression model was applied to the test data set, 6 referrals which 
were found to carry either a JAK2 V617F or CALR mutation (‘MPN’) were 
incorrectly predicted to have ‘No mutation’ by the model, these can be referred to as 
false negatives.  Each of these referrals was reviewed to establish whether they had 
additional clinical features that would have indicated the presence of disease.  In two 
instances, the patient had previously been diagnosed with an MPN and was on 
treatment at the time of investigation and consequently had normal full blood count 
indices on the referred sample.  One of the referrals was from a patient who had a 
previously diagnosed, co-existing plasma cell neoplasm, this may have resulted in 
impaired haematopoiesis which would account for the normal full blood count at the 
time of referral.   
 
 
 
A further sample was from a patient who had been recently received chemotherapy 
for a non-haematological malignancy and one referral had normal full blood count 
indices.  In these two specimens, the JAK2 V617F mutations was reported as being 
present at a low level (estimated to be <10% allelic burden based on area under 
peak).    The final misclassified ‘MPN’ did have an isolated increased platelet count 
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of 569x109/L, at the time of writing the patient had not undergone any further 
investigations and no further clinical information was available. 
 
Of the 6 false negatives, only 4 were determined to be genuine referral for the 
investigation of a suspected MPN.  Three of the 4 may have been misclassified due 
to the lack of abnormal blood count parameters.  In 2/3 of these, impaired 
haematopoiesis attributable to another malignancy may have masked the underlying 
MPN and this information was not recorded on the request form, highlighting the 
importance of providing relevant clinical details to enable appropriate processing of 
specimens.  Only one sample that had a clearly abnormal full blood count would 
have been misclassified by this model.   
 
7.4.9.2 Analysis of false positive classifications 
 
Analysis of the test data set also identified 82 samples with ‘No mutation’ that were 
misclassified as being ‘MPN’ by the model, herein referred to as false positives.  
Due to limitations in access to clinical data, only those referrals from within the 
Leeds Teaching Hospitals could be reviewed further (n=12).  Of the patients 
reviewed, the majority (n=10) were described as having an underlying reactive cause 
which accounted for deranged full blood count results.  In 3/10 referrals, an acute 
episode of illness coincided with investigation and the full blood count parameters 
returned to normal following recovery.  A chronic reactive process was identified as 
the probable cause in 7/10 referrals; with chronic iron deficiency stemming from 
chronic blood loss in 4 of these, active rheumatoid arthritis present in 2 and anaemia 
of chronic disease in one other.   
 
Hypoxia secondary to smoking and pulmonary disease was determined to be the 
cause of polycythaemia in one of the 2 remaining specimens which did not have 
reactive conditions.  The final ‘false positive’ referral was followed up by bone 
marrow investigations which confirmed a diagnosis of ET. 
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If this data is representative of the false positives classified, it would indicate that an 
alternative cause for the abnormal blood features can be identified in the majority of 
referrals with no mutation detected and that, in a large proportion, the features begin 
to normalise shortly after investigation.  If reactive causes were excluded prior to 
referral for JAK2 V617F and CALR mutational screening, these specimens would not 
have been received for investigations. 
 
7.5 Random forest model development 
 
The premise of Random Forest analysis is described in 3.7.3.1.  This modelling 
approach is sometimes referred to as ‘black box’ method as it is not visible to the 
user how the outcome is determined and the weighting of the variables in relation to 
the outcome is difficult to visualise.  Random Forest analysis, by its nature, applies 
arbitrary thresholds to the data in order to form the branches of decision trees.  This 
approach is similar to the way in which clinical guidelines have been set out, albeit 
on a much larger and more complex scale. 
 
7.5.1 Random forest analysis 
 
Using the data set created in 7.3.1, a Random Forest model was built using the 
randomForest statistical package, selecting to perform 10-fold cross validation on a 
set of 500 distinct decision trees as part of the model training process.  The initial 
step of the model training process calculated the optimal number of branches per 
tree, in this analysis the model accuracy was highest when decision trees of no more 
than 7 branches were used (Table 7-12).   
Table 7-12. Performance of optimised Random Forest model on training data. 
 Actual MPN Actual no mutation 
Predicted MPN 873 158 
Predicted no mutation 165 1100 
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When this optimised model was applied to the data (Table 7-12), it produced a 
sensitivity of 84.10% and specificity of 87.44% on the training data set.   
 
7.5.2 Testing the model on an unseen data set 
 
Using the same test data set as described in 7.4.8.1, the Random Forest model was 
reapplied (Table 7-13) and performance characteristics calculated.  The model 
sensitivity was 97.37% and specificity was 15.09%. 
 
 Actual MPN Actual no mutation 
Predicted MPN 74 242 
Predicted no mutation 2 43 
Table 7-13. Performance of optimised Random Forest model on test dataset. 
 
 
 
 
 
 
7.5.3 Analysis of misclassified data 
 
7.5.3.1 False negatives 
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In this analysis only 2 MPNs were predicted to have no mutation when the random 
forest model was applied to the test data.  One of these had also been misclassified 
by the Logistic Regression model and was found to be from a patient with an 
existing diagnosis of ET, who was on treatment at the time of referral.  The other 
false negative produced by this model was a referral with an isolated thrombocytosis 
of 1087x109/L; unfortunately, no additional clinical information or follow up was 
available. 
 
7.5.3.2 False positives 
 
The random forest analysis incorrectly classified 242 samples with no mutation as an 
MPNs.  Thirty-three of these false positives had been referred from within Leeds 
Teaching Hospitals and clinical records were reviewed.    
 
Sixteen of these 33 referrals were due to features of suspected polycythaemia.  Ten 
were attributable to smoking and/or alcohol intake – with full blood count indices 
resolving to within reference ranges at following reduced intake.  Therapy related 
polycythaemia was diagnosed in a further 2 - both of which were due to testosterone 
replacement.  The remaining 4/16 were without obvious cause, but all resolved 
shortly after investigation.  Of the remaining 17 referrals, 1 referral had pancytopenia 
and was found to have a pre-exiting diagnosis of Refractory Cytopenia with Multi-
lineage Dysplasia and Fibrosis.  Four referrals were from patients suffering from 
thrombotic events and 12 from patients with an isolated thrombocytosis.  In the 12 
patients with thrombocytosis, 4 were attributed to iron deficiency, a further 4 to 
chronic reactive conditions and one was following splenectomy, no underlying cause 
could be identified in the final 3.   
Bone marrow investigations were performed in the 3 instances where an underlying 
cause was not documented, a diagnosis of ET was made in one specimen, systemic 
mastocytosis in the second and the final bone marrow showed a reactive picture.   
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7.6 Gradient-boosted modelling 
 
The final statistical modelling approach applied to the data set was gradient boosting.  
The basic premise of this technique is described in section 3.7.3.3.  Like Random 
Forest modelling, this is a ‘black box’ analysis and is also an ensemble technique 
combining multiple different decision tress classifiers.  Gradient-boosting differs 
from Random Forest analysis, in that the vote produced by each classifier within the 
ensemble is given a weighting depending upon the overall performance of that 
classifier.  The final classification is based upon ‘proportional representation’ rather 
than each classifier making an equal contribution to the overall decision. 
 
7.6.1 Development of gradient boosted model 
 
The gradient boosted model was built using features from the ‘caret’ and ‘gbm’ 
packages in RStudio and the data-set described in section 7.3.1.  Repeated cross-
validation was performed with 10 samples, repeating the process 10 times.  The 
process was run in triplicate, with increasing interaction depths (set at 1, 3 and 5).  
Each iteration was also run in duplicate, with increasing numbers of decision trees 
(ranging from 50 to 1500, in increasing increments of 30), over 3 different shrinkage 
thresholds (0.1, 0.01 and 0.001) with a minimum of 20 observations per node. 
 
The ‘best’ model was determined according to the overall model accuracy, this was 
achieved when the 1300 trees were used, with an interaction depth of 5 and 
shrinkage of 0.01.  A comparison of the models produced during the training process 
is shown in 
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Figure 7-6. 
Figure 7-6. Graphical representation showing Gradient boosted model 
performance during training. 
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The relative influence of each of the explanatory variables can also be visualised (see 
Figure 7-7), and shows that Platelet count (relative influence = 43.52), Haemoglobin 
(relative influence = 16.19) and MCHC (relative influence = 12.06) are the most 
influential measurements when using this modelling approach. 
 
Figure 7-7 Relative influence of each explanatory variable determined by 
gradient boosted regression analysis. 
 
The performance of the optimised gradient boosted model is shown in Table 7-14.  
The ‘best’ gradient boosted model achieved a sensitivity of 90.81% and specificity 
of 91.99%. 
 
 Actual MPN Actual no mutation 
Predicted MPN 929 102 
Predicted no mutation 94 1171 
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Table 7-14. Performance of optimised Gradient Boosted model on training 
dataset. 
 
 
7.6.2 Application of gradient boosted model to test data 
 
The optimised gradient boosted model was applied to the test data set described in 
7.4.8.1, and performance characteristics calculated.  The results of this analysis are 
shown in Table 7-15. 
 
 Actual MPN Actual no mutation 
Predicted MPN 63 37 
Predicted no mutation 13 248 
Table 7-15. Performance of optimised Gradient Boosted model on test dataset. 
 
The model sensitivity was 63.00% and specificity was 95.02%. 
 
7.6.3 Misclassified Data 
 
Gradient boosted modelling produced the highest number of false negatives of all 
three approaches when applied to the test data with 13 misclassifications versus 6 
produced by the logistic regression model and 2 by the random forest analysis.  This 
is the equivalent of 37.00% of referrals with a JAK2 V617F or CALR mutation 
failing to be predicted as such by the model.  This is a significantly lower level of 
sensitivity than achieved by the previous two modelling approaches and suboptimal 
when compared to the use of clinical guidelines alone.  For this reason, no further 
investigation of the misclassified data was performed. 
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7.7 Discussion 
 
Within the field of haematological malignancies, the reporting of statistical analyses 
in publications is commonplace.  The majority of clinical and biological journal 
articles contain some form of statistical analysis to indicate the significance of the 
data within.  However, the application of a predictive statistical model in clinical or 
diagnostic practice has not been previously reported in the diagnosis of MPNs.  The 
aim of this chapter was to investigate the utility of predictive statistical modelling as 
an alternative or adjunct to existing clinical and diagnostic guidelines. 
   
The current clinical guidelines are skewed towards a high sensitivity for the 
detection of MPN’s.  However; this comes at the expense of specificity, with over 
half of referrals that meet the criteria not having a diagnosable disease.  In addition 
to this, data presented in 5.2, shows that, in practice, the frequency of diagnosis of 
classical MPNs in the group of patients referred for investigation is very low, at 
19%.  Follow-up investigations are performed infrequently, with only 10.86% of 
patients who test wild type for JAK2 V617F and CALR 9 mutations undergoing a 
bone marrow biopsy.  For these reasons, it was felt that this was an area where 
improved efficiency in diagnostic processes could have significant benefits for both 
health care providers and patients.   
 
Selecting a suitable classifier approach for the data is a subjective process.  There are 
a vast range of predictive statistical modelling methods available that could, in 
theory, be applied to the data.  Initially, a comparison of eight different supervised 
classifiers was performed using WEKA.  Whilst this approach has not been reported 
in the context of either classical MPN diagnosis or indeed clinical referral practice in 
general, it has been applied within the diagnosis of other haematological 
malignancies, including the analysis of gene expression data in Diffuse Large B-cell 
Lymphoma (Care et al., 2013; Sha et al., 2015)    
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The concept of choosing the ‘best classifier’ is entirely dependent upon the overall 
goal of the model.  In this case, success would be measured against the metrics of the 
existing clinical/diagnostic guidelines, aiming to maintain sensitivity at the level 
achieved by the guidelines as a minimum, whilst achieving the maximum specificity 
possible.  This would ensure that the model ‘misses’ a minimal number of MPNs, 
whilst minimising the number of patients that would undergo investigation.  The 
general comparison performed in WEKA indicated that logistic regression, random 
forest and gradient boosted analysis were selected for further development. 
 
The first step of model development was the selection of a suitable data set.  The 
identification of ‘cases’ for inclusion did not pose any issues and was comprised of 
data from 1266 referrals which were received by HMDS for the investigation of a 
suspected MPN and which had a diagnosis confirming this.  The selection of a 
suitable comparison population was less simple.  The statistical model was intended 
to be used primarily within the clinical laboratory setting, with a view to acting as a 
form of triage to determine which referrals would undergo molecular screening.  It 
was not intended to discriminate between ‘normal’ individuals from the general 
population and those with an MPN, but rather to try and identify true MPN’s from 
within the population of patients referred with suspected disease.  On this basis, it 
was decided that a comparison group of ‘normal’ individuals would not be suitable 
and instead the control group should consist of patients referred for the investigation 
of a suspected MPN, who were not confirmed as having the disease. 
 
It was recognised that the use of this comparison population has some drawbacks.  
Samples referred for the investigation of a suspected MPN currently undergo 
screening for JAK2 V617F and CALR exon 9 mutations, alongside morphological 
assessment.  However, it is well reported that these two mutations are not present in 
all cases of MPN, a small proportion will carry a mutation in JAK2 exon 12 (1-2% of 
PV cases) or MPL exon 10 (3-5% of ET and 5-10% of PMF) and a proportion of 
MPN patients will not have a demonstrable mutation requiring diagnosis by bone 
marrow morphology.  The low frequency of Exon 12 and MPL mutations makes it 
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economically impractical to perform screening for these mutations on all JAK2 
V617F and CALR exon 9 wild type samples in routine practice.  Unfortunately, as 
the data shown in section 5.3 demonstrates, following initial molecular screening, the 
majority of patients with a non-diagnostic peripheral blood screen do not receive a 
follow-up bone marrow referral (89.14% of cases) and therefore the presence of an 
MPN cannot be fully excluded in the majority of cases.  The number of patients in 
which disease has been fully excluded is both small, and as the data demonstrates, 
the group of patients in which this is achieved are not representative of the referred 
population as a whole, having significantly different blood count parameters 
compared to those who were not followed up (Figure 5-3).  It is estimated that 
undiagnosed MPNs account for less than 5% of the comparison group, as this was 
the most representative sample group available, the decision was made to use it in 
model development.  
 
A total of 13 explanatory variables were selected for potential inclusion in a 
statistical model.  These were age, gender, haemoglobin, red cell count, haematocrit, 
mean cell volume, mean cell haemoglobin, mean corpuscular haemoglobin 
concentration, white cell count, neutrophil count, lymphocyte count, monocyte count 
and platelet count.  The first modelling approach used was logistic regression 
analysis, prior to model development, was to ensure that the data was in the 
appropriate form for analysis.  Q-Q plots were used to identify variables which 
required transformation and where necessary this was performed.  In addition to 
these data transformations, a matrix of plots showing each of the variables paired 
against each other to look for evidence of collinearity between variables.  
Collinearity occurs where two (or more) variables are measuring the same effect and 
are therefore not independent of one another. 
 
The initial logistic regression analysis included all the explanatory variables, the 
model showed statistically significant weightings for all but 4 of the variables.   
However, the presence of linear relationships as indicated by the paired data plots, 
would suggest that using all the variables would not produce a robust statistical 
model.  To confirm the presence and magnitude of collinearity in the model, the size 
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of variance inflation factors associated with each attribute were calculated.  This 
showed prominent levels of multicollinearity between red cell associated variables 
and between those deriving from white blood cell populations.  As stated, 
multicollinearity occurs when variables are not independent of one another, and as 
such it was expected as the majority of variables included in the model are related – 
Hb, RBC, MCV, MCH, MCHC and HCT are all measurements related to the same 
cell population (erythrocytes) and WBC is a cumulative measure of the neutrophil, 
lymphocyte and monocyte populations. 
 
To address the collinearity involving white cell parameters, it was decided to remove 
WBC from the analysis.  The rationale for this was that it did not represent a single 
cellular population and was to some extent a duplication of data contributed by the 
other WBC related parameters.  The decision was also made to remove monocyte 
count from the analysis as a review of the full blood count data showed that it was 
not consistently reported by the analyser and was therefore a less reliable variable.  
The linear relationships seen between the red blood cell related parameters was 
addressed by removing MCH and HCT from the analysis – the rationale for this was 
that these parameters were not directly measured by our full blood count analyser 
and were instead derived from other measured parameters.   
 
The logistic regression analysis was reperformed using the smaller selection of 
variables and the variance inflation factors were recalculated.  Multicollinearity was 
still present involving Haemoglobin, RBC and MCV.  To determine which of these 
variables should be excluded from the analysis, each was removed in turn and 
logistic regression analysis performed.  Removing RBC from the model resulted in 
the sufficiently low VIF values and the best predictive power. 
 
Once the issues of collinearity had been addressed, attribute selection was performed 
using LASSO regression.  This technique restricts the absolute size of regression 
coefficients, with the effect of shrinking those with the lowest values towards zero. 
In doing so, the variables with the least influence can be removed with the benefit of 
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creating a simplified model.  The ‘best’ model as determined by LASSO regression 
did not result in the shrinkage of any of the included variables.  
 
The final model selection would include; Age, Gender, Haemoglobin, MCV, 
MCHC, Neutrophil, Lymphocyte and Platelet counts as its explanatory variables.  
Performance metrics were determined for the model and a c index of 0.887 indicated 
that the model had strong predictive value. 
 
The logistic regression model calculates the likelihood of the outcome (in this model, 
the likelihood of having a classical MPN or not) as log odds, set on a scale between 
0 and 1.  The threshold at which the model categorises a sample as a probable 
classical MPN or not can make a significant difference to the performance of the 
model in practice.  To optimise the performance of the model, the most suitable 
threshold needed to be determined.  There are several considerations to take into 
account when selecting the optimal threshold for class determination.  Firstly, the 
threshold which gives the ‘best’ model performance was determined, that is, the 
threshold which resulted in the highest level of sensitivity and specificity combined 
– thus resulting in the most ‘accurate’ model overall.  A threshold of 0.56 was 
calculated as achieving this, and further analysis of the performance metrics showed 
that using this threshold would achieve a sensitivity of 0.82 and specificity of 0.83. 
 
However, this model was intended to improve upon the performance of the current 
clinical guidelines that have a sensitivity of 0.87, which is superior to that achieved 
by the logistic regression model using the 0.56 threshold.  The reduced sensitivity of 
the model would result in an increase in the number of ‘cases’ missed which would 
have negative implications for patients.  In this case the ‘best’ model in statistical 
terms was not the ‘best’ model for the intended purpose.  Instead, a threshold which 
would give the maximum specificity whilst achieving a minimum sensitivity of 0.87 
would be optimal.  Performance characteristics were calculated across a wide range 
of thresholds to manually determine if this was possible.  A threshold of 0.7 was able 
to achieve a higher sensitivity than the guidelines (0.89) whilst achieving an 
improved specificity (0.73 vs 0.50 achieved by guidelines). 
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The performance of the model on the case control data set does not necessarily 
reflect the performance of the model in ‘real life’.  The data set was selected to have 
approximately even proportions of MPNs:No mutation samples with a ratio of 
0.74:1, this was not reflective of the true incidence of classical MPNs in our referral 
population where the ratio is approximately 0.2:1.  To determine how effective the 
model would be in practice, it was applied to a separate cohort of 361 suspected 
MPN referrals was used as a validation data set and performance characteristics 
measured.  The model performance was comparable on the validation data to the 
training data, achieving sensitivity of 0.92 and specificity of 0.71.      
 
Referrals which were misclassified by the model were identified.  Only 6 samples 
with a classical MPN were misclassified by the logistic regression model, of which 2 
were actually known classical MPN patients who were on treatment at the time of 
investigation and a further 2 had low allelic burden of JAK2 V617F (<10%), a 
further case had another coexisting haematological neoplasm which may affect the 
predictive capabilities of the model.  The final classical MPN missed by this model 
had an isolated thrombocytosis with a platelet count of 569x109/L, well above the 
upper limits of the normal range.  Excluding the two known classical MPN patients 
would increase the sensitivity of the model slightly to 0.95.  
 
As expected by the lower specificity of the model compared to its sensitivity, the 
model misclassified a larger number of referrals as MPNs, with a total of 82.  
Clinical records were reviewed in the 12/82 cases referred from Leeds Teaching 
Hospitals.  The majority (10/12) of these had an underlying reactive condition which 
would account for the abnormal blood count parameters, and in all cases blood 
counts did return to normal levels following investigation.  Two of the referrals did 
not have underlying reactive conditions, 1 was deemed to be due to smoking related 
hypoxia and the final referral had a bone marrow performed which confirmed a 
diagnosis of triple negative ET. 
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The development of a random forest model was in many ways easier than logistic 
regression.  The software package used incorporated cross-validation processes as 
well as optimisation of tree size.  In addition to this, random forest analysis is a 
‘black box’ technique, in which the processes taking place between data input and 
output are hidden from the user.  The ‘best’ model produced using random forest 
analysis produced a sensitivity of 0.84 and specificity of 0.87.  Application of the 
model to the validation data set produced a higher level of sensitivity (0.97) 
however, but the specificity was very low at 0.15.  Analysis of the MPNs missed by 
the model (n=2) revealed that whilst 1 of the referrals was from a known ET on 
treatment (with normal full blood count parameters), however, the second was a 
referral with an isolated thrombocytosis of 1087x109/L. 
 
A larger number of samples with no mutations were misclassified as MPNs by the 
random forest analysis (n=242).  Thirty-three of these were from Leeds Teaching 
Hospitals and clinical documents were reviewed in all cases.  Suspected 
polycythaemia was indicated in 16/33, 10 of these were attributed to smoking and/or 
alcohol use, and 2 were thought to be a side effect of testosterone therapy.  The 
remaining 4 referrals with suspected polycythaemia were without identifiable cause, 
all of which resolved following investigation.  In the 17 non-polycythaemic false 
positives, 4 were thought to be due to iron deficiency related thrombocytosis, 4 were 
due to chronic reactive conditions including rheumatoid arthritis, 4 following 
thrombotic events, 1 due to prior splenectomy and 1 was in a patient who had been 
previously diagnosed with refractory cytopenia with multi-lineage dysplasia and 
fibrosis.  The remaining 3 had no identifiable cause for investigation and underwent 
bone marrow analysis.  ET was diagnosed in one case, systemic mastocytosis was 
found in a further individual and the final case showed reactive changes only.      
 
Gradient boosted modelling initially appeared to offer the best levels of specificity 
(89.82%) and sensitivity (91.21%) with both exceeding that achieved by the use of 
current clinical guidelines alone (best sensitivity 88.07% (WHO), best specificity of 
49.55%(BCSH)).  Model optimisation was the most complex of the three techniques 
and required the longest computational processing time.  However, when applied to 
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the test data set, the model performance deteriorated significantly and had much 
poorer predictive power than either logistic regression or random forest analysis.    
 
In summary, the logistic regression model performed better than both the random 
forest analysis and gradient boosted model in the classification of suspected MPN 
referrals.  The overall performance was superior to that achieved using the clinical 
guidelines alone and if used, may reduce significantly the number of patients 
undergoing investigation for suspect MPNs.  In addition, the use of logistic 
regression has the added benefit of weighting each variable allowing for some 
evaluation of how different biological parameters contribute to the probability of 
disease.  The data within this chapter would indicate that MCHC and lymphocyte 
count have the biggest weighting within the model, both in an additive way.  In real 
terms, higher MCHC and lymphocyte counts increase the likelihood that a referral 
will not have a mutation of JAK2 or CALR detected.  There are no publications that 
specifically identify lymphocyte counts as being of significance in MPN diagnosis.  
However, reduced B cell progenitors are a frequent finding in myelodysplastic 
syndrome (Jacobs et al.) and it could be hypothesised that lymphocyte count may be 
an indicator of overall haematopoietic function.  Likewise, MCHC may be a general 
indicator of effective haematopoiesis.   Increased values for the other scalar 
explanatory variables or male gender act in a subtractive manner and increase the 
probability that a referral will be classified as a case. 
 
The comparable performance of the model on both the test and validation cohorts is 
a good indicator that the model is robust and fit for purpose.  To assess the impact 
that the implementation of this model would have in practice, a further data set of 
referrals of suspected MPNs will be analysed using the model in the next chapter. 
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8. Assessing the impact of utilising a predictive statistical 
model in routine diagnostic practice 
 
The development and validation of the predictive logistic regression model for the 
diagnosis of MPNs demonstrates a clear statistical improvement over the use of 
clinical guidelines alone.  However, the use of such models in clinical and/or 
laboratory practice has not been reported in this field and the acceptance of such an 
approach by clinicians and patients may be challenging.  It requires a change in 
approach and will contradict both current diagnostic guidelines as well as modifying 
current clinical practice.   
 
Demonstrating that the model performance is superior to current methods goes 
partway towards justifying its use.  In addition to this, it must also be shown that it 
does not compromise patient safety, and that implementation would not have a 
detrimental effect on workload, resources and in the case of HMDS, income 
generation.  In this chapter, the impact of utilising the predictive logistic regression 
model will be examined in more detail. 
 
8.1 The data used to assess impact 
 
As detailed in 3.5.2.5, all referrals received by HMDS for the investigation of 
suspected MPNs during the 2016 calendar year were selected for assessment of the 
model in ‘real life’.  Sample group 6 was initially composed of 2174 referrals, with 
438 confirmed diagnoses of MPN and 1740 with no mutation detected.  Following 
removal of duplicate patient referrals and exclusion of those in which clinical details 
did not indicate a suspected MPN (therefore were not screened for JAK2 V617F or 
CALR mutations) or where peripheral blood was not received for full blood count 
analysis, the data set was reduced to 1581 referrals (see Figure 8-1).  
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The data set contained; 801 male and 780 female referrals (ratio 1.03:1) aged 
between 16 and 94 years of age (median age – 61 years).  A diagnosis of MPN was 
confirmed in 305/1581 referrals with the remaining 1276/1581 referrals having no 
mutation in JAK2 or CALR detected. 
 
Figure 8-1. Selection of referrals for analysis of model impact in routine 
diagnostic practice. 
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8.2 How would the model be used in practice? 
 
This model relies upon accurate full blood count data, and as described in 3.3, it is 
not practical to perform full blood count analysis prior to consultation at the patient’s 
initial visit to clinic.  Therefore, in the first instance, the predictive model has been 
designed to be used within HMDS (or a similar laboratory) as a form of sample 
triage, although it could also be used in a clinical setting if desired.  The statistical 
model is intended to guide and support existing practice rather than replace it and so 
it was envisioned that the prediction produced by the model would be used alongside 
morphological assessment to indicate whether a specimen underwent further 
investigations following full blood count assessment. 
 
Using the optimised threshold of 0.7 (as described in 7.4.7.2) referrals which were 
classified as an MPN by the model (predicted risk <0.7) would undergo molecular 
screening for JAK2 V617F and CALR exon 9 mutations.  Those which returned a 
predicted risk of >=0.7 would be predicted to not be an MPN and would not be 
investigated any further.  An exception to this, would be where there were clinical 
features recorded (such as splenomegaly or unexplained thrombotic events) or 
morphological features (for example, the presence of tear drop poikylocytes) were 
indicative of an underlying pathological process.   
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Figure 8-2. Proposed workflow diagram incorporating predictive modelling. 
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8.3 How would the application of predictive logistic 
regression model have impacted on workload in 2016? 
 
The logistic regression model developed in chapter 7 was applied to the data set 
described in 8.1.  Referrals were categorised as ‘MPN’ and ‘not MPN’ based on the 
model’s prediction.  This resulted in 37.13% (n=587) referrals being categorised as 
‘MPN’ and the remaining 62.87% (n=994) referrals being classed as ‘not MPN’ by 
the model. 
 
8.3.1 Model performance 
 
Using the performance metrics detailed in previous chapters, the logistic regression 
model showed a sensitivity of 0.88 and specificity of 0.75. 
 
 Actual MPN Actual no mutation 
Predicted MPN 267 320 
Predicted no mutation 38 956 
Figure 8-3. Performance of predictive model on suspected MPN referrals 
received during 2016. 
 
8.3.2 Would the genuine MPN referrals have been missed in 
practice? 
 
When the data was analysed further, 38 of the referrals which were predicted as not 
being MPNs, which were subsequently found to have an MPN.  As in section 
7.4.9.1, the request data, and where possible, clinical records were reviewed.  Upon 
further investigation 14/38 false negatives were found to have a previously 
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diagnosed MPN and were on treatment at the time of referral, accounting for the 
normal full blood count data. 
 
Of the remaining 24, 5 had been referred due to unexplained thrombotic events, 
clinical features which have been prompted investigation according to the workflow 
diagram outlined (Figure 8-2).  Two referrals were concurrently undergoing 
investigation for other possible haematological malignancies.  In one case, a patient 
was suspected as having MDS or PMF due to worsening cytopenia and the clinical 
details supported investigation.  In the second case, the patient was referred with 
clinical details of suspected PMF and/or a lymphoproliferative disorder and 
morphological features supported the suspicion of PMF which would have resulted 
in investigations proceeding, despite the prediction of the statistical model.     
 
One of the remaining false negatives did not demonstrate JAK2 V617F or CALR 
exon 9 mutations in the specimen used in this analysis and was initially reported as 
non-diagnostic, however, morphological examination of the peripheral blood had 
evidence of tear drop poikylocytes which would have prompted investigation.  A 
subsequent bone marrow received on this patient confirmed the diagnosis of an 
MPN.   
 
A further 3, presented with elevated haemoglobin and haematocrit but no additional 
clinical information was available to indicate whether this was persistent or whether 
other causes had been excluded.  As JAK2 mutations are found in >95% of cases of 
PV, it is likely that these would have been investigated despite the model 
classification as the exclusion value of an unmutated result is very high. 
 
An isolated mild thrombocytosis was present in a further 6 referrals, this was 
documented as being persistent by the referring clinician in 2/6 of these, the other 4 
referrals would not have been investigated any further. 
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The final 7 referrals in this group had normal full blood count indices and, without 
exception, these referrals were received with no additional clinical information and 
would not have undergone further investigation as a result of the model prediction.   
 
Overall, a total of 11 individuals with a demonstrable mutation would have been 
rejected by the laboratory on the basis of the prediction provided by the statistical 
model combined with the absence of clinical and morphological evidence to support 
further investigation. 
 
Removal of the known MPNs on treatment and reclassification of those which would 
have undergone investigation on the basis of clinical and morphological assessment 
adjusted the performance to a sensitivity of 0.96 and specificity of 0.75. 
8.3.3 False positives 
 
The predictive logistic regression model misclassified 320 non-diagnostic referrals 
as an MPN.  Request data and clinical records were examined in the 24/320 referrals 
received from Leeds Teaching Hospitals.  Subsequent bone marrow assessment was 
performed in only 5/24 of these referrals; an MPN was not confirmed in any of these 
instances.  Another haematological malignancy was found in 2/24 individuals 
(multiple myeloma n=1 and hairy cell leukaemia n=1).  Reactive causes were 
diagnosed in 11/24 referrals with a further 3/24 thought to be caused by lifestyle 
choices (smoking and alcohol related).  In the remaining 3 referrals, no identifiable 
cause was found and at the time of writing, no further investigations had been 
performed.  
 
8.4 What would the practical impact of using the model 
have been? 
 
8.4.1 Cost burden analysis 
174 
 
 
 
To establish the impact that adopting a predictive model would have had financially 
over this time period a cost-burden analysis was performed.  This is achieved by 
considering each of the steps undertaken in the laboratory during the process of 
investigating a suspected MPN and calculating the associated costs.  Full details of 
the cost breakdown are included in the appendix (Figure 10-1 through Figure 10-6).  
The total cost of processing a suspected MPN referral in the laboratory was 
calculated to be £33.97p. 
 
During 2016, the 1581 referrals included in this analysis were processed at a total 
cost of £53,706.57p to the laboratory.  The implementation of the predictive model 
developed in this work would have resulted in only 601 referrals of these referrals 
being investigated, at a total cost of £20,415.97p to the laboratory.  This would have 
resulted in an overall cost saving of £33,290.60p.  With estimated savings of around 
£170,000 over a 5-year period. 
 
8.4.2 Impact on income generation 
 
The cost savings described in 8.4.1 represent the expenditure within the laboratory, 
however, this is only part of the picture.  Every referral processed by HMDS for 
investigation of a suspected MPN currently incurs a charge for the referring hospital 
of £200.  It is proposed that, following implementation of the statistical model, 
referrals that did not meet criteria for full investigation would incur a reduced charge 
of £100.  Based on the 2016 referral figures, 960 referrals would have been invoiced 
at the lower charge, which would result in a reduction in income of £96000. 
8.4.3 Impact on staff time 
 
Reducing the number of specimens undergoing laboratory investigations would 
decrease the amount of staff time required to provide this service.  Cost burden 
analyses estimate that each referral requires approximately 1hr of staff time to 
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process and report.  A reduction of 960 specimens would free 18.85 hours of staff 
time on average per week in HMDS. 
 
8.4.4 Equipment availability 
 
In addition to the staff time that could be released, a reduction in workload would 
also decrease the amount of equipment time requirement.  As shown in Table 8-1, 
this would free over 290 hours of equipment time annually. 
   
Equipment Requirement/sample(s) Saving/annum (based 
on 960 fewer referrals) 
Automated DNA 
extraction 
40 minutes / 12 samples 53 hours and 20 minutes 
PCR protocol 2 hours / 24 samples 80 hours 
Fragment analysis 40 minutes / 4 samples 160 hours 
Table 8-1. Potential equipment usage savings associated with reduced referral 
numbers. 
 
 
 
 
 
8.4.5 Clinical savings 
 
In addition to the financial and time savings that can be made in the laboratory, there 
are also potentially significant savings for clinical departments.  Implementing the 
use of predictive modelling tools in the haematology clinic setting, prior to referral to 
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HMDS, would have allowed 960 patients to be discharged to primary care following 
their initial visit.  At a cost of £109 per appointment (2017/18 NHS National Tariff), 
this would have saved £104,640.     
 
8.5 Developing a user interface 
 
The wider implementation of this predictive model requires some form of user 
interface.  To this end, I have developed a web-based application into which a 
clinician or scientist can input the relevant values from patient details and full blood 
count results.  The application then uses the model developed in this work to 
calculate the likelihood of the patient having an MPN and displays this to the user 
alongside a statement indicating whether the result meets the criteria for further 
laboratory testing.  The model can be access through the following web address: 
 https://classicalmpnpredictor.shinyapps.io/MPNpredictor/   
Screenshots follow which show the user interface prior to the input of new data 
(Figure 8-4), along with examples of the output when the model predicts a high 
likelihood of the patient having an MPN (Figure 8-5) as well as a low likelihood 
prediction (Figure 8-6). 
  
 
1
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Figure 8-4 Screenshot (1) User interface prior to input of new patient data 
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Figure 8-5 Screenshot (2) User interface output when prediction is high likelihood of MPN 
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Figure 8-6 Screenshot (3) User interface when prediction is low likelihood of MPN 
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8.6 Discussion/summary 
 
During the 2016 calendar year, 1518 referrals were made which were suitable for 
analysis by the model.  Whilst that does not represent the total number of referrals 
that underwent JAK2 V617F and CALR exon 9 mutation screening, it does comprise 
the total of referrals which were recorded as being made solely for the investigation 
of a suspected MPN.  
 
The initial model performance is comparable with that reported during both its 
development and validation.  With both sensitivity and specificity exceeding the 
level achieved using the criteria set out by current published guidelines alone. 
Furthermore, during the investigation of false negative predictions, it was found that 
a significant proportion of misclassified referrals were either known MPN’s on 
active therapy or had clinical/morphological features which would have indicated 
that mutational screening was justified.  Removal or reclassification of these referrals 
from the analysis further improved the sensitivity of the model. 
 
In analysing the false negative predictions, 7/11 of the cases would have been 
rejected under the proposed system had normal full blood count parameters.  The 
finding of a mutation alone, would not have been sufficient to meet current 
diagnostic criteria and therefore the diagnosis of an MPN could not have been made.  
It could also be argued that these referrals would not have been made in the first 
instance, were the referring clinician following current recommended guidelines.  It 
is also recognised that mutations including JAK2 V617F and those found in CALR 
exon 9 are found in both normal individuals (Jaiswal et al., 2014), and that whilst 
uncommon, can also be found in disorders outside of the classical MPNs (Linda M. 
Scott, 2014; Scott et al., 2005).  This would suggest that in isolation, the presence of 
a mutation should be treated with caution.  
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Statistically, the predictive model has consistently demonstrated a higher level of 
sensitivity than the use of the clinical guidelines, which indicates that the number of 
false negatives produced by the model is lower than expected using the guidelines 
alone.  Whilst, there may be differences in the specific individuals who would have 
been missed by each approach, the overall impact is lower when the statistical model 
is used.  As such, there is no evidence that there would be a negative impact on 
patient safety. 
 
The utilisation of the proposed predictive statistical model would have had a 
significant financial impact.  Considering laboratory and clinical costings, the use of 
predictive modelling would have had an estimated overall cost saving of 
£52,490.60p during the 2016 period, with projected savings in excess of £262,000 
over a 5-year period.  In addition to the financial savings, 960 clinic appointments 
could have been made available and HMDS could have reallocated 290 hours of 
equipment resources and a 0.5 whole time equivalent member of staff to alternative 
service requirements. 
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9. General Discussion 
9.1 Overview 
 
This thesis is the first reported example of predictive statistical modelling being used 
to determine the appropriateness of investigations in suspected myeloproliferative 
neoplasms.  The clinical laboratory setting in which this work has taken place 
allowed access to an unparalleled dataset reflecting a wide population of patients 
undergoing such investigations.  The methods used in this work demonstrate that 
current referral behaviour could potentially be improved and that adherence to 
published guidelines is often impractical in a clinic setting.  Furthermore, this work 
has objectively quantified the efficiency of clinical guidelines and highlights the 
potential opportunity to re-evaluating the current scheme.  The data presented 
proposes an alternative approach to the identification of patients with probable 
classical MPNs by applying statistical modelling to biological variables, some of 
whose utility is previously unreported in the context of classical MPNs.  
 
9.2 Molecular screening for classical MPNs 
 
The MPNs are a heterogenous group of disorders classified together under a single 
term.  They exhibit a range of molecular defects, but none of these are disease 
defining.  Whilst upwards of 99% of confirmed cases of PV have a demonstrable 
JAK2 (V617F or Exon 12) mutations, prior to the identification of mutations in the 
Calreticulin gene, mutations of JAK2 V617F and MPL were identifiable in little 
more than half of those individuals with confirmed ET or PMF.  It is estimated that 
CALR mutations increase the proportion of ET and PMF diagnoses with a 
demonstrable mutation to over two thirds, this still leaves a significant proportion of 
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cases without an identified molecular aberration.  These patients would require bone 
marrow assessment to confirm the presence of disease. 
 
At the outset of this work, mutations in the CALR gene had not been identified and 
the discovery of mutations in this gene in 2012 altered the course of this research. 
The omission of such a high frequency mutation from statistical analysis would have 
significantly limited the impact of this work therefore the development and 
validation of a diagnostic assay for identifying mutations in this gene was critical, 
not only for the meaningful completion of this thesis, but also for routine clinical 
laboratory use.  Data presented within this thesis highlights the significant work that 
is required for the development and validation of a new assay for use in a diagnostic 
laboratory.  Mutations as significant, or with as high frequency, as CALR are rarely 
identified, and this work also offers a unique insight into the impact of introducing 
new molecular assays on referral behaviour 
 
There was very limited information about the clinical and laboratory features of 
CALR mutations at the time that this work was undertaken.  The only published data 
available on the features of CALR mutations had been derived from patients with a 
WHO confirmed diagnoses of ET in whom bone marrow morphology was a 
prerequisite.  As, from our data, bone marrow aspiration is performed on younger 
patients with higher platelet counts than seen in the overall population referred for 
investigation of suspected MPN, it was hypothesised that the published data may 
have been naturally biased towards this cohort of patients.  This could potentially 
account for the published features associated with CALR mutations (younger age, 
higher platelet count).   
 
This work set out to determine whether the clinical and laboratory findings from the 
publications were also seen in the population of patients referred to a diagnostic 
laboratory.  Data presented in this work demonstrates that both the clinical and 
laboratory features of CALR mutated patients described in the literature were 
consistent with those found in a routine diagnostic laboratory.  Having confirmed 
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that our population of MPN patients are comparable to those identified in other 
centres, I am confident that conclusions drawn from this work will be applicable on a 
wider scale.   
 
9.3 Clinical practice - guidelines vs reality 
 
The identification of molecular markers of disease should, in theory, improve the 
efficiency of diagnostic practice.  This does not, however, appear to be the case in 
the diagnosis of the myeloproliferative neoplasms.  The data presented in this thesis 
show that the introduction of molecular screening tests has been accompanied by 
significant increases in referral numbers but has had negligible impact on the number 
of confirmed diagnoses.   
 
It was hypothesised that the increasing disparity between referrals and diagnoses 
may be reflective of high numbers of inappropriate referrals.  The auditing of clinical 
practice showed that, for logistical reasons, JAK2 V617F and CALR mutational 
screening is being requested without first confirming the reported abnormal blood 
counts.  In patients where the clinical suspicion is low, the results appear to be 
treated as a test of exclusion, rather than as a support tool to restrict investigations to 
those patients in whom true clinical suspicion is present and who demonstrate 
persistently abnormal blood counts.  Indeed, published data indicates that a third of 
ET and PMF patients will not demonstrate a mutation of JAK2 V617F or CALR, 
however in our cohort less than 10% of referrals with no evidence of a JAK2 V617F 
or CALR mutation in the peripheral blood screens were investigated further.  
  
9.4 Predictive modelling 
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Clinical guidelines for the investigation of suspected myeloproliferative disorders 
have evolved over the past 50 years.  However, during this time there has not been a 
critical appraisal of their performance.  Amendments to the guidelines have largely 
been driven by either the addition of genetic markers or adjustments in FBC 
parameter thresholds and the basic structure of the criteria have remained unchanged.  
Furthermore, it is unclear how the original diagnostic variables and thresholds used 
in the criteria were originally identified.     
HMRN has demonstrated that the socio-demographic profile of the population 
HMDS serves is comparable to the national average.  Furthermore, the HILIS 
database contains biological and demographic data on each referral.  Given that, 
from 2005 to 2017, HMDS investigated over 18,000 cases for suspected classical 
MPNs, the data used within this thesis offers an unparalleled data set for the 
development of a predictive statistical model.  Indeed, using logistic regression 
analysis of full blood count parameters in conjunction with demographic 
information, it is possible to correctly classify over 95% of referrals who will 
demonstrate the presence of a JAK2 V617F or CALR mutation.  In contrast to current 
referral practice whereby >80% of referrals do not have a JAK2 V617F or CALR 
mutation, the classifier would remove cases from further referral and reduce this 
figure to <30%. 
9.5 Implementing changes in clinical practice 
 
Initially, it is intended that the predictive model developed in this work, will be used 
as an adjunct to current screening protocols in the diagnostic laboratory.  Full blood 
count and demographic information from suspected classical MPN referrals will be 
inputted into the app and the classified as having a either a high or low likelihood of 
having a classical MPN.  Those classified as having a low likelihood will not be 
investigated unless clinical or morphological evidence indicates otherwise (such as 
thrombotic complications, hepatosplenomegaly or morphological abnormalities 
(tear-drop poikylocytes or leucoerythroblastic features).  Samples classified as 
having a high likelihood of being an MPN, will undergo screening for JAK2 and 
CALR mutations.  Those in which a JAK2 V617F or CALR mutation is detected will 
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be reported as per current protocols.  Whereas those in which neither mutation is 
identified without would be reported as having no mutation in JAK2 V617F/CALR 
with a comment to indicate that if there is no reactive cause for clinical/laboratory 
features, a bone marrow would be indicated.    
 
 
Adopting such an approach during 2016 would have a significant impact in HMDS, 
saving over 290 hours of equipment time and the equivalent of a 0.5 whole-time 
equivalent staff member time each year.  The reduction in workload associated with 
adopting this predictive model would reduce the departmental income by 
approximately £96000 per annum.  However, the staff time and equipment made 
available would allow other areas of the service to expand and recoup lost income.  
Furthermore, all patients with suspected classical MPNs are seen in clinic on a 
minimum of 2 occasions.  If the use of this model could be incorporated into clinical 
practice and used by clinicians prior to referral to the laboratory, it would have 
reduced this to a single clinic appointment in over 60% of referrals received in 2016.  
Using the figures stated in chapter 7, this could have potentially saved 994 clinic 
appointments in 2016, at a cost of £120 per appointment (according to the NHS 
national tariff 2016/17) this could have saved an additional £119,280, as well as 
decreasing pressure on clinical services and reducing patient anxiety.  Taking both 
laboratory and clinical costings into account there are potential overall savings for 
the NHS in the region of £52,000 per annum.  
 
The integration of predictive statistical modelling into routine clinical practice is the 
ultimate endpoint of this work.  In doing so, it would offer greater benefits, in terms 
of financial savings (both laboratory and clinical) and patient pathway efficiency 
(reduced waiting times and appointment requirements) than restricting it’s use to the 
diagnostic laboratory.  The app developed in this work offers a simple, accessible 
way for clinicians to quickly establish the appropriateness of testing in their patients.  
However, successful implementation would require some modifications to current 
working practices to ensure that the data inputted was up to date and accurate.  This 
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would require clinician engagement and a willingness to alter the way in which 
patients are seen in clinic.  Demonstrating the value of using this model in a 
prospective cohort will build clinician trust and it is hoped that this will lead to 
adoption of this model in the diagnostic pathway for patients with suspected classical 
MPNs.  
 
 
9.6 Impact on patient experience 
 
It is acknowledged that many patients respond positively to an active investigatory 
approach.  However, this does not necessarily mean that JAK2 V617F and CALR 
exon 9 mutational screening should be seen as a preliminary investigation.  Data 
from the clinical audit presented in section 5.5 showed that in more than half of 
referrals audited, persistent abnormal blood count parameters were demonstrated 
prior to requesting JAK2 V617F and CALR exon 9 mutational screening.  In these 
patients, an active testing approach could be employed without the inclusion of 
mutational screening. 
   
One can appreciate that requesting JAK2 V617F and CALR mutational screening 
during the initial clinic consultation may save time.  Hospital services are under 
mounting pressure to reduce waiting times and reduce costs.  These pressures may 
contribute to the premature requesting of JAK2 V617F and CALR mutational 
screening.  The proposed implementation of the model during the lab following 
consultation and for the haematology laboratory to then use the modelling app to 
determine whether the specimen be referred onwards for JAK2 V617F and CALR 
exon 9 mutational screening.  Alternatively, if point of care testing were available in 
the haematology outpatient clinic, it may be feasible to perform the full blood count 
prior to consultation and for the clinician to use the app to determine the 
appropriateness of further investigation themselves. 
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9.7 Further work 
 
The data used to develop this model is taken from a restricted geographical 
population.  HMRN publications show that this population is comparable to that of 
the national population but demonstrating the performance of this model on an 
independent geographical cohort would be valuable.  As such, it is intended that the 
model will be applied to a series of independent referrals, possibly in a different 
geographical location to confirm its suitability.   
 
The inclusion of MPL and JAK2 Exon 12 mutations in this work was restricted by 
the low frequency of bone marrow aspirates received.  As a pilot study, a recent 
HILIS database search identified a total of 27 MPL exon 10 or JAK2 exon 12 
mutated MPNs which were suitable for assessment using the predictive model app.  
The model predicted the correct class membership in 24/27 cases (sensitivity = 
88.89%).  Whilst encouraging, the sample size is insufficient to draw any meaningful 
conclusions.  Further validation is planned to be performed on a dataset tested for all 
4 mutations (JAK2 V617F, JAK2 exon 12, MPL and CALR) thereby helping to 
establish the value of this model in the identification of patients who would benefit 
from upfront JAK2 exon 12 and/or MPL mutation analysis. 
 
The investigation of suspected classical MPNs is one of many potential applications 
of predictive statistical modelling in a haematological setting.  This could potentially 
include a similar approach utilising FBC parameters in conjunction with patient 
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demographics in a range of conditions.  For example, to better target the population 
referred for screening in suspected Paroxysmal Nocturnal Haemoglobinuria (PNH), 
or the identification of a reactive eosinophilia or monocytosis from their malignant 
counterparts.  Furthermore, given the diagnostic challenge in the identification of 
MDS from other non-clonal cytopenias, or clonal haematopoiesis of indeterminate 
potential, full blood count data could be supplemented with additional laboratory 
data (for example immunophenotypic characteristics).  Following completion of this 
work, it is anticipated that further research could be undertaken in these areas.  
 
In conclusion, predictive statistical modelling has the potential to beneficially alter 
the way in which samples are referred for laboratory investigations in suspected 
malignant conditions.   This work provides potential evidence of the positive impact 
this approach would have in the investigation of suspected classical MPNs. 
Demonstrating that better targeting the population for investigation would reduce 
both laboratory and clinical workloads, decrease clinic waiting times and would 
result in significant financial savings.  Furthermore, this would allow resources to be 
directed towards those clinically appropriate investigations which would ultimately 
improve patient care. 
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10. Appendices 
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10.1 Materials 
 
Description Catalogue/Product 
number 
Manufacturer 
Albumin, Bovine A-3059 Sigma Chemical 
Company 
Ammonium Chloride 55 Vickers Laboratory 
Ltd 
AmpliTaq Gold DNA polymerase 
kit 
4311816 Applied Biosystems 
Ethanol  P20809 VWR International 
Facsflow 342003 Becton Dickinson 
Genescan 500 Rox dye Size 
Standard 
4310361 Life Technologies 
Hi-Di Formamide solution 43311320 Applied Biosystems 
QIAamp DNA Mini Kit  5136 Qiagen Ltd 
UltraPURE, DNAse, RNAse free 
Water 
10977-035 Invitrogen 
Primers custom product Sigma-Genosys 
100mM dNTP mix  39026 Bioline 
Molecular biology grade water  10977-035 Gibco 
Table 10-1 Details of reagents used in fluorescent fragment analysis experiments 
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Target Sequence 
JAK2 COMMON REVERSE 56-FAMN/CTG AAT AGT CCT ACA 
GTG TTT TCA GTT TCA 
JAK2 WILD TYPE SPECIFIC 
FORWARD 
ATC TAT AGT CAT GCT GAA AGT 
AGG AGA AAG 
JAK2 MUTANT SPECIFIC 
FORWARD 
AGC ATT TGG TTT TAA ATT ATG 
GAG TAT ATT 
CALR EXON 9 REVERSE AGA CAT TAT TTG GCG CGG 
CALR EXON 9 FORWARD 5HEX/TGA GGT GTG TGC TCT 
GCC T 
Table 10-2 Primer sequences for amplification and fluorescent fragment analysis of 
JAK V617F and CALR exon 9 mutations 
 
REAGENT CONCENTRATION VOLUME/40 TESTS 
 Ultrapure H2O  829 μL 
ABI 10x gold buffer 1x 100 μL 
JAK2 fluorescent reverse 
primer 
5pmol final concentration 2 μL 
JAK2 wild type forward 
primer 
5pmol final concentration 2 μL 
JAK2 mutant forward 
primer 
5pmol final concentration 2 μL 
DNTP 125µM final concentration 5 μL 
MgCl2 1.5mM final concentration 60 μL 
Taq polymerase 0.5 Units 0.1µL 
DNA   
Table 10-3 Reagent list for JAK2 V617F mutations screen PCR reaction 
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REAGENT CONCENTRATION VOLUME/40 TESTS 
Ultrapure H2O  831 μL 
ABI 10x gold buffer 1x 100 μL 
CALR fluorescent forward 
primer 
5pmol 2 μL 
CALR reverse primer 5pmol 2 μL 
DNTP 125µM final concentration 5 μL 
MgCl2 1.5mM final concentration 60 μL 
Taq polymerase 0.5 Units 0.1µL 
DNA   
Table 10-4 Reagent list for CALR exon 9 mutation screen PCR reaction 
 
STEP TEMPERATURE TIME 
Pre-activation 95˚C 10 minutes 
35 cycles as follows:   
Denaturation 95°C 30 seconds 
Annealing 58°C 30 seconds 
Extension 72°C 30 seconds 
Followed by:   
Final step   
Extension 72°C 7 minutes 
Hold 4°C ∞ 
Table 10-5 Thermal cycle settings for combined JAK2/CALR PCR. 
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10.2 R Scripts for Statistical Model Development, Testing and 
Validation 
 
10.2.1 Data preparation 
 
# LIBRARIES REQUIRED TO PERFORM ANALYSIS # 
library(MASS) 
library(faraway) 
library(rgl) 
library(caret) 
library(gmodels) 
library(ROCR) 
library(rms) 
 
#READ IN DATA# 
dfr <- read.csv("modelling_data_v1.csv", header=T)  
 
#CHECK DATA STRUCTURE, LEVELS OF FACTORS# 
str(dfr)  
 
#OVERVIEW SUMMARY OF ALL DATA# 
summary(dfr)  
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#SELECT COHORT OF SAMPLES WITH FULL MOLECULAR ANALYSIS AND 
COMPLETE FULL BLOOOD COUNT DATA# 
complete <- dfr[dfr$molecular!='JAK2_NEG',] 
summary(complete) 
idx1 <- is.na(complete$hct) 
complete <- complete[idx1==FALSE,] 
idx2 <- is.na(complete$plt) 
complete <- complete[idx2==FALSE,] 
summary(complete) 
str(complete) 
 
#CLASS PERFORMANCE 
#IF WE PREDICTED THAT EACH REFERRAL WAS A CASE IRRESPECTIVE OF THE 
DATA WHAT WOULD BE #THE SUCCESS OF THE PREDICTOR - THIS GIVES A 
BASELINE AGAINST WHICH TO EVALUATE THE #PERFORMANCE OF A 
CLASSIFIER 
 
base_performance <- 1266/2970 #NUMBER OF CASES/TOTAL NUMBER OF 
REFERRALS# 
base_performance 
 
#IN THIS DATASET THE BASE PERFORMANCE IS 0.4263 - A CLASSIFIER WOULD 
NEED TO EXCEED THIS TO BE MORE SUCCESSFUL THAN THE BASELINE# 
 
#QQ PLOTS OF EACH VARIABLE# 
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qqnorm(complete$age) 
qqnorm(complete$plt)  
qqnorm(log(complete$plt)) 
qqnorm(sqrt(complete$plt))  
qqnorm(complete$hb)  
qqnorm(complete$wbc) 
qqnorm(log(complete$wbc)) 
qqnorm(sqrt(complete$wbc))  
qqnorm(complete$rbc)  
qqnorm(complete$mcv)  
qqnorm(complete$lymph)  
qqnorm(log(complete$lymph))  
qqnorm(complete$neutr) 
qqnorm(log(complete$neutr)) 
qqnorm(complete$mono)  
qqnorm(log(complete$mono)) 
qqnorm(complete$hct)  
qqnorm(complete$mch) 
qqnorm(log(complete$mch)) 
qqnorm(complete$mchc) 
qqnorm(log(complete$mchc)) 
qqnorm(sqrt(complete$mchc)) 
 
 
#ALTER FUNCTIONAL FORM OF VARIABLES AS INDICATED BY QQ PLOTS# 
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complete$wbc <- (log(complete$wbc)) 
complete$plt <- (sqrt(complete$plt)) 
complete$hct <- (log(complete$hct)) 
complete$lymph <- (log(complete$lymph)) 
complete$neutr <- (log(complete$neutr)) 
complete$mono <- (log(complete$mono)) 
complete$mch <- (log(complete$mch)) 
complete$mchc <- (log(complete$mchc)) 
 
str(complete) 
 
###### PLOTTING PAIRS ###### 
pairs_data <- data.frame(with(complete, cbind(age, hb, lymph, neutr, mono, plt, mchc, mch, 
hct, wbc))) 
pairs(pairs_data) 
 
10.2.2 Logistic regression model 
 
#INCLUDE ALL VARIABLES IN MODEL TO BEGIN WITH# 
model1 <- glm(case_control ~ age + gender + hb + rbc + hct + mcv + mch + mchc + wbc + 
lymph + neutr + mono + plt, family=binomial, data=complete) 
summary(model1) 
plot(model1) 
 
#ASSESS COLINEARITY IN MODEL# 
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vif(model1) 
sqrt(vif(model1)) 
 
#THERE IS MULTICOLINEARITY IN THE MODEL AS INDICATED BY THE PAIRS 
PLOTS# 
#REMOVAL OF VARIABLES WITH LEAST STATISTICALLY SIGNIFICANT 
WEIGHTINGS# 
#MCH, WBC, MONO AND HCT REMOVED# 
 
model2 <- glm(case_control ~ age + gender + hb + rbc + mcv + mchc + lymph + neutr + plt, 
family=binomial, data=complete) 
summary(model2) 
vif(model2) 
 
#LASSO REGRESSION FOR ATTRIBUTE SELECTION# 
 
#CREATING A DATASET FOR PENALISED MODELLING# 
 
pen_data <- data.frame(with(complete, 
cbind(case_control,age,gender,hb,rbc,mcv,mchc,lymph,neutr,plt))) 
x <- as.matrix(pen_data[,2:10]) 
y <- as.matrix(pen_data[,1]) 
 
grid <- seq(0, 100000, by=10)/100000 
mod.lasso <- glmnet(x, y, alpha=1, family="binomial", lambda=grid) 
plot(mod.lasso, xvar="lambda", label=T, lwd=1) 
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grid <- seq(0, 100000, by=10)/100000 
cv.out=cv.glmnet(x,y,alpha=1, lambda=grid, family="binomial", nfolds=10) 
plot(cv.out) 
 
bestlam=cv.out$lambda.min 
lasso_coef <- as.matrix(coef(mod.lasso, s=bestlam)) 
chosen_variables_max <- rownames(lasso_coef)[lasso_coef!=0] 
chosen_variables_max <- chosen_variables_max[-1] 
rownames(lasso_coef)[lasso_coef!=0] 
 
bestlam=cv.out$lambda.1se 
lasso_coef <- as.matrix(coef(mod.lasso, s=bestlam)) 
chosen_variables_min <- rownames(lasso_coef)[lasso_coef!=0] 
chosen_variables_min <- chosen_variables_min[-1] 
rownames(lasso_coef)[lasso_coef!=0] 
 
 
# CALCULATE RELAXED LASSO MODELS BASED ON LASSO SELECTION. 
NOTICE "BEST" LASSO # 
# MODEL DOES NOT SHRINK AWAY ANY VARIABLES # 
 
 
mod_max <- glm(as.formula(paste("case_control ~ ", paste(chosen_variables_max, 
collapse="+"))), data=pen_data) 
summary(mod_max) 
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mod_min <- glm(as.formula(paste("case_control ~ ", paste(chosen_variables_min, 
collapse="+"))), data=pen_data) 
summary(mod_min) 
 
#MODEL PERFORMANCE USING USING THE LRM FUNCTION RATHER THAT 
GLM# 
 
lrm_model <- lrm(case_control ~ age + gender + hb + rbc + mcv + mchc + lymph + neutr + 
plt, data=complete, x=TRUE, y=TRUE) 
lrm_model 
 
#CORRELATIONSTATISTICS SHOWN ARE: # 
#C - C INDEX = AUC # 
#DXY - SOMERS' D = (NC-ND)/(NC+ND) - DOES NOT INCLUDE 1/2 TIES # 
#DXY CAN ALSO BE CALCULATED FROM C USING =2(C-1/2) # 
#GAMMA - GOODMAN AND KRUSKAL'S GAMMA = (NC-ND)/(NC+ND) # 
#TAU-A - KENDALL RANK COEFFICIENT = NC-ND/N(N-1)/2 - DOES NOT INCLUDE 
ADJUSTMENTS FOR TIES # 
 
validate(lrm_model, method="cross") 
 
#MODEL EVALUATION AND VALIDATION# 
 
#SETTING CLASS VALUES FOR ACTUAL AND PREDICTED OUTCOMES# 
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actual_outcome <- as.factor(complete$case_control) 
predicted_probability <- as.numeric(predict(model2, complete, type='response')) 
predicted_outcome <- as.factor(ifelse(predicted_probability<='0.70', 'case','control')) 
 
 
#SHOW A SIMPLE 2X2 TABLE OF THESE TWO CLASSES# 
 
table(actual_outcome, predicted_outcome) 
 
#CROSSTABLE FUNCTION ADDS A FEW EXTRA DETAILS TO THE TABLE (FROM 
GMODELS PACKAGE) # 
 
CrossTable(actual_outcome, predicted_outcome) 
 
#using caret package to create a confusion matrix with performance measures# 
 
confusionMatrix(predicted_outcome, actual_outcome, positive="case") 
 
#KAPPA STATISTIC - ADJUSTS THE ACCURACY OF THE MODEL BY TAKING 
INTO ACCOUNT THE POSSIBILITY OF A CORRECT PREDICTION BASED ON 
CHANCE ALONE # 
#<0.2=POOR AGREEMENT, >0.8=VERY GOOD AGREEMENT # 
 
#MODEL SENSITIVITY - THIS IS THE MEASURE OF TRUE POSITIVES/(TRUE 
POSITIVES + # 
#FALSE NEGATIVES) # 
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rec <- sensitivity(predicted_outcome, actual_outcome, positive="case") 
rec 
 
#MODEL SPECIFICITY - THIS IS THE MEASURE OF TRUE NEGATIVES/(TRUE 
NEGATIVES + # 
# FALSE POSITIVES) # 
 
spec <- specificity(predicted_outcome, actual_outcome, positive="case") 
spec 
 
#MODEL PRECISION - LIKELYHOOD OF MODEL CORRECTLY CLASSIFYING A 
POSITIVE (ALSO CALLED # 
# POSITIVE PREDICTIVE VALUE) # 
 
prec <- posPredValue(predicted_outcome, actual_outcome, positive="case") 
prec 
 
#F MEASURE - COMBINATION OF PRECISION AND RECALL INTO A SINGLE 
VALUE # 
 
f <- (2*prec*rec)/(prec+rec) 
f 
 
 
#VISUALISING PERFORMANCE USING ROCR# 
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pred <- prediction(predictions=predicted_probability, labels=actual_outcome) 
 
perf <- performance(pred, measure = "sens", x.measure = "spec") 
plot(perf) 
 
perf.auc <- performance(pred, measure="auc") 
unlist(perf.auc@y.values) 
 
perf@alpha.values[[1]][which.max(perf@x.values[[1]]+perf@y.values[[1]])] 
max(perf@x.values[[1]]+perf@y.values[[1]]) 
 
########################################################################### 
#EXAMPLE SCRIPT FOR MANUAL THRESHOLD SELECTION# 
#REPEATED AT MULTIPLE VALUES OF PREDICTED_PROBABILITY# 
 
actual_outcome <- as.factor(complete$case_control) 
predicted_probability <- as.numeric(predict(model4, complete, type='response')) 
predicted_outcome <- as.factor(ifelse(predicted_probability<='0.05', 'case','control')) 
confusionMatrix(predicted_outcome, actual_outcome, positive="case") 
 
###########################################################################
# 
 
#TESTING LOGISTIC REGRESSION MODEL ON NEW DATA DATASET# 
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#MODEL VALIDATION ON A NEW DATA SET - SCRIPT IS LARGELY REPEATED# 
 
test_data <- read.csv("2015qmnrequests.csv", header=T) #READ IN NEWDATA# 
str(test_data) 
 
 
#MAKE ADJUSTMENTS TO VARIABLE TYPES AND FUNCTIONAL FORMS TO 
MATCH ORIGINAL# #DATASET# 
 
test_data$smoker <- as.factor(test_data$smoker) 
test_data$thrombosis <- as.factor(test_data$thrombosis) 
test_data$bp <- as.factor(test_data$bp) 
test_data$dm <- as.factor(test_data$dm) 
test_data$treatment <- as.factor(test_data$treatment) 
test_data$dead <- as.factor(test_data$dead) 
test_data$status <- as.factor(test_data$status) 
test_data$cause.of.death <- as.factor(test_data$cause.of.death) 
test_data$time <- as.factor(test_data$time) 
 
str(test_data) 
 
idx1 <- is.na(test_data$hct) 
complete_test <- test_data[idx1==FALSE,] 
idx2 <- is.na(complete_test$plt) 
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complete_test <- complete_test[idx2==FALSE,] 
summary(complete_test) 
 
complete_test$wbc <- (log(complete_test$wbc)) 
complete_test$plt <- (sqrt(complete_test$plt)) 
complete_test$hct <- (log(complete_test$hct)) 
complete_test$lymph <- (log(complete_test$lymph)) 
complete_test$neutr <- (log(complete_test$neutr)) 
complete_test$mono <- (log(complete_test$mono)) 
complete_test$mch <- (log(complete_test$mch)) 
complete_test$mchc <- (log(complete_test$mchc)) 
 
#MODEL EVALUATION AND VALIDATION# 
 
#SETTING CLASS VALUES FOR ACTUAL AND PREDICTED OUTCOMES# 
test_outcome <- as.factor(complete_test$case_control) 
test_probability <- as.numeric(predict(model2, complete_test, type='response')) 
test_predicted_outcome <- as.factor(ifelse(test_probability <='0.70', 'case','control')) 
 
print(test_probability) 
print(test_predicted_outcome) 
print(test_outcome) 
 
#SHOW A SIMPLE 2X2 TABLE OF THESE TWO CLASSES# 
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table(test_outcome, test_predicted_outcome) 
 
 
#CROSSTABLE FUNCTION ADDS A FEW EXTRA DETAILS TO THE TABLE (FROM 
GMODELS PACKAGE) # 
 
CrossTable(test_outcome, test_predicted_outcome) 
 
#USING CARET PACKAGE TO CREATE A CONFUSION MATRIX WITH 
PERFORMANCE MEASURES# 
 
confusionMatrix(test_predicted_outcome, test_outcome, positive="case") 
 
rec <- sensitivity(test_predicted_outcome, test_outcome, positive="case") 
rec 
 
spec <- specificity(test_predicted_outcome, test_outcome, positive="case") 
spec 
 
prec <- posPredValue(test_predicted_outcome, test_outcome, positive="case") 
prec 
 
negprec <- negPredValue(test_predicted_outcome, test_outcome, positive="case") 
negprec 
 
f <- (2*prec*rec)/(prec+rec) 
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f 
 
#VISUALISING PERFORMANCE USING ROCR# 
 
 
pred2 <- prediction(predictions = test_probability, labels=test_outcome) 
 
perf2 <- performance(pred2, measure = "tpr", x.measure = "fpr") 
plot(perf2) 
 
perf.auc <- performance(pred, measure="auc") 
unlist(perf.auc@y.values) 
 
 
#EXTRACTING MISMATCHES FROM LOGISTIC REGRESSION FOR 
INVESTIGATION# 
 
#MISMATCHES FROM TRAINING SET# 
 
complete$predicted <- predicted_outcome 
lrm_mismatches <- complete[complete$case_control!=complete$predicted,] 
lrm_mismatches 
 
 
#WRITE DATA TO FILE# 
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write.csv(lrm_mismatches, "lrm_mismatches.csv") 
 
#MISMATCHES IN TEST SET# 
 
complete_test$probability <- test_probability 
complete_test$predicted <- test_predicted_outcome 
lrm_test_mismatches <- 
complete_test[complete_test$case_control!=complete_test$predicted,] 
 
#WRITE DATA TO FILE# 
write.csv(lrm_test_mismatches, "lrm_test_mismatches2.csv") 
 
 
 
 
 
 
10.2.3 Random forest analysis 
 
 
#RANDOMFOREST CLASSIFICATION# 
#TO BE RUN IN CONJUNCTION WITH LOGISTIC REGRESSION SCRIPT AS 
VARIABLES AND DATASETS #HAVE BEEN CREATED/MODIFIED USING SCRIPT 
FROM PREVIOUS ANALYSIS 
 
library(randomForest) 
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#SELECT DATA FOR RANDOM FOREST ANALYSIS - REMOVING ALL CASES 
WITH NA VALUES IN # 
#BOTH TRAINING AND TEST SETS - REQUIRES TEST_DATA FROM LOGISTIC 
REGRESSION SCRIPT # 
 
rf_data <- complete[,c("request_number", "year","case_control","age","hb", 
"rbc","wbc","lymph","plt","hct", "gender", "mchc", "mch", "neutr", "mono", "mcv")] 
rfidx1 <- is.na(rf_data$lymph) 
rf_data <- rf_data[rfidx1==FALSE,] 
rfidx2 <- is.na(rf_data$neutr) 
rf_data <- rf_data[rfidx2==FALSE,] 
rfidx3 <- is.na(rf_data$mono) 
rf_data <- rf_data[rfidx3==FALSE,] 
summary(rf_data) 
 
rf_test <- test_data[,c("request_number", "year", "source_type" , "case_control","age","hb", 
"rbc","wbc","lymph","plt","hct", "mcv", "gender", "mchc", "mch", "neutr", "mono")] 
rftidx1 <- is.na(rf_test$lymph) 
rf_test <- rf_test[rftidx1==FALSE,] 
rftidx2 <- is.na(rf_test$neutr) 
rf_test <- rf_test[rftidx2==FALSE,] 
rftidx3 <- is.na(rf_test$mono) 
rf_test <- rf_test[rftidx3==FALSE,] 
summary(rf_test) 
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#RANDOM FOREST MODEL INCLUDES ALL EXPLANATORY VARIABLES# 
 
rf_model<-train(case_control ~ age + gender + hb + rbc + wbc + neutr + lymph + mono + plt 
+ hct + mchc + mch + mcv, data=rf_data, method="rf", na.action=na.exclude, 
                trControl=trainControl(method="cv", number=10), 
                prox=TRUE,allowParallel=TRUE) 
 
 
print(rf_model) 
 
print(rf_model$finalModel)   
 
saveRDS(rf_model, "my-fitted-rf.rds") 
 
fit <- readRDS("my-fitted-rf.rds") 
 
fit <- rf_model 
 
#USING RANDOM FOREST MODEL TO PREDICT OUTCOME ON BOTH TEST SET 
AND TRAINING SET# 
 
predict(fit, rf_data) 
predict(fit, rf_test) 
 
rf_test_outcome <- as.factor(rf_data$case_control) 
rf_predicted_outcome <- (predict(rf_model,rf_data)) 
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summary(rf_test_outcome) 
summary(rf_predicted_outcome) 
 
rf_test_outcome2 <- as.factor(rf_test$case_control) 
rf_predicted_outcome2 <- (predict(fit,rf_test)) 
CrossTable(rf_test_outcome, rf_predicted_outcome) 
table(rf_test_outcome, rf_predicted_outcome) 
 
CrossTable(rf_test_outcome2, rf_predicted_outcome2) 
table(rf_test_outcome2, rf_predicted_outcome2) 
ConfusionMatrix(rf_test_outcome2, rf_predicted_outcome2) 
 
#PLOT THE ACCURACY OF THE CROSS VALIDATION WITH INCREASING 
NUMBERS OF # 
#RANDOMLY SELECT VARIABLES# 
 
plot(rf_model) 
 
#EXTRACTING THE MISMATCHES FROM THE MODEL FOR FURTHER 
INVESTIGATION# 
 
rf_data$predicted <- predict(fit, rf_data) 
rf_test$predicted <- predict(fit, rf_test) 
 
rf_mismatches <- rf_data[rf_data$case_control!=rf_data$predicted,] 
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write.csv(rf_mismatches, "random_forest_mismatches.csv") 
 
rftest_mismatches <- rf_test[rf_test$case_control!=rf_test$predicted,] 
write.csv(rftest_mismatches, "random_forest_test_mismatches.csv") 
10.2.4 Gradient boosted model 
 
#GRADIENT BOOSTING# 
#USING CARET AND GBM PACKAGES# 
 
#CREATE DATASET FOR ANALYSIS - USING DATASETS DEFINED IN THE 
LOGISTIC REGRESSION ANALYSIS SCRIPT# 
 
idxc1 <- is.na(complete$neutr) 
gbm_data <- complete[idxc1==FALSE,] 
idxc2 <- is.na(gbm_data$lymph) 
gbm_data <- gbm_data[idxc2==FALSE,] 
idxc3 <- is.na(gbm_data$mono) 
gbm_data <- gbm_data[idxc3==FALSE,] 
 
fitControl <- trainControl( 
  method = "cv", 
  number = 10) 
 
fitControl <- trainControl( 
  method = "repeatedcv", 
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  number = 10, 
  repeats = 10) 
 
 
gbmGrid <-  expand.grid(interaction.depth = c(1, 3, 5), 
                        n.trees = (1:30)*50, 
                        shrinkage = c(0.1, 0.01, 0.001), 
                        n.minobsinnode = 20 
) 
 
 
gbmmodel<-train(case_control ~ age + gender + hb + mcv + mchc + neutr + lymph + plt,  
                data=gbm_data,  
                method="gbm",  
                distribution="bernoulli", 
                trControl=fitControl, 
                tuneGrid=gbmGrid, 
                verbose=FALSE) 
 
 
 
gbm_fit <- gbmmodel 
gbm_fit 
summary(gbm_fit, las=2, cex.names=0.7) 
ggplot(gbm_fit) 
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trellis.par.set(caretTheme()) 
plot(gbm_fit)  
 
#CREATE DATASETS WITH BOTH ACTUAL AND PREDICTED OUTCOMES# 
 
gbm_outcome <- as.factor(gbm_data$case_control) 
gbm_predicted_outcome <- (predict(gbm_fit,gbm_data)) 
 
#DISPLAY ACTUAL AND PREDICTED OUTCOMES AS MATRIX# 
 
CrossTable(gbm_outcome, gbm_predicted_outcome) 
table(gbm_outcome, gbm_predicted_outcome) 
confusionMatrix(gbm_outcome, gbm_predicted_outcome, positive='case') 
 
#PLOT MODEL# 
plot(gbmmodel) 
 
#SUMMARY OF PERFORMANCE# 
 
gbmrec <- sensitivity(gbm_predicted_outcome, gbm_test_outcome, positive="case") 
gbmrec 
 
#MODEL SPECIFICITY - THIS IS THE MEASURE OF TRUE NEGATIVES/(TRUE 
NEGATIVES +# 
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#FALSE POSITIVES) # 
 
gbmspec <- specificity(gbm_predicted_outcome, gbm_test_outcome, positive="case") 
gbmspec 
 
#MODEL PRECISION - LIKELYHOOD OF MODEL CORRECTLY CLASSIFYING A 
POSITIVE #  
# (ALSO CALLED POSITIVE PREDICTIVE VALUE) # 
 
gbmprec <- posPredValue(gbm_predicted_outcome, gbm_test_outcome, positive="case") 
gbmprec 
 
gbmnegprec <- negPredValue(gbm_predicted_outcome, gbm_test_outcome, positive="case") 
gbmnegprec 
 
#F MEASURE - COMBINATION OF PRECISION AND RECALL INTO A SINGLE 
VALUE# 
 
gbmf <- (2*gbmprec*gbmrec)/(gbmprec+gbmrec) 
gbmf 
 
 
 
#READ IN MODEL VALIDATION DATA# 
 
gmb_2015 <- read.csv("2015qmnrequests.csv", header=T) 
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#ALTER FUNCTIONAL FORMS OF EACH VARIABLE AS PER TEST MODEL# 
 
gmb_2015$wbc <- (log(gmb_2015$wbc)) 
gmb_2015$plt <- (sqrt(gmb_2015$plt)) 
gmb_2015$hct <- (log(gmb_2015$hct)) 
gmb_2015$lymph <- (log(gmb_2015$lymph)) 
gmb_2015$neutr <- (log(gmb_2015$neutr)) 
gmb_2015$mono <- (log(gmb_2015$mixed)) 
 
idxc1 <- is.na(gmb_2015$neutr) 
gmb_2015a <- gmb_2015[idxc1==FALSE,] 
idxc2 <- is.na(gmb_2015a$lymph) 
gmb_2015a <- gmb_2015a[idxc2==FALSE,] 
idxc3 <- is.na(gmb_2015a$mono) 
gmb_2015a <- gmb_2015a[idxc3==FALSE,] 
 
#PREDICT FIT OF MODEL ON VALIDATION DATASET# 
 
gbm_test <- predict(gbm_fit, newdata=gmb_2015a) 
 
gbm_test_outcome <- as.factor(gmb_2015a$case_control) 
gbm__test_predicted_outcome <- (predict(gbm_fit, gmb_2015a)) 
 
#VIEW ACTUAL AND PREDICTED OUTCOMES IN MATRIX# 
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CrossTable(gbm_test_outcome, gbm__test_predicted_outcome) 
table(gbm_test_outcome, gbm__test_predicted_outcome) 
confusionMatrix(gbm_test_outcome, gbm__test_predicted_outcome, positive='case') 
 
#WRITE MISMATCHED DATA TO FILE FOR INVESTIGATIONS# 
 
gmb_2015a$predicted <- gbm__test_predicted_outcome 
gbm_test_mismatches <- gmb_2015a[gmb_2015a$case_control!=gmb_2015a$predicted,] 
write.csv(gbm_test_mismatches, "gbm_test_mismatches.csv") 
 
10.2.5 Logistic regression model impact assessment 
 
#Model impact on 2016 data - script is largely repeated to evaluate model on # 
#new dataset # 
########################################################################### 
#READ IN NEW DATA# 
 
test16_data <- read.csv("2016_qmpns.csv", header=T)  
str(test16_data) 
 
 
#MAKE ADJUSTMENTS TO VARIABLE TYPES AND FUNCTIONAL FORMS TO 
MATCH ORIGINAL# #DATASET# 
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test_data$smoker <- as.factor(test_data$smoker) 
test_data$thrombosis <- as.factor(test_data$thrombosis) 
test_data$bp <- as.factor(test_data$bp) 
test_data$dm <- as.factor(test_data$dm) 
test_data$treatment <- as.factor(test_data$treatment) 
test_data$dead <- as.factor(test_data$dead) 
test_data$status <- as.factor(test_data$status) 
test_data$cause.of.death <- as.factor(test_data$cause.of.death) 
test_data$time <- as.factor(test_data$time) 
 
str(test_data) 
 
#REMOVE INCOMPLETE RECORDS# 
 
idx1 <- is.na(test16_data$hct) 
complete_test16 <- test16_data[idx1==FALSE,] 
idx2 <- is.na(complete_test16$plt) 
complete_test16 <- complete_test16[idx2==FALSE,] 
summary(complete_test) 
idx3 <- is.na(complete_test16$lymph) 
complete_test16 <- complete_test16[idx3==FALSE,] 
idx4 <- is.na(complete_test16$neutr) 
summary(complete_test16) 
complete_test16 <- complete_test16[idx4==FALSE,] 
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complete_test16$wbc <- (log(complete_test16$wbc)) 
complete_test16$plt <- (sqrt(complete_test16$plt)) 
complete_test16$hct <- (log(complete_test16$hct)) 
complete_test16$lymph <- (log(complete_test16$lymph)) 
complete_test16$neutr <- (log(complete_test16$neutr)) 
complete_test16$mixed <- (log(complete_test16$mixed)) 
 
str(complete_test16) 
complete_test16$mcv <- as.numeric(complete_test16$mcv) 
 
#MODEL EVALUATION AND VALIDATION# 
 
#SETTING CLASS VALUES FOR ACTUAL AND PREDICTED OUTCOMES# 
 
test16_outcome <- as.factor(complete_test16$case_control) 
test16_probability <- as.numeric(predict(model2, complete_test16, type='response')) 
test16_predicted_outcome <- as.factor(ifelse(test16_probability <= 0.7, 'case','control')) 
 
test16_probability 
 
#SHOW A SIMPLE 2X2 TABLE OF THESE TWO CLASSES# 
 
table(test16_outcome, test16_predicted_outcome) 
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#CROSSTABLE FUNCTION ADDS A FEW EXTRA DETAILS TO THE TABLE (FROM 
GMODELS PACKAGE) # 
 
CrossTable(test16_outcome, test16_predicted_outcome) 
 
#USING CARET PACKAGE TO CREATE A CONFUSION MATRIX WITH 
PERFORMANCE MEASURES# 
 
confusionMatrix(test16_predicted_outcome, test16_outcome, positive="case") 
 
rec16 <- sensitivity(test16_predicted_outcome, test16_outcome, positive="case") 
rec16 
 
spec16 <- specificity(test16_predicted_outcome, test16_outcome, positive="case") 
spec16 
 
prec16 <- posPredValue(test16_predicted_outcome, test16_outcome, positive="case") 
prec16 
 
negprec16 <- negPredValue(test16_predicted_outcome, test16_outcome, positive="case") 
negprec16 
 
f16 <- (2*prec16*rec16)/(prec16+rec16) 
f16 
 
#VISUALISING PERFORMANCE USING ROCR# 
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pred2 <- prediction(predictions = test_probability, labels=test_outcome) 
 
perf2 <- performance(pred2, measure = "tpr", x.measure = "fpr") 
plot(perf2) 
 
perf.auc <- performance(pred, measure="auc") 
unlist(perf.auc@y.values) 
 
 
#EXTRACTING MISMATCHES FROM LOGISTIC REGRESSION FOR 
INVESTIGATION# 
 
 
#MISMATCHES IN TEST16 SET# 
complete_test16$predicted <- test16_predicted_outcome 
lrm_test16_mismatches <- 
complete_test16[complete_test16$case_control!=complete_test16$predicted,] 
write.csv(lrm_test16_mismatches, "lrm_test16_mismatches.csv") 
 
#SUMMARY DATA FOR CHAPTER 7# 
summary(test16_data) 
summary(complete_test16) 
summary(test16_predicted_outcome=='control') 
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10.3 Cost Burden Analysis
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Figure 10-1 Summary of Cost Burden Analysis for Fluorescent PCR detection of JAK2 V617F and CALR mutations. 
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Figure 10-2. Cost Burden Analysis (sample receipt) - detailed breakdown of costings for sample receipt, full blood count analysis, 
morphological preparation, registration and screening. 
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Figure 10-3. Cost Burden Analysis (DNA extraction) - detailed breakdown of costings for DNA extraction process. 
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Figure 10-4. Cost Burden Analysis (PCR) - detailed breakdown of costings for PCR amplification process. 
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Figure 10-5. Cost Burden Analysis (Fragment Analysis) - detailed breakdown of costings for fluorescent fragment analysis of PCR 
products. 
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Figure 10-6. Cost Burden Analysis (Data transfer, analysis and reporting) - detailed breakdown of costings for the interpretation and 
reporting of JAK2 V617F and CALR mutation analysis. 
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ABBREVIATIONS 
 
A ALANINE 
ABL ABELSON 
AML ACUTE MYELOID LEUKAEMIA 
ASO ALLELE SPECIFIC OLIGONUCLEOTIDE 
ATP ADENOSINE TRIPHOSPHATE 
AUROC AREA UNDER RECEIVER OPERATOR CURVE 
B/NK B/NK CELL PROGENITOR 
BCR BREAKPOINT CLUSTER REGION 
BCSH BRITISH COMMITTEE FOR STANDARDS IN HAEMATOLOGY 
BLAST BASIC LOCAL ALIGNMENT SEARCH TOOL 
BM BONE MARROW 
BP BASE PAIRS 
BSA BOVINE SERUM ALBUMIN 
C/EBPα CCAAT/ENHANCER-BINDING PROTEIN ALPHA 
CAD COMPUTER AIDED DESIGN 
CALR CALRETICULIN 
CD CLUSTER OF DIFFERENTIATION 
CGL CHRONIC GRANULOCYTIC LEUKAEMIA 
CMP COMMON MYELOID PROGENITOR 
DNA DEOXYRIBONUCLEIC ACID 
DOH DEPARTMENT OF HEALTH 
ECMP EUROPEAN CLINIAL AND MOLECULAR PATHOLOGY 
EDTA ETHYLENEDIAMINETETRAACETIC ACID 
EPO ERYTHROPOIETIN 
EPOR ERYTHROPOIETIN RECEPTOR 
ER ENDOPLASMIC RETICULUM 
ESR ERYTHROCYTE SEDIMENTATION RATE 
ET ESSENTIAL THROMBOCYTHAEMIA 
ETP EARLY THYMIC PROGENITOR 
F PHENYLALANINE 
F  FEMALE 
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FAB FRENCH-AMERICAN-BRITISH 
FAM FAM FLUOROPHORE 
FBC FULL BLOOD COUNT 
FN FALSE NEGATIVE 
FP FALSE POSITIVE 
GATA-1 ERYTHROID TRANSCRIPTION FACTOR (GATA-BINDING 
FACTOR 1) 
GMP GRANULOCYTE MACROPHAGE PROGENITOR 
GRADE GRADING OF RECOMMENDATIONS, ASSESSMENT, 
DEVELOPMENT AND EVALUATION 
GWAS GENOME WIDE ASSOCIATION STUDIES 
HB HAEMOGLOBIN 
HCT HAEMATOCRIT 
HEX HEX FLUOROPHORE 
HILIS HMDS INTERGRATED LABORATORY INFORMATION 
SYSTEM 
HMDS HAEMATOLOGICAL MALIGNANCY DIAGNOSTIC SERVICE 
HMRN HAEMATOLOGICAL MALIGNANCY RESEARCH NETWORK 
HSC HAEMATOPOIETIC STEM CELL 
ICD  INTERNATIONAL CLASSIFICATION OF DISEASE 
ICD-O INTERNATIONAL CLASSIFICATION OF DISEASE – 
ONCOLOGY 
IL-6 INTERLEUKIN-6 
ITP IDIOPATHIC THROMBOCYOPENIA PURPURA 
JAK2 JANUS KINASE 2 
K LYSINE 
KDEL LYSINE, ASPARTIC ACID, GLUTAMIC, LEUCINE 
L LEUCINE 
LASSO LEAST ABSOLUTE SHRINKAGE AND SELECTION OPERATOR 
LYMPH LYMPHOCYTE 
M MALE 
MCH MEAN CELL HAEMOGLOBIN 
MCHC MEAN CORPUSCULAR HAEMOGLOBIN CONCENTRATION 
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MCV MEAN CELL VOLUME 
MDS MYELODYSPLASTIC SYNDROME 
MEP MEGAKARYOCYTIC ERYTHROID PROGENITOR 
MEP MEGAKARYOCYTIC/ERYTHROID PROGENITOR 
MLP MULTI-LYMPHOID PROGENITOR 
MONO MONOCYTE 
MPD MYELOPROLIFERATIVE DISORDER 
MPL MYELOPROLIFERATIVE LEUKAEMIA PROTEIN 
MPN MYELOPROLIFERATIVE NEOPLASM 
MPP  MULTI-POTENT STEM CELL 
MPS MYELOPROLIFERATIVE SYNDROME 
MPV MEDICAL PRACTICE VARIATION 
NCBI NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION 
NEUTR NEUTROPHIL 
NH4CL AMMONIUM CHLORIDE 
NHS NATIONAL HEALTH SERVICE 
NICE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 
PCR POLYMERASE CHAIN REACTION 
PNH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA 
PI3K PHOSPHOINOSITIDE 3-KINASE 
PLT PLATELET 
PMF PRIMARY MYELOFIBROSIS 
PV POLYCYTHAEMIA VERA 
PVSG POLYCYTHAEMIA VERA STUDY GROUP 
R ARGININE 
RBC RED BLOOD CELL 
ROC RECEIVER OPERATOR CURVE 
RCF RELATIVE CENTRIFUGAL FORCE 
SNP SINGLE NUCLEOTIDE POLYMORPHISM 
SQL STRUCTURED QUERY LANGUAGE 
STAT5 SIGNAL TRANSDUCER AND ACTIVATOR OF 
TRANSCRIPTION 5 
TM MELTING TEMPERATURE 
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TN TRUE NEGATIVE 
TP TRUE POSITIVE 
TPO THROMBOPOIETIN 
TVSG THROMBOCYTHAEMIA VERA STUDY GROUP 
UCSC UNIVERISTY OF CALIFORNIA, SANTA CRUZ 
UKAS UNITED KINGDOM ACCREDITATION SERVICE 
V VALINE 
W  TRYPTOPHAN 
WBC WHITE BLOOD CELL 
WHO WORLD HEALTH ORGANISATION 
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